2017 Annual

HEDIS/ CAHPS Report

Comparative Analysis of Audited Results from TennCare MCOs





Table of Contents

List of Tables	4
List of Figures	6
Acknowledgements, Acronyms and Initialisms	.10
Executive Summary	.13
Background	.14
HEDIS Measures—Domains of Care	.14
Effectiveness of Care Measures	.14
Prevention and Screening	15
Respiratory Conditions	17
Cardiovascular Conditions	18
Diabetes	18
Musculoskeletal Conditions	19
Behavioral Health	19
Medication Management	21
Overuse/Appropriateness	21
Measures Collected Through CAHPS Health Plan Survey	22
Access/Availability of Care Measures	.22
Utilization and Risk-Adjusted Utilization	.24
Experience of Care	.25
CAHPS Health Plan Survey 5.0H Adult Version (CPA) an 5.0H Child Version (CPC)	
Children With Chronic Conditions (CCC)	26
Health Plan Descriptive Information Measures	.27
Measures Collected Using Electronic Clinical Data Systems (ECDS)	.27

Medicaid Results	28
Statewide Performance	28
Individual Plan Performance—HEDIS Measures .	37
Individual Plan Performance—CAHPS	47
Medicaid HEDIS Trending—Statewide Weighted Rates	51
Effectiveness of Care Measures	52
Prevention and Screening	52
Respiratory Conditions	62
Cardiovascular Conditions	67
Diabetes	69
Musculoskeletal Conditions	71
Behavioral Health	72
Medication Management	76
Overuse/Appropriateness	77
Access/Availability of Care Measures	79
Utilization Measures	84
CHIP HEDIS/CAHPS Results	85
APPENDIX A Utilization Measure Medicaid Results Benchmarks	
Utilization Additional Measure Descriptions	. A-1
Utilization Measures: Medicaid Plan-Specific Rates/National Benchmarks	. A- 3
APPENDIX B HEDIS 2016 National Medicaid Means and Percentiles	
APPENDIX C MCO Medicaid Population in Member Months	. C-1
APPENDIX D Measure Reporting Options	. D-1

Table of Contents

APPENDIX E Additional CHIP Measures, Frequency and Population by Member Months	
Additional Utilization Measures: CHIP Plan-S	•
Utilization Measures: CHIP—Antibiotic Utiliz Total (ABX)	
Health Plan Descriptive Information	E-10
HPA Population in CHIP Member Months	E-10

List of Tables

Table C15. Combination vaccinations for Childhood Immunization Status (C15)	16
Table 1a. HEDIS 2017 State to National Medicaid Rates: Effectiveness of Care Measures	29
Table 1b. HEDIS 2017 State to National Medicaid Rates: Measures Where Lower Rates Indicate Better Performance	34
Table 2. HEDIS 2017 State to National Medicaid Rates: Access/Availability of Care Measures	35
Table 3. HEDIS 2017 State to National Medicaid Rates: Utilization Measures	36
Table 4. HEDIS 2017 Rating Color and Measure Designations	37
Table 5a. HEDIS 2017 Plan-Specific Medicaid Rates: Effectiveness of Care Measures	38
Table 5b. HEDIS 2017 Plan-Specific Medicaid Rates: Effectiveness of Care Measures Where Lower Rates Indicate Better Performance	45
Table 6. HEDIS 2017 Plan-Specific Medicaid Rates: Access/Availability of Care Measures	45
Table 7. HEDIS 2017 Plan-Specific Medicaid Rates: Utilization Measures	47
Table 8. 2017 CAHPS Rating Color and Measure Designations	47
Table 9. 2017 CAHPS 5.0H Adult Medicaid Survey Results	48
Table 10. 2017 CAHPS 5.0H Child Medicaid Survey Results (General Population)	49
Table 11. 2017 CAHPS 5.0H Child Medicaid Survey Results (Children with Chronic Conditions)	50
Table 12. HEDIS 2017 CHIP Rates	85
Table 13. HEDIS 2017 CHIP Rates Where Lower Rates Indicate Better Performance	88
Table 14. 2017 CAHPS 5.0H Child CHIP Survey Results (General Population)	89
Table 15. 2017 CAHPS 5.0H Child CHIP Survey Results (Children with Chronic Conditions)	89
Table A. HEDIS 2017 Medicaid Plan-Specific Rates with HEDIS 2016 National Benchmarks: Utilization Measures	A-3
Table B. HEDIS 2016 National Medicaid Means and Percentiles	B-1
Table C1. HEDIS 2017 MCO Medicaid Population Reported in Member Months by Age and Sex—AG	C-1
Table C2. HEDIS 2017 MCO Medicaid Population Reported in Member Months by Age and Sex—BC and TCS	C-2
Table C3. HEDIS 2017 MCO Medicaid Population Reported in Member Months by Age and Sex—UHC	C-4
Table D. 2017 Measure reporting options: Administrative/Hybrid	D-1

List of Tables

Table E1. HEDIS 2017 Utilization Measures: CHIP—FPC and W15	E-1
Table E2. HEDIS 2017 Utilization Measures: CHIP—Frequency of Selected Procedures (FSP)	E-1
Table E3. HEDIS 2017 Utilization Measures: CHIP—Ambulatory Care: Total (AMB)	E-2
Table E4a. HEDIS 2017 Utilization Measures: CHIP—Inpatient Utilization General Hospital/Acute Care: Total (IPU)	E-2
Table E4b. HEDIS 2017 Utilization Measures: CHIP—Inpatient Utilization General Hospital/Acute Care: Total (IPU)	E-3
Table E5. HEDIS 2017 Utilization Measures: CHIP—Total IAD and Total MPT Rates	E-3
Table E6. HEDIS 2017 Utilization Measures: CHIP—Antibiotic Utilization	E-5
Table E7. HEDIS 2017 Utilization Measures: CHIP—Antibiotics of Concern Utilization	E-7
Table E8. HEDIS 2017 Utilization Measures: CHIP—All Other Antibiotics Utilization	E-8
Table E8. HEDIS 2017 Utilization Measures: CHIP—Standardize Healthcare-Associated Infection Ratio (HAI)	E-9
Table E9. Board Certification (BCR)	E-10
Table E10. HPA CHIP Population in Member Months	E-10

List of Figures

Fig. 1.	Adult BMI Assessment (ABA)52	Fig. 17.	CIS: PCV	56
Fig. 2.	Weight Assessment and Counseling for	Fig. 18.	CIS: HepA	56
	Nutrition and Physical Activity for Children/Adolescents (WCC)— BMI	Fig. 19.	CIS: RV	56
	Percentile: 3–11 years 52	Fig. 20.	CIS: Flu	56
Fig. 3.	WCC—BMI Percentile: 12-17 years52	Fig. 21.	CIS: Combination 2	57
Fig. 4.	WCC—BMI Percentile: Total 52	Fig. 22.	CIS: Combination 3	57
Fig. 5.	WCC—Counseling for Nutrition: 3–11	Fig. 23.	CIS: Combination 4	57
	years53	Fig. 24.	CIS: Combination 5	57
Fig. 6.	WCC—Counseling for Nutrition: 12–17 years53	Fig. 25.	CIS: Combination 6	58
Fig. 7	WCC—Counseling for Nutrition: Total 53	Fig. 26.	CIS: Combination 7	58
Fig. 7.	•	Fig. 27.	CIS: Combination 8	58
Fig. 8.	WCC—Counseling for Physical Activity: 3–11 years53	Fig. 28.	CIS: Combination 9	58
Fig. 9.	WCC—Counseling for Physical Activity: 12–	Fig. 29.	CIS: Combination 10	59
	17 years 54	Fig. 30.	Immunizations for Adolescents (IMA):	
Fig. 10.	9 9		Meningococcal	59
	Total 54	Fig. 31.	IMA: Tdap/Td	59
Fig. 11.	Childhood Immunization Status (CIS):	Fig. 32.	HPV: Adolescents	59
Fig. 10	DTap	Fig. 33.	IMA: Combination 1	60
_	CIS: IPV	Fig. 34.	Lead Screening in Children (LSC)	60
Fig. 13.		Fig. 35.	Breast Cancer Screening (BCS)	60
Fig. 14.	CIS: HiB55	Fig. 36.	Cervical Cancer Screening (CCS)	60
Fig. 15.	CIS: HepB55	Fig. 37.	Chlamydia Screening in Women (CHL): 16	
Fig. 16.	CIS: VZV55	1 19. 07.	20 years	

Fig. 38.	CHL: 21-24 years 61	Fig. 53.	MMA—Medication Compliance 75%: Total . 65
Fig. 39.	CHL: Total61	Fig. 54.	Asthma Medical Ratio (AMR): 5-11 years . 65
Fig. 40.	Appropriate Testing for Children With	Fig. 55.	AMR: 12–18 years
	Pharyngitis (CWP)62	Fig. 56.	AMR: 19–50 years
Fig. 41.	Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	Fig. 57.	AMR: 51–64 years
Fig. 42.	Pharmacotherapy Management of COPD	Fig. 58.	AMR: Total 66
g=.	Exacerbation (PCE): Systemic	Fig. 59.	Controlling High Blood Pressure (CBP) 67
	Corticosteroid	Fig. 60.	Persistence of Beta-Blocker Treatment After
Fig. 43.	PCE: Bronchodilator62		a Heart Attack (PBH)67
Fig. 44.	Medication Management for People With Asthma (MMA)—Medication Compliance	Fig. 61.	SPC—Received Statin Therapy: Males 21-75 years67
	50%: 5–11 years 63	Fig. 62.	SPC—Received Statin Therapy: Females 40 -
Fig. 45.	MMA—Medication Compliance 50%: 12–18		75 years 67
	years	Fig. 63.	SPC—Received Statin Therapy: Total 68
Fig. 46.	MMA—Medication Compliance 50%: 19-50 years63	Fig. 64.	SPC—Statin Adherence 80%: Males 21-75 years
Fig. 47.	MMA—Medication Compliance 50%: 51–64 years63	Fig. 65.	SPC—Statin Adherence 80%: Females 40 - 75 years
Fig. 48.	MMA—Medication Compliance 50%: Total . 64	Fig. 66.	SPC—Statin Adherence 80%: Total 68
Fig. 49.	MMA—Medication Compliance 75%: 5–11 years64	Fig. 67.	Comprehensive Diabetes Care (CDC): HbA1c Testing 69
Fig. 50.	MMA—Medication Compliance 75%: 12–18 years64	Fig. 68.	CDC: HbA1c Control (<7.0%) 69
Fig. 51.	MMA—Medication Compliance 75%: 19–50	Fig. 69.	CDC: HbA1c Control (<8.0%) 69
119. 01.	years64	Fig. 70.	CDC: Retinal Eye Exam Performed 69
Fig. 52.	MMA—Medication Compliance 75%: 51–64	Fig. 71.	CDC: Medical Attention for Nephropathy 70

Fig. 72.	CDC: Blood Pressure Control (<140/90 mm Hg)70	Fig. 87.	Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM): 1-5
Fig. 73.	CDC: HbA1c Poor Control (>9.0%)* 70		Years74
Fig. 74.	SPD—Received Statin Therapy: 40-75	Fig. 88.	APM: 6-11 Years 74
	years70	Fig. 89.	APM: 12-17 Years 75
Fig. 75.	SPD—Statin Adherence 80%: 40-75 years 71	Fig. 90.	APM: Total
Fig. 76.	Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART) 71	Fig. 91.	Annual Monitoring for Patients on Persistent Medications (MPM): ACE Inhibitors or
Fig. 77.	Antidepressant Medication Management		ARBs
	(AMM): Effective Acute Phase Treatment 72	Fig. 92.	MPM: Digoxin
Fig. 78.		Fig. 93.	MPM: Diuretics
	Treatment	Fig. 94.	MPM: Total
Fig. 79.	Follow-Up Care for Children Prescribed ADHD Medication (ADD): Initiation Phase	Fig. 95.	Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)*77
Fig. 80.	ADD: Continuation and Maintenance Phase72	Fig. 96.	Appropriate Treatment for Children With
Fig. 81.	Follow-Up After Hospitalization for Mental	3	Upper Respiratory Infection (URI)
	Illness (FUH): 7-Day Follow-Up	Fig. 97.	Avoidance of Antibiotic Treatment in Adults
Fig. 82.	FUH: 30-Day Follow-Up73		With Acute Bronchitis (AAB)77
Fig. 83.	Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are	Fig. 98.	Use of Imaging Studies for Low Back Pain (LBP)77
	Using Antipsychotic Medication (SSD) 73	Fig. 99.	Use of Multiple Concurrent Antipsychotics in
Fig. 84.	Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)		Children and Adolescents (APC): 1-5 Years*78
Fig. 85.	Cardiovascular Monitoring for People With	Fig. 100.	APC: 6-11 Years*78
	Cardiovascular Disease and Schizophrenia (SMC)74	J	APC: 12-17 Years* 78
Fig. 86.	Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) 74	Fig. 102.	APC: Total*78

Fig. 10	3. Adults' Access to Preventive/Ambulatory Health Services (AAP): 20–44 years79	Fig. 114	IET—Engagement of AOD Treatment: Total81
_	4. AAP: 45–64 years	Fig. 115	Prenatal and Postpartum Care (PPC): Timeliness of Prenatal Care82
Fig. 10	5. Children and Adolescents' Access to Primary Care Practitioners (CAP): 12–24 months 79	Eig 116	PPC: Postpartum Care82
	Care Fractitioners (CAF). 12–24 months 79	rig. 110	FFC. FOStpartuili Care
Fig. 10	6. CAP: 25 months-6 years79	Fig. 117	Use of First-Line Psychosocial Care for
Fig. 10	7. CAP: 7-11 years 80		Children and Adolescents on Antipsychotics (APP): 1-5 Years
Fig. 10	B. CAP: 12–19 years80	Fia 118	APP: 6-11 Years82
Fia. 10	9. Initiation and Engagement of Alcohol and		
	Other Drug (AOD) Dependence Treatment	Fig. 119	APP: 12-17 Years 83
	(IET)—Initiation of AOD Treatment: 13-17	Fig. 120	APP: Total 83
	years 80	Fig. 121.	Frequency of Ongoing Prenatal Care (FPC):
Fig. 11	D. IET—Initiation of AOD Treatment: ≥18	1.19. 12.1	≥ 81%
	years80	Fig. 122	Well-Child Visits in the First 15 Months of
Fig. 11	1. IET—Initiation of AOD Treatment: Total 81	Ü	Life (W15): 6 or More Visits84
Fig. 11.	2. IET—Engagement of AOD Treatment: 13–17 years81	Fig. 123	Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)
Fig. 11:	3. IET—Engagement of AOD Treatment: ≥18 vears81	Fig. 124	Adolescent Well-Care Visits (AWC) 84

Acknowledgements, Acronyms and Initialisms 1,2

APMMetabolic Monitoring for Children and Adolescents on Antipsychotics	AABAvoidance of Antibiotic Treatment in Adults With Acute Bronchitis
APPUse of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics	AAP Adults' Access to Preventive/ Ambulatory Health Services
ARB Angiotensin Receptor Blocker	ABA Adult BMI Assessment
ART Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis	ABX Antibiotic Utilization
AWCAdolescent Well-Care Visits	ACE Angiotensin Converting Enzyme
BC Volunteer State Health Plan, Inc,	ADDFollow-Up Care for Children Prescribed ADHD Medication
as BlueCare Tennessee	ADHD Attention-Deficit/Hyperactivity Disorder
BCE/BCM/BCW BC in the Tennessee East, Middle and West Grand Regions	AHRQ Agency for Healthcare Research and Quality
BCS Breast Cancer Screening	AG Amerigroup Community Care, Inc., as Amerigroup
BlueCare®; BlueCare Tennessee SM registered or service marks of The BlueCross BlueShield Association	AGE/AGM/AGWAG in the Tennessee East, Middle and West Grand Regions
BlueCross BlueShield of Tennessee; BlueCare licensees	AMBAmbulatory Care
of The BlueCross BlueShield Association	AMI Acute Myocardial Infarction
BMI Body Mass Index	AMM Antidepressant Medication Management
BPBlood Pressure	AMRAsthma Medication Ratio
BRBiased Rate	AODAlcohol or Other Drug
CAHPS® refers to the Consumer Assessment of Healthcare Providers and Systems	APCUse of Multiple Concurrent Antipsychotics in Children and Adolescents

¹ The source for data contained in this publication is Quality Compass® 2016 and is used with the permission of the National Committee for Quality Assurance (NCQA).Quality Compass 2016 includes certain CAHPS data. Any data display, analysis, interpretation, or conclusion based on these data is solely that of the authors, and NCQA specifically disclaims responsibility for any such display, analysis, interpretation, or conclusion. Quality Compass is a registered trademark of NCQA. CAHPS® is a registered trademark of the Agency for Healthcare Research and Quality (AHRQ).

² Other company and product names may be trademarks of the respective companies with which they are associated. The mention of such companies and product names is with due recognition and without intent to misappropriate such names or marks.

Acknowledgements, Acronyms and Initialisms

CAPChildren and Adolescents' Access to Primary Care Practitioners
CBP Controlling High Blood Pressure
CCCChildren With Chronic Conditions
CCS Cervical Cancer Screening
CDC Comprehensive Diabetes Care
CHL Chlamydia Screening in Women
CISChildhood Immunization Status
CPACAHPS Health Plan Survey 5.0H Adult Version
CPCCAHPS Health Plan Survey 5.0H Child Version
COPDChronic Obstructive Pulmonary Disease
CVD Cardiovascular Disease
CWP Appropriate Testing for Children With Pharyngitis
CY
DMARD Disease-Modifying Anti-Rheumatic Drug
DTaPDiphtheria, Tetanus and Acellular Pertussis Vaccination
ECDS Electronic Clinical Data Systems
ED Emergency Department
ENP Enrollment by Product Line
FluInfluenza
FPC Frequency of Ongoing Prenatal Care
FSPFrequency of Selected Procedure
FUH Follow-Up After Hospitalization for Mental Illness
FUM Follow-Up After ED Visit for Mental Illness
FUA Follow-Up After ED Visit for Alcohol and Other Drug Dependence

FVA Flu vaccinations for adults ages 18 to	64
HbA1cHemoglobin A1c, also ca Glycosylated Hemoglobin, Glycohemoglo	
HEDIS [®] refers to the Healthcare Effectiveness Data Information Set and is a registered trademark of NO	
HCFA Tennessee Divisio Health Care Finance and Administra	
HepA Hepatitis A Vaccina	tion
HepB Hepatitis B Vaccina	tion
HiB H (Haemophilus) Influenza Type B Vaccina	tion
HPV Human Papillomavirus Vac	cine
HTNHypertens	sion
IAD Identification of Alcohol and Other Drug Serv	ices
IET Initiation and Engagemen AOD Dependence Treatm	
IMA Immunizations for Adolesce	ents
IP; IPUInpation – General Hospital/Acute C	
IPVPolio Vaccina	tion
LBPUse of Imaging Studies for Low Back F	Pain
LDL-CLow-Density Lipoprotein Cholest	erol
LSC Lead Screening in Child	lren
MCO Managed Care Organiza	tion
MMAMedication Management for People With Asth	ıma
MMR Measles, Mumps and Rubella Vaccina	tion
MPMAnnual Monitoring for Patie on Persistent Medicati	
MPTMental Health Utiliza	tion

Acknowledgements, Acronyms and Initialisms

MSC Medical Assistance With Smoking and Tobacco Use Cessation	SM
MY Measurement Year	SM
NA Not Applicable	
NB	SPC
NCQA National Committee for Quality Assurance	SPE
NCQA HEDIS Compliance Audit $^{\text{\tiny TM}}$ trademark of NCQA	SPF
NCS	SSI
NR	
NQNot Required	Str
OB-GYN Obstetrician-Gynecologist	Ter
PBH Persistence of Beta-Blocker Treatment After a Heart Attack	Td;
PCE Pharmacotherapy Management of COPD Exacerbation	TCS
PCP Primary Care Practitioner	
PCVPneumococcal Conjugate Vaccination	UH
PMPYPer Member Per Year	UH
PPC Prenatal and Postpartum Care	
Qsource® a registered trademark	UN
Quality Compass®a registered trademark of NCQA, the comprehensive national database of	URI
health plans' HEDIS and CAHPS results	٧Z١
RReportable	W1
RA	W3
RV Rotavirus Vaccination	
SAA Adherence to Antipsychotic Medications	WC

SMC	
SMD Diabetes Monitoring for F With Diabetes and Schizoph	
SPC Statin Therapy for Patients With	h CVD
SPD Statin Therapy for Patients With Dia	abetes
SPR	
SSD Diabetes Screening for F With Schizophrenia or Bipolar Dis Who Are Using Antipsychotic Medic	sorder
Strep Streptoo	coccus
TennCare HCFA Medicaid program in Tenn	iessee
Td; Tdap Tetanus, Diphtheria Toxoids Va Td and Acellular Pertussis Va	
TCSVolunteer State Health Plan, Inc. TennCare Select stat	
UHC	
UHCE/UHCM/UHCW UHC in the Tennessee Middle and West Grand Re	-
UNUn-Aı	udited
URIUpper Respiratory Infection, and the mea Appropriate Treatment for Children Wit	
VZV Chicken Pox/Varicella Zoster Vaccin	nation
W15Well-Child Visits in the First 15 Months	of Life
W34 Well-Child Visits in the Third, Fourth, and Sixth Years	
WCCWeight Assessment and Counseling for Nu and Physical Activity for Children/Adoles	

Executive Summary

Medicaid managed care organizations (MCOs) are required to report a full Healthcare Effectiveness Data and Information Set (HEDIS) as a part of the accreditation mandates in Tennessee. The HEDIS requirement is an integral part of the accreditation process of the National Committee for Quality Assurance (NCQA). In 2006, Tennessee became the first state in the nation requiring all MCOs to become accredited by NCQA, an independent, not-for-profit organization that assesses and scores MCO performance on important dimensions of care and service in a broad range of health issues.

More than 90% of health plans in America use the HEDIS tool because its standardized measures of MCO performance allow comparisons to national averages and benchmarks as well as between a state's MCOs, and over time. The Consumer Assessment of Healthcare Providers and Systems (CAHPS) set of standardized surveys is included in HEDIS to measure members' satisfaction with their care. This 2017 HEDIS/CAHPS Report summarizes the results for the MCOs contracting with TennCare, the Medicaid program of the Tennessee Division of Health Care Finance and Administration (HCFA).

For an overview of the performance of TennCare's MCOs, a calculated weighted average of the scores of all those reporting is provided alongside national averages in the <u>Statewide</u>

Performance section. MCO-specific measures are presented in the Individual Plan Performance section for cross-comparison with color-coding for national and state benchmark comparison where available/applicable. Weighted average performances of Tennessee's MCOs since 2006 on certain measures are presented in the HEDIS Trending section. The HEDIS and CAHPS results for CoverKids, Tennessee's Children's Health Insurance Plan (CHIP) are reported separately in CHIP HEDIS/CAHPS Results.

Appendix A contains a comprehensive table of plan-specific results for HEDIS 2017 Utilization Measures and HEDIS 2016 national benchmarks. The table in Appendix B contains the HEDIS 2016 National Medicaid Means and Percentiles for reference to these benchmarks, and the table in Appendix C reveals populations reported by MCOs in member months by age and sex for HEDIS 2017. Appendix D presents the reporting options for each measure, whether administrative, hybrid or both. Appendix E offers additional utilization measures, frequencies and population by member months for the CHIP.

Background

HEDIS Measures—Domains of Care

HEDIS is an important tool designed to ensure the public has the information needed to reliably compare the performance of managed healthcare plans. Standardized methodologies incorporating statistically valid samples of members ensure the integrity of measure reporting and help purchasers make more reliable, relevant comparisons between health plans. HEDIS measures are subject to a NCQA HEDIS Compliance Audit that must be conducted by an NCQA-certified HEDIS Compliance Auditor under the auspices of an NCQA-licensed organization. This ensures the integrity of the HEDIS collection and calculation process at each MCO through an overall information systems capabilities assessment, followed by an evaluation of the ability to comply with HEDIS specifications.

The HEDIS rates presented in this report refer to data collected during the review period of the previous calendar year (CY), from January 1 to December 31. For HEDIS 2017 results, CY2016 was the review period. Similarly, comparative data presented in this report from the HEDIS 2016 Medicaid Means and Percentiles reflect data procured during CY2015.

HEDIS 2017 assesses care across body systems, access to and satisfaction with healthcare services and specific utilization

through a total of 91 measures (Commercial, Medicare and Medicaid) across seven domains of care:

- Effectiveness of Care
- Access/Availability of Care
- Utilization and Risk Adjusted Utilization
- Relative Resource Use
- Experience of Care (CAHPS Survey Results)
- Health Plan Descriptive Information
- Measures Collected Using Electronic Clinical Data Systems (ECDS)

The following brief descriptions of selected HEDIS measures were extracted from NCQA's HEDIS 2017 Volume 2: Technical Specifications, which includes additional information related to each measure. The measures presented in this report reflect data submitted from the following domains of care: Effectiveness of Care, Access/Availability of Care, Utilization, and Experience of Care. Per NCQA, Relative Resource Use measures were not collected for HEDIS 2017.

Effectiveness of Care Measures

The measures in the Effectiveness of Care domain assess the quality of clinical care delivered within an MCO. Measures in this domain address how well the MCO delivers widely accepted preventive services and recommended screening for common diseases. The domain also includes some measures for

overuse and patient safety and addresses four major aspects of clinical care:

- 1. How well the MCO delivers preventive services and keeps members healthy
- 2. Whether members are offered the most up-to-date treatments for acute episodes of illness and get better
- 3. How well the MCO delivers care and assistance with coping to members with chronic diseases
- 4. Whether members can get appropriate tests

Starting with HEDIS 2008 reporting, Effectiveness of Care measures were grouped into more specific clinical categories, which have slightly changed:

- Prevention and Screening
- Respiratory Conditions
- Cardiovascular Conditions
- Diabetes
- Musculoskeletal Conditions
- Behavioral Health
- Medication Management
- Overuse/Appropriateness
- Measures collected by the CAHPS Health Plan Survey

Only certain measures from these categories are presented in this report, which does not include the additional category in this domain specific to Medicare. For some measures, eligible members cannot have more than one gap in continuous enrollment of up to 45 days during the measurement year (MY).

Prevention and Screening

Immunization measures follow guidelines for immunizations from the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices. HEDIS implements changes (e.g., new recommendations) after three years, to account for the measures' look-back period and to allow the industry time to adapt to new guidelines.

Adult BMI Assessment (ABA)

ABA measures the percentage of members 18 to 74 years of age who had an outpatient visit and whose body mass index (BMI) was documented during the MY or the year prior to the MY.

Weight Assessment and Counseling for Nutrition and Physical Activity for Children/ Adolescents (WCC)

WCC measures the percentage of members 3 to 17 years of age who had an outpatient visit with a primary care practitioner (PCP) or obstetrician-gynecologist (OB-GYN) and who had evidence of BMI percentile documentation, counseling for nutrition and counseling for physical activity during the MY.

Note: Because BMI norms for youth vary with age and gender, this measure evaluates whether BMI percentile is assessed not an absolute BMI value.

Childhood Immunization Status (CIS)

CIS assesses the percentage of children who became two years of age and who, on or before two years of age, had four diphtheria, tetanus, acellular pertussis (DTaP); three polio (IPV); one measles, mumps, and rubella (MMR); three *Haemophilus* influenza type B (HiB); three hepatitis B (HepB);

one chicken pox/varicella zoster (VZV); four pneumococcal conjugate (PCV); one hepatitis A (HepA); two or three rotavirus (RV); and two influenza (Flu) vaccines. The measure calculates a rate for each vaccine and nine separate combination rates numbered 2 to 10 as shown in **Table CIS**.

	Table CIS. Combination Vaccinations for Childhood Immunization Status (CIS)									
#	DTaP	IPV	MMR	HiB	НерВ	VZV	PCV	НерА	RV	Flu
2	✓	\checkmark	\checkmark	\checkmark	\checkmark	✓				
3	✓	✓	✓	✓	✓	✓	✓			
4	✓	✓	✓	✓	✓	✓	✓	✓		
5	✓	✓	✓	✓	✓	✓	✓		\checkmark	
6	✓	✓	✓	✓	✓	✓	✓			✓
7	✓	✓	✓	✓	✓	✓	✓	✓	✓	
8	✓	✓	✓	✓	✓	✓	✓	✓		✓
9	✓	✓	✓	✓	✓	✓	✓		✓	✓
10	✓	✓	✓	✓	✓	✓	✓	✓	✓	√

Immunizations for Adolescents (IMA)

IMA measures the percentage of adolescents 13 years of age who had one dose of meningococcal vaccine and one dose of tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), and three doses of the human papillomavirus vaccine (HPV) by the 13th birthday, calculating the rate for each vaccine and two combinations: meningococcal and Tdap/Td; and meningococcal, Tdap/Td and HPV.

IMA criteria was revised for HEDIS 2017 to remove polysaccharide vaccines. The HPV measure for female adolescents was retired for HEDIS 2017 and incorporated into IMA. Revised to indicate that prior year rates may not be used to reduce the sample for IMA hybrid methodology.

Lead Screening in Children (LSC)

LSC assesses the percentage of children two years of age who had one or more capillary or venous lead blood tests for lead poisoning on or before the second birthday.

Breast Cancer Screening (BCS)

BCS measures the percentage of female members 50 to 74 years of age who had a mammogram to screen for breast cancer between October 1 two years prior to the MY, and through December 31 of the MY.

Note: This measure does not include biopsies, breast ultrasounds, MRIs or diagnostic screenings because they are not appropriate methods for primary breast cancer screening. HEDIS 2016 added new value sets to identify bilateral mastectomy.

Cervical Cancer Screening (CCS)

CCS measures the percentage of women 21 to 64 years of age who were appropriately screened for cervical cancer using either of the following criteria:

- Women age 21–64 who had cervical cytology performed every three years
- Women age 30–64 who had cervical cytology/HPV co-testing performed every five years

Note: For HEDIS 2017, medical record requirements clarified that reflex testing would not meet criteria for hybrid specification.

Chlamydia Screening in Women (CHL)

CHL assesses the percentage of women 16 to 24 years of age who were identified as sexually active and who had at least one test for chlamydia during the MY. This measure calculates a total rate as well as two age stratifications:

- ♦ Women age 16–20
- ♦ Women age 21–24

Respiratory Conditions

Appropriate Testing for Children With Pharyngitis (CWP)

CWP measures the percentage of children 3 to 18 years of age who were diagnosed with pharyngitis, dispensed an antibiotic prescription on or during the three days after the episode date, and received a group A streptococcus (strep) test for the episode. A higher rate represents better performance (i.e., appropriate testing).

<u>Use of Spirometry Testing in the Assessment and Diagnosis</u> of COPD (SPR)

SPR reports the percentage of members 40 years of age and older with a new diagnosis or newly active chronic obstructive pulmonary disease (COPD) who received appropriate spirometry testing to confirm the diagnosis.

Pharmacotherapy Management of COPD Exacerbation (PCE)

PCE assesses the percentage of COPD exacerbation for members 40 years of age and older who had an acute inpatient (IP) discharge or emergency department (ED) visit on or between January 1 and November 30 of the MY and who were dispensed appropriate medications. Two rates are reported:

- Dispensed a systemic corticosteroid (or there was evidence of an active prescription) within 14 days of the event
- Dispensed a bronchodilator (or there was evidence of an active prescription) within 30 days of the event

Note: The eligible population for this measure is based on acute IP discharges and ED visits, not on members. The denominator may include multiple events for the same individual. For HEDIS 2017, the exclusion was deleted for Episode Dates when there was a readmission or an ED visit within 14 days.

Medication Management for People With Asthma (MMA)

MMA records the percentage of members 5 to 64 years of age during the MY who were identified as having persistent asthma and were dispensed appropriate medications that they remained on during the treatment period.

Two rates are reported for the percentage of members who remained on an asthma controller medication:

- For at least 50% of their treatment period
- For at least 75% of their treatment period

For MMA, a total rate and four age stratifications are reported:

◆ 5–11 years

♦ 19–50 years

• 12–18 years

♦ 51–64 years

Asthma Medication Ratio (AMR)

AMR assesses the percentage of members 5 to 64 years of age who were identified as having persistent asthma and had a ratio

of controller medications to total asthma medications of 0.50 or greater during the MY. This measure calculates a total rate as well as four age stratifications:

◆ 5–11 years

♦ 19–50 years

◆ 12–18 years

◆ 51–64 years

Cardiovascular Conditions

Controlling High Blood Pressure (CBP)

CBP reports the percentage of members 18 to 85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled during the MY, a single rate based on a sum of the following criteria groups by age:

- Members 18–59 years whose BP was <140/90 mm Hg
- Members 60–85 years with a diagnosis of diabetes whose BP was <140/90 mm Hg
- Members 60–85 years without a diagnosis of diabetes whose BP was <150/90 mm Hg

<u>Persistence of Beta-Blocker Treatment After a Heart Attack</u> (PBH)

PBH measures the percentage of members 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of acute myocardial infarction (AMI) and who received persistent beta-blocker treatment for six months after discharge.

Statin Therapy for Patients With Cardiovascular Disease (SPC) SPC reports the percentage of members identified as having clinical atherosclerotic cardiovascular disease (CVD) and who met the following criteria:

- Received Statin Therapy—Members who were dispensed at least one high or moderate-intensity statin medication during the MY
- Statin Adherence 80% Members who remained on a high or moderate-intensity statin medication for at least 80% of the treatment period

For SPC, a total rate and two stratifications of gender and age (as of December 31 of the MY) are reported:

- Males 21–75 years
- Females 40–75 years

Diabetes

Comprehensive Diabetes Care (CDC)

The CDC composite of seven rates measures an MCO's performance on clinical management in aspects of diabetic care through the percentage of a single sample of diabetic members (type 1 and type 2) 18 to 75 years of age who met the criteria by having the following during the MY:

- Hemoglobin A1c (HbA1c) blood test
- Poorly controlled diabetes (HbA1c >9.0%)

 Note: a lower rate indicates better performance (i.e., low rates of poor control indicate better care)
- Controlled diabetes (most recent HbA1c <8.0%)

- Controlled diabetes (most recent HbA1c <7.0%) for a selected population
- Eye exam (retinal)
- Medical attention for nephropathy
- Controlled blood pressure (<140/90 mm Hg)

Note: HEDIS 2017 added glycohemoglobin, glycated hemoglobin and glycosylated hemoglobin as acceptable HbA1c tests.

Statin Therapy for Patients With Diabetes (SPD)

SPD reports the percentage of members 40 to 75 years of age who do not have atherosclerotic CVD and met the following criteria reported as two rates:

- Received Statin Therapy—Members who were dispensed at least one statin medication of any intensity during the MY
- Statin Adherence 80% Members who remained on a statin medication of any intensity for at least 80% of the treatment period

Musculoskeletal Conditions

<u>Disease-Modifying Anti-Rheumatic Drug Therapy for</u> Rheumatoid Arthritis (ART)

ART assesses whether members who were diagnosed with rheumatoid arthritis (RA) were prescribed a disease-modifying anti-rheumatic drug (DMARD) to attenuate the damaging progression, reduce inflammation and improve functional status. The rate is the percentage of members diagnosed with RA, and not HIV or pregnancy, who were dispensed at least one ambulatory prescription for a DMARD during the MY.

Behavioral Health

Antidepressant Medication Management (AMM)

AMM measures the percentage of members 18 years of age and older who were treated with antidepressant medication, had a diagnosis of major depression and who remained on an antidepressant medication treatment. Two rates are reported:

- Effective Acute Phase Treatment—The percentage who remained on medication for a at least 84 days (12 weeks)
- ◆ Effective Continuation Phase Treatment—The percentage who remained on medication for at least 180 days (6 months)

Follow-Up Care for Children Prescribed ADHD Medication (ADD)

ADD assesses the percentage of children newly prescribed attention-deficit/hyperactivity disorder (ADHD) medication who had at least three follow-up care visits within a 10-month period, one of these visits must have been within 30 days of the earliest ambulatory prescription dispensed for ADHD medication, at which time the member must have been 6 to 12 years of age. Two rates are reported:

- Initiation Phase—The percentage who had one follow-up visit with a practitioner with prescribing authority during the 30-day Initiation Phase
- Continuation and Maintenance Phase—The percentage who remained on the medication for at least 210 days and who, in addition to the Initiation Phase follow-up, had at

least two follow-up visits with a practitioner within 270 days (nine months) of the end of the Initiation Phase

Follow-Up After Hospitalization for Mental Illness (FUH)

FUH examines continuity of care for mental illness through the percentage of discharges for members six years of age and older who were hospitalized for selected mental illness diagnoses and who had a follow-up visit with a mental health practitioner. Two rates are reported as the percentage of discharges for which the member received follow-up within the following:

- 7 days of discharge
- 30 days of discharge

<u>Follow-Up After Emergency Department Visit for Mental</u> Illness (FUM)

FUM is the percentage of members 6 years of age and older with a principal diagnosis of mental illness, who had a follow-up visit for mental illness. Two rates are reported as the percentage of ED visits for which the member received follow-up within the following:

- 7 days of discharge
- 30 days of discharge

Follow-Up After Emergency Department Visit for Alcohol and Other Drug Dependence (FUA)

FUA is the percentage of members 6 years of age and older with a principal diagnosis of mental illness, who had a follow-up visit for mental illness. Two rates are reported as the percentage of ED visits for which the member received follow-up within the following:

- 7 days of discharge
- 30 days of discharge

For FUA, a total rate and two age stratifications are reported:

- ♦ 13–17 years
- ♦ 18 years and older

<u>Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)</u>

SSD measures the percentage of members 18 to 64 years of age with schizophrenia or bipolar disorder who were dispensed an antipsychotic medication and had a diabetes screening test during the MY.

<u>Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)</u>

SMD is the percentage of members 18 to 64 years of age with schizophrenia and diabetes who had both a low-density lipoprotein cholesterol (LDL-C) test and an HbA1c test during the MY.

<u>Cardiovascular Monitoring for People With Cardiovascular</u> Disease and Schizophrenia (SMC)

SMC reports the percentage of members 18 to 64 years of age with schizophrenia and CVD who had an LDL-C test during the MY.

Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

SAA assesses the percentage of members with schizophrenia who were 19 to 64 years of age during the MY who were dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.

Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)

APM measures the percentage of children and adolescents 1 to 17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. It calculates a total rate as well as three age stratifications:

◆ 1–5 years

◆ 12–17 years

◆ 6–11 years

Medication Management

<u>Annual Monitoring for Patients on Persistent Medications (MPM)</u>

MPM reports the percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the MY and at least one therapeutic monitoring event for the therapeutic agent in the MY. Three rates are reported separately and as a sum total rate:

- Annual monitoring for members on angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blocker (ARB)
- Annual monitoring for members on digoxin
- Annual monitoring for members on diuretics

Overuse/Appropriateness

Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)

NCS records the percentage of adolescent females 16 to 20 years of age who were screened unnecessarily for cervical cancer.

Note: A lower rate indicates better performance.

Appropriate Treatment for Children With Upper Respiratory Infection (URI)

This measures the percentage of children 3 months to 18 years of age who were given a diagnosis of upper respiratory infection (URI) and were not dispensed an antibiotic prescription. This measure is reported as an inverted rate [1 - (numerator/eligible population)], with a higher rate indicating appropriate treatment of children with URI (i.e., the proportion for whom antibiotics were not prescribed).

<u>Avoidance of Antibiotic Treatment in Adults With Acute</u> <u>Bronchitis (AAB)</u>

AAB reports the percentage of adults 18 to 64 years of age with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription. This measure is reported as an inverted rate [1 - (numerator/eligible population)], with a higher rate indicating appropriate treatment of adults with acute bronchitis (i.e., the proportion for whom antibiotics were not prescribed).

Use of Imaging Studies for Low Back Pain (LBP)

LBP assesses the percentage of members with a primary diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis. This measure is reported as an inverted rate [1 - (numerator/eligible population)], with a higher rate indicating an appropriate treatment of low back pain (i.e., the proportion for whom imaging studies did not occur).

<u>Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)</u>

APC measures the percentage of children and adolescents 1 to 17 years of age who were on two or more concurrent antipsychotic medications. This measure calculates a total rate as well as three age stratifications:

◆ 1–5 years

♦ 12–17 years

♦ 6–11 years

Note: For this measure, a lower rate indicates better performance (i.e., low rates of concurrent antipsychotics indicate better care).

Measures Collected Through CAHPS Health Plan Survey

Flu vaccinations for adults ages 18 to 64 (FVA)

FVA reports the percentage of members 18 to 64 years of age who received a flu vaccination between July 1 of the MY and the date when the CAHPS Health Plan Survey 5.0H Adult Version (CPA) was completed.

Medical Assistance With Smoking and Tobacco Use Cessation (MSC)

This measure is collected using the survey methodology to arrive at a rolling average that represents the percentage of members 18 years of age and older who were current smokers or tobacco users seen during the MY.

MSC assesses the following facets of providing medical assistance with smoking and tobacco use cessation:

- Advising Smokers and Tobacco Users to Quit—Those who received advice to quit
- Discussing Cessation Medications Those for whom cessation medications were recommended or discussed
- Discussing Cessation Strategies Those for whom cessation methods or strategies were provided or discussed

Percentage of Current Smokers is not a HEDIS performance measure, but provides additional information to support analysis of other MSC data. The MCOs started reporting this data in 2015 in CAHPS results; subsequently, the rates have been added to this report.

Access/Availability of Care Measures

The measures in the Access/Availability of Care domain evaluate how members access important and basic services of their MCO. Included are measures of overall access, how many members are actually using basic MCO services, and the use and availability of specific services.

Adults' Access to Preventive/Ambulatory Health Services (AAP) This measures the percentage of members 20 years and older who had an ambulatory or preventive care visit during the MY to assess whether adult members have access to/receive such services. MCOs report a total rate and three age stratifications:

♦ 20–44 years

• \geq 65 years

◆ 45–64 years

Note: Rates for adults 65 years of age and older are not included in this report as those services would be provided by Medicare. Because the total rate would include this age group, it has been excluded from this report as well.

<u>Children and Adolescents' Access to Primary Care</u> Practitioners (CAP)

CAP assesses general access to care for children and adolescents through the percentage of members 12 months to 6 years of age who had a visit with a PCP (e.g., pediatrician, family physician) during the MY, and members 7 to 19 years of age who had a visit with a PCP during the MY or the year prior. MCOs report four separate percentages:

• 12–24 months

- ◆ 7–11 years
- 25 months 6 years
- ◆ 12–19 years

<u>Initiation and Engagement of Alcohol and Other Drug</u> Dependence Treatment (IET)

IET assesses adolescent and adult members 13 years of age and older who demonstrated a new episode of alcohol or other drug (AOD) dependence and received the following:

- Initiation of AOD Treatment Initial treatment through an inpatient AOD admission, outpatient visit, intensive outpatient encounter or patient hospitalization within 14 days of diagnosis
- Engagement of AOD Treatment—Two or more services with an AOD diagnosis within 30 days of the initiation visit in addition to initiating treatment

MCOs report a total rate and two age stratifications for each:

♦ 13–17 years

♦ \geq 18 years

Prenatal and Postpartum Care (PPC)

PPC measures the percentage of live birth deliveries between November 6 of the year prior to the MY and November 5 of the MY. For these women, the composite assesses the percentage of deliveries where members received the following PPC facets:

- Timeliness of Prenatal Care—Received a prenatal care visit as a member of the MCO in the first trimester or within 42 days of MCO enrollment
- Postpartum Care—Had a postpartum visit on or between
 21 and 56 days after delivery

<u>Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)</u>

APP measures the percentage of children and adolescents 1 to 17 years of age who had a new prescription for an antipsychotic medication and had documentation of psychosocial care as

first-line treatment. MCOs report a total rate and three age stratifications:

◆ 1–5 years

◆ 12–17 years

◆ 6–11 years

Utilization and Risk-Adjusted Utilization

This domain name was adjusted for HEDIS 2017, but still consists of utilization measures designed to capture the frequency of certain services provided for MCOs' internal evaluation only; NCQA does not view higher or lower service counts as indicating better or worse performance. **Risk-Adjusted Utilization** measures are for commercial or Medicare lines, and so are not included in this report. Two kinds of measures are included in **Utilization**:

- Measures that express rates of service in per 1,000 member years/months (defined/reported in <u>Appendix A</u>)
- Measures as percentages of members receiving specified services (similar to Effectiveness of Care Domain, defined in this section with data in the <u>Results tables</u>)

The two Medicaid categories (Disabled and Low-Income) for Utilization Measures are reported separately and as a total rate. However, the total rate includes the category of Medicaid and Medicare dual eligibles, and those members are part of dual-eligible special needs plans (D-SNPs) reported separately to HCFA via Qsource's *Annual HEDIS D-SNPs Report*.

Frequency of Ongoing Prenatal Care (FPC)

FPC is the percentage of members who delivered a child between November 6 of the year prior to the MY and November 5 of the MY, and received the expected number of prenatal care visits. This measure uses the same denominator, structure and calculation guidelines as PPC. Rates are reported by the percentage of expected visits:

♦ < 21%

♦ 61−80%

◆ 21−40%

♦ ≥ 81%

◆ 41−60%

Well-Child Visits in the First 15 Months of Life (W15)

W15 assesses the percentage of members who turned 15 months old during the MY and who had the following number of well-child visits with a PCP during their first 15 months of life: zero, one, two, three, four, five, or six or more. This measure uses the same structure and calculation guidelines as those in the Effectiveness of Care domain.

Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)

W34 reports the percentage of members who were 3 to 6 years of age who had one or more well-child visits with a PCP during the MY. This measure uses the same structure and calculation guidelines as those in the Effectiveness of Care domain.

Adolescent Well-Care Visits (AWC)

AWC assesses the percentage of enrolled members 12 to 21 years of age who had at least one comprehensive well-care visit

with a PCP or an OB-GYN practitioner during the MY. This measure uses the same structure and calculation guidelines as those in the Effectiveness of Care domain.

Experience of Care

For a plan's results in this domain to be considered reliable, the Medicaid MCO must follow one of the standard CAHPS protocols or an enhanced protocol approved by NCQA. Details regarding this calculation methodology and the questions used in each composite are included in *HEDIS 2016, Volume 3: Specifications for Survey Measures*.

CAHPS Health Plan Survey 5.0H Adult Version (CPA) and 5.0H Child Version (CPC)

The CPA and CPC are tools for measuring consumer healthcare satisfaction with the quality of care and customer service provided by their MCOs.

These survey tools include five composites asked of members (CPA) or parents of child members (CPC):

- Getting Needed Care
- Getting Care Quickly
- How Well Doctors Communicate
- Customer Service
- Shared Decision Making

Each composite category represents an overall aspect of plan quality, how well the MCO meets members' expectations.

There are four global rating questions that use a 0–10 scale to assess overall experience:

- Rating of All Health Care
- Rating of Personal Doctor
- Rating of Specialist Seen Most Often
- Rating of Health Plan

For these scaled responses, a 0 represents the 'worst possible' and 10 represents the 'best possible' healthcare received in the last six months. Summary rates represent the percentage of members who responded with a 9 or 10. Additional Health Promotion and Education as well as Coordination of Care questions use the same calculations.

For any given CPA and CPC question used in a composite, the percentage of respondents answering in a certain way is calculated for each MCO. Summary rates represent the percentage of members who responded in the most positive way, as defined by NCQA. The following descriptions provide a brief explanation of the five composite categories.

Getting Needed Care

The Getting Needed Care Composite measures the ease with which members were able to access care, tests, or treatments needed in the last 6 months. The summary rate represents the percentage of members who responded 'Always' or 'Usually' to specified questions.

Getting Care Quickly

The Getting Care Quickly Composite measures the ease with which members were able to access care quickly, including getting appointments as soon as needed, in the last 6 months. The summary rate represents the percentage of members who responded 'Always' or 'Usually' to specified questions.

How Well Doctors Communicate

The How Well Doctors Communicate Composite evaluates provider-patient communications for the last 6 months by asking members how often their personal doctor listens carefully, explains things in a way to easily understand, shows respect for what they have to say and spends enough time with them. The summary rate represents the percentage of members who responded 'Always' or 'Usually' to specified questions.

Customer Service

The Customer Service Composite measures how often members were able to get information and help from an MCO and how well they were treated by the MCO's customer service in the last 6 months. The summary rate represents the percentage of members who responded 'Always' or 'Usually' to specified questions.

Shared Decision Making

The Shared Decision Making Composite measures how often doctors offered choices regarding healthcare, mentioned the good and bad things associated with each treatment option, the extent to which doctors requested input regarding healthcare preferences, and how often doctors involved members in the decision-making process, according to their preference. The summary rate represents the percentage of members who responded 'Yes' to specified questions. Means and variances are not calculated for this composite.

Children With Chronic Conditions (CCC)

The CAHPS Consortium decided in 2002 to integrate a new set of items in the 3.0H version of the CAHPS Health Plan Survey child questionnaires (now 5.0H) to better address the needs of children with chronic conditions, commonly referred to as children with special healthcare needs. CCC is designed for children with a chronic physical, developmental, behavioral or emotional condition and who also require health and related services of a type or amount beyond that generally required by children. Three composites summarize parents' satisfaction with basic components of care essential for successful treatment, management and support of children with chronic conditions:

- Access to Specialized Services
- Family Centered Care: Personal Doctor Who Knows Child
- Coordination of Care for CCC

Summary rates are reported for each composite and are reported individually for two concepts:

- Access to Prescription Medicines
- Family Centered Care: Getting Needed Information

Health Plan Descriptive Information Measures

These measures help describe an MCO's structure, staffing and enrollment—factors that contribute to its ability to provide effective healthcare to Medicaid members.

Enrollment by Product Line (ENP)

ENP reports the total number of members enrolled in the product line, stratified by age and gender (for the MCOs, reported as ENPA: Total Medicaid). These results are included in <u>Appendix D</u> as population in member months by MCO and Tennessee Grand Region served.

Measures Collected Using Electronic Clinical Data Systems (ECDS)

This domain requires automated and accessible data by the healthcare team at the point of care, data shared between clinicians and health plans to promote quality improvement across the care continuum. To qualify for HEDIS ECDS reporting, the data must use standard layouts, meet the measure specification requirements and the information must be accessible by the care team responsible for the member's healthcare needs.

This domain is not required to be reported by the MCOs, hence, not included in this report.

Medicaid Results

Statewide Performance

In conjunction with NCQA accreditation, TennCare MCOs are required to submit a full set of audited HEDIS measures to NCQA and TennCare each year. For HEDIS 2017, this included the statewide MCO Volunteer State Health Plan, Inc., doing business as TennCareSelect (TCS), and three statewide MCOs doing business in each respective Grand Region (East, Middle and West): Amerigroup Community Care, Inc., as Amerigroup (AG—AGE, AGM and AGW); Volunteer State Health Plan, Inc., as BlueCare Tennessee (BC—BCE, BCM and BCW); and UnitedHealthcare Plan of the River Valley, Inc., as UnitedHealthcare (UHC—UHCE, UHCM and UHCW).

Tables 1 (a and b), 2 and 3 summarize the weighted average TennCare score for each of the selected HEDIS 2016 and HEDIS 2017 measures as well as the HEDIS 2016 Medicaid National Average. The Medicaid National Average represents the sum of the reported rates divided by the total number of health plans

reporting the rate. Weighted state rates are determined by applying the size of the eligible population within each plan to their overall results. Using this methodology, plan-specific findings contribute to the TennCare statewide estimate, proportionate to eligible population size.

Where possible in **Tables 1** (a and b), 2 and 3, the statewide changes for each measure reported during both HEDIS 2016 and HEDIS 2017 are presented. The column titled 'Change 2016 to 2017' indicates whether there was an improvement (♠) or a decline (♣) in statewide performance for the measure from HEDIS 2016 to HEDIS 2017. Cells are shaded gray for those measures that were not calculated or for which data were not reported. Each year some measures' technical specifications change. Based on whether the changes are significant or minor, the measures may need to be trended with caution or may not be able to be trended. At the time this report was finalized, NCQA did not determine the ability for 2017 measures to be trended.

Table 1a. HEDIS 2017 State to National Medicaid Rates: Effectiveness of Care Measures						
	Weighted	State Rate	HEDIS 2016	Change		
Measure	2016	2017	Medicaid National Avg.	2016 to 2017		
Prevention and Screening						
Adult BMI Assessment (ABA)	82.46%	86.96%	80.77%	1		
Weight Assessment and Counseling for Nutrition and Physical Activity for Child	dren/Adolesce	ents (WCC):				
BMI Percentile: 3–11 years	71.33%	75.08%	64.83%	1		
12–17 years	65.74%	71.33%	63.19%	•		
Total	69.55%	73.88%	64.37%	•		
Counseling for Nutrition: 3–11 years	62.76%	66.25%	61.62%	1		
12–17 years	54.98%	61.33%	57.30%			
Total	60.29%	64.66%	60.22%	1		
Counseling for Physical Activity: 3–11 years	53.08%	55.64%	52.40%	+		
12–17 years	54.47%	59.45%	55.24%	+		
Total	53.59%	56.89%	53.44%	1		
Childhood Immunization Status (CIS):						
DTaP/DT	76.91%	73.60%	76.33%	•		
IPV	91.23%	89.47%	87.70%	•		
MMR	88.46%	86.49%	89.21%	+		
HiB	88.77%	86.28%	87.62%	+		
НерВ	92.14%	90.60%	87.70%	+		
VZV	88.52%	86.55%	88.79%	+		
PCV	79.20%	75.52%	76.53%			
НерА	87.18%	85.67%	83.70%	+		
RV	69.62%	68.68%	67.94%	+		
Influenza	42.86%	37.56%	45.74%	+		
Combination 2	74.27%	70.82%	72.46%	+		
Combination 3	71.08%	68.02%	68.99%	+		
Combination 4	70.27%	67.66%	65.91%	+		

	Weighted	State Rate	HEDIS 2016	Change
Measure	2016	2017	Medicaid National Avg.	2016 to 2017
Combination 5	57.87%	56.44%	57.21%	
Combination 6	37.28%	32.31%	39.01%	
Combination 7	57.32%	56.20%	55.17%	
Combination 8	37.02%	32.19%	38.01%	•
Combination 9	31.78%	28.06%	33.86%	•
Combination 10	31.64%	27.94%	33.24%	
Immunizations for Adolescents (IMA):	·		•	
Meningococcal	67.84%	69.74%	74.79%	1
Tdap/Td	81.80%	82.75%	83.36%	1
HPV*	15.89%	13.23%	22.71%	•
Combination 1	67.13%	68.87%	72.66%	1
Combination 2**		12.55%		
Lead Screening in Children (LSC)	70.29%	70.64%	66.50%	1
Breast Cancer Screening (BCS)	54.47%	54.90%	58.50%	1
Cervical Cancer Screening (CCS)	55.60%	59.21%	55.85%	1
Chlamydia Screening in Women (CHL):				
16-20 years	48.17%	49.57%	51.49%	1
21–24 years	54.61%	57.38%	60.65%	1
Total	51.19%	52.76%	55.27%	•
Respiratory Conditions				
Appropriate Testing for Children With Pharyngitis (CWP)	79.45%	82.67%	71.12%	1
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	31.36%	31.72%	30.96%	1
Pharmacotherapy Management of COPD Exacerbation (PCE):				
Systemic corticosteroid	52.23%	47.75%	67.10%	+
Bronchodilator	75.41%	72.71%	79.92%	•

	Weighted		HEDIS 2016	Change
Measure	2016	2017	Medicaid National Avg.	2016 to 2017
Medication Management for People With Asthma (MMA):	<u>.</u>			_
Medication Compliance 50%***: 5–11 years	54.71%	50.03%		•
12–18 years	51.61%	51.10%		•
19–50 years	60.00%	54.39%		
51–64 years	66.13%	65.73%		•
Total	55.05%	51.60%		
Medication Compliance 75%: 5–11 years	26.87%	24.38%	28.33%	•
12–18 years	26.63%	25.20%	26.33%	
19–50 years	38.38%	30.06%	37.72%	•
51–64 years	42.90%	46.15%	50.01%	•
Total	29.35%	26.28%	32.67%	
Asthma Medical Ratio (AMR):			•	
5–11 years	77.09%	80.13%	70.15%	1
12–18 years	64.97%	71.17%	59.13%	•
19–50 years	48.93%	44.53%	48.90%	•
51–64 years	45.36%	45.32%	51.72%	
Total	66.25%	67.93%	59.67%	•
Cardiovascular Conditions				
Controlling High Blood Pressure (CBP)	55.10%	55.63%	54.74%	•
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	75.75%	79.19%	80.43%	•
Statin Therapy for Patients with Cardiovascular disease (SPC)†:			•	
Received Statin Therapy: Males 21–75 years	66.61%	70.66%		
Females 40–75 years	66.05%	66.32%		
Total	66.34%	68.50%		
Statin Adherence 80%: Males 21-75 years	56.17%	57.13%		
Females 40–75 years	50.77%	53.09%		
Total	53.56%	55.19%		

	Weighted	State Rate	HEDIS 2016 Medicaid National Avg.	Change 2016 to 2017
Measure	2016	2017		
Diabetes				
Comprehensive Diabetes Care (CDC):				
HbA1c Testing	82.59%	82.51%	85.94%	#
HbA1c Control (<7.0%)	34.64%	37.43%	32.36%	1
HbA1c Control (<8.0%)	47.62%	49.07%	45.54%	•
Retinal Eye Exam Performed	42.87%	44.87%	52.68%	•
Medical Attention for Nephropathy	90.89%	89.06%	90.01%	•
Blood Pressure Control (<140/90 mm Hg)	58.22%	58.35%	59.04%	1
Statin Therapy for Patients with Diabetes (SPD)†	•	•	•	
Received Statin Therapy: 40-75 years	53.06%	54.06%		1
Statin Adherence 80%: 40–75 years	48.03%	50.57%		1
Musculoskeletal Conditions				
Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)	62.66%	63.65%	71.69%	1
Behavioral Health				
Antidepressant Medication Management (AMM):				
Effective Acute Phase Treatment	47.75%	46.52%	54.45%	
Effective Continuation Phase Treatment	32.19%	30.56%	39.44%	•
Follow-Up Care for Children Prescribed ADHD Medication (ADD):			•	
Initiation Phase	49.26%	44.95%	42.20%	#
Continuation and Maintenance Phase	63.14%	59.45%	50.93%	
Follow-Up After Hospitalization for Mental Illness (FUH):				
7-Day Follow-Up	55.95%	58.82%	43.71%	
30-Day Follow-Up	70.63%	71.29%	61.29%	•

	Weighted	State Rate	HEDIS 2016	Change
Measure	2016	2017	Medicaid National Avg.	2016 to 2017
Follow-Up After Emergency Department Visit for Mental Illness (FUM)**:				
7-Day Follow-Up		36.45%		
30-Day Follow-Up		56.59%		
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Depend	ence (FUA)	**:		
7-Day Follow-Up: 13–17 years		11.96%		
18 years and older		8.37%		
Total		8.66%		
30-Day Follow-Up: 13–17 years		17.28%		
18 years and older		10.64%		
Total		11.19%		
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	81.20%	82.51%	80.37%	•
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	69.70%	70.29%	68.20%	•
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	82.89%	80.49%	78.47%	+
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	58.62%	58.68%	57.88%	+
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM):				
1–5 Years	13.59%	13.33%	16.70%	
6–11 Years	28.71%	27.92%	26.16%	+
12–17 Years	37.69%	37.93%	32.05%	1
Total	34.10%	34.12%	29.84%	1
Medication Management				
Annual Monitoring for Patients on Persistent Medications (MPM):				
ACE Inhibitors or ARBs	90.46%	90.30%	87.51%	+
Digoxin	54.95%	58.22%	54.01%	•
Diuretics	90.92%	90.70%	87.49%	

Table 1a. HEDIS 2017 State to National Medicaid Rates: Effectiveness of Care Measures					
	Weighted	State Rate	HEDIS 2016	Change	
Measure	2016	2017	Medicaid National Avg.	2016 to 2017	
Total	90.31%	90.22%	87.28%	+	
Overuse/Appropriateness					
Appropriate Treatment for Children With Upper Respiratory Infection (URI)	79.25%	81.85%	87.76%	•	
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)	30.49%	32.61%	28.09%	•	
Use of Imaging Studies for Low Back Pain (LBP)	65.56%	61.94%	73.57%	•	
Measures Collected Though CAHPS					
Flu vaccinations for adults ages 18 to 64 (FVA)	36.92%	40.31%	38.46%	•	
Medical Assistance With Smoking and Tobacco Use Cessation (MSC):					
Advising Smokers and Tobacco Users to Quit	77.05%	77.12%	75.89%	•	
Discussing Cessation Medications	43.01%	44.72%	48.12%	•	
Discussing Cessation Strategies	38.28%	38.55%	43.28%	•	
Supplemental Data - % Current Smokers††	37.28%	36.94%	31.02%		

^{*}For HEDIS 2017, the HPV measure was integrated into the IMA measure for reporting purposes and expanded to both genders.

†Benchmarks are not reported by Quality Compass for 2016 first-year measures.

†† For this measure, rate is not intended to indicate good or poor performance, but for informative purposes to monitor population of current smokers.

For the Effectiveness of Care Measures presented in **Table 1b**, a lower rate (particularly one below the national average) is an indication of better performance (1). A decrease in rates from the prior year also indicates improvement.

Table 1b. HEDIS 2017 State to National Medicaid Rates: Measures Where Lower Rates Indicate Better Performance					
		State Rate			
Measure	2016 2017			2016 to 2017	
Diabetes					
Comprehensive Diabetes Care (CDC):					
HbA1c Poor Control (>9.0%)	43.23%	41.92%	45.35%	•	

^{**}First-year measure.

^{***}Benchmarks are currently not reported by Quality Compass for this rate.

Table 1b. HEDIS 2017 State to National Medicaid Rates: Measures Where Lower Rates Indicate Better Performance					
	Weighted	State Rate	HEDIS 2016	Change	
Measure	2016	2017	Medicaid 2 National Avg.	2016 to 2017	
Overuse/Appropriateness					
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)	5.25%	3.83%	2.71%	•	
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC):					
1–5 Years	1.49%	2.94%	0.66%	+	
6-11 Years	1.71%	1.77%	1.82%	-	
12–17 Years	3.41%	3.22%	3.00%	•	
Total	2.78%	2.72%	2.49%	•	

 $\label{thm:constraints} \textbf{Table 2} \ \text{summarizes results for the Access/Availability Domain of Care}.$

Table 2. HEDIS 2017 State to National Medicaid Rates: Access/Availability of Care Measures					
Management	Weighted State Rat		HEDIS 2016	Change	
Measure	2016	2017	Medicaid National Avg.	2016 to 2017	
Adults' Access to Preventive/Ambulatory Health Services (AAP):					
20-44 years	73.00%	74.37%	77.27%		
45–64 years	84.97%	85.11%	85.52%	+	
Children and Adolescents' Access to Primary Care Practitioners (CAP):					
12–24 months	91.77%	93.70%	94.69%		
25 months-6 years	85.15%	84.48%	87.24%	•	
7–11 years	91.15%	89.55%	90.23%	+	
12–19 years	87.78%	86.19%	88.60%	+	
Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatm	ent (IET):				
Initiation of AOD Treatment: 13–17 years	49.11%	48.29%	42.25%	•	
≥18 years	33.36%	35.62%	37.94%	•	
Total	34.22%	36.30%	38.23%	•	

Table 2. HEDIS 2017 State to National Medicaid Rates: Access/Availability of Care Measures						
Measure	Weighted State Rate		HEDIS 2016	Change		
	2016	2017	Medicaid National Avg.	2016 to 2017		
Engagement of AOD Treatment: 13–17 years	25.96%	25.65%	15.44%	•		
≥18 years	8.70%	10.34%	9.69%	•		
Total	9.64%	11.16%	10.23%	•		
Prenatal and Postpartum Care (PPC):						
Timeliness of Prenatal Care	76.34%	76.94%	80.03%	•		
Postpartum Care	55.57%	59.35%	60.93%	•		
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP):						
1–5 Years	30.51%	39.18%	49.04%	•		
6-11 Years	53.91%	53.69%	58.83%	•		
12–17 Years	53.50%	58.23%	59.12%	•		
Total	52.80%	56.04%	57.44%	1		

Table 3 summarizes results for the Utilization measures included in the Utilization and Risk-Adjusted Utilization Domain of Care.

Table 3. HEDIS 2017 State to National Medicaid Rates: Utilization Measures							
Measure	Weighted State Rate		HEDIS 2016 Medicaid	Change 2016 to			
	2016	2017	National Avg.				
Frequency of Ongoing Prenatal Care (FPC):							
≥ 81 percent	55.51%	57.09%	56.61%	+			
Well-Child Visits in the First 15 Months of Life (W15):							
6 or More Visits	57.63%	60.94%	59.35%	1			
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)	68.01%	69.18%	71.27%	1			
Adolescent Well-Care Visits (AWC)	42.34%	46.61%	48.89%	1			

Individual Plan Performance—HEDIS Measures

This section is intended to provide an overview of individual plan performance using appropriate and available comparison data. The results highlight those areas where each MCO is performing in relation to the HEDIS 2016 National Medicaid Means and Percentiles for select MCO-reported HEDIS measures. Qsource uses these data to determine overall TennCare plan performance in a distribution of statistical values that represent the lowest to highest percentiles achieved. For example, the 50th percentile represents the point at which half of the reported rates are below and half of the reported rates are above that value.

Tables 5 (a and b), 6 and 7 display the plan-specific performance rates for each measure selected from the Effectiveness of Care, Access/Availability of Care, and Utilization and Risk-Adjusted Utilization domains. **Table 4** details the potential color-coding and measure designations used in **Tables 5a** through 7 to indicate the rating of the MCO percentile achieved, and provides additional related comments. While Medical Assistance With Smoking and Tobacco Use Cessation is an Effectiveness of Care measure, results are reported through the CPA as noted in **Tables 1a** and **5a**.

Table 4. HEDIS 2017 F	Rating Color and Measure De	signations
Color Designation	Percentile MCO Achieved	Additional Comments
	Greater than 75th	No additional comments
	25th to 75th	No additional comments
	Less than 25th	No additional comments
	No Rating Available	Benchmarking data not available
Measure Designation		Definition
R	Reportable, a reportable rate wa	s submitted for the measure.
NA		Il denominator, i.e., the MCO followed the specifications, but <30) to report a valid rate, hence results are not presented.
NB	No Benefit, the MCO did not offe health, chemical dependency).	r the health benefit required by the measure (e.g., mental
NR	Not Reported, the MCO chose no	t to report the measure.
NQ	Not Required, the MCO was not	required to report the measure.

Table 4. HEDIS 201	Table 4. HEDIS 2017 Rating Color and Measure Designations									
BR	Biased Rate, the calculated rate was materially biased.									
UN	Un-Audited, the MCO chose to report a measure that is not required to be audited. This result applies to only a limited set of measures.									

Table 5a. HEDIS 2017 Plan-S	pecific N	Medicaid	Rates: I	Effective	ness of	Care Me	asures				
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UНСМ	UHCW	HEDIS 2016 National Medicaid 50th Percentile
Prevention and Screening											
Adult BMI Assessment (ABA)	81.21%	90.02%	89.33%	81.48%	82.77%	90.00%	65.57%	93.48%	88.08%	87.77%	84.54%
Weight Assessment and Counse	ling for N	lutrition a	and Physi	ical Activ	ity for Ch	ildren/A	dolescent	ts (WCC)	•		
BMI Percentile: 3-11 years	74.91%	84.56%	79.04%	67.83%	69.45%	75.27%	70.00%	72.30%	79.06%	77.36%	68.22%
12–17 years	67.32%	72.39%	78.01%	70.40%	71.85%	77.21%	66.30%	64.00%	66.67%	80.71%	65.74%
Total	72.22%	80.79%	78.70%	68.61%	70.24%	75.91%	68.37%	69.73%	75.52%	78.52%	67.54%
Counseling for Nutrition: 3–11 years	63.08%	77.52%	69.07%	61.19%	60.36%	69.09%	51.30%	66.91%	70.40%	64.91%	63.33%
12–17 years	58.82%	56.72%	68.79%	62.40%	61.48%	64.71%	54.14%	56.80%	62.16%	67.86%	57.35%
Total	61.57%	71.06%	68.98%	61.56%	60.73%	67.64%	52.55%	63.77%	68.04%	65.93%	62.65%
Counseling for Physical Activity: 3–11 years	53.05%	69.80%	57.39%	47.55%	50.55%	61.45%	41.74%	56.12%	60.29%	50.19%	53.99%
12–17 years	58.17%	54.48%	63.12%	60.00%	61.48%	66.18%	50.28%	56.00%	59.46%	64.29%	55.75%
Total	54.86%	65.05%	59.26%	51.34%	54.15%	63.02%	45.50%	56.08%	60.05%	55.06%	55.38%
Childhood Immunization Status	(CIS):										
DTaP/DT	67.13%	75.23%	68.52%	77.62%	72.75%	72.51%	64.23%	78.35%	77.37%	69.83%	77.97%
IPV	86.34%	90.05%	87.27%	92.21%	90.75%	87.59%	80.05%	92.21%	91.48%	87.10%	89.78%
MMR	82.41%	88.19%	86.57%	89.29%	87.10%	84.91%	76.40%	90.02%	86.13%	84.18%	90.47%

Table 5a. HEDIS 2017 Plan-Specific Medicaid Rates: Effectiveness of Care Measures											
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UНСМ	UHCW	HEDIS 2016 National Medicaid 50th Percentile
HiB	81.25%	87.27%	83.56%	89.78%	86.13%	86.37%	76.16%	89.29%	87.35%	84.43%	89.37%
НерВ	88.43%	90.51%	90.51%	94.16%	89.78%	88.81%	80.05%	93.92%	91.48%	89.05%	90.05%
VZV	81.48%	88.89%	85.65%	88.81%	88.56%	84.43%	75.18%	90.02%	88.56%	82.24%	89.97%
PCV	68.75%	78.01%	68.06%	79.56%	75.91%	72.26%	68.37%	79.56%	81.75%	70.56%	78.59%
НерА	80.56%	87.96%	86.34%	88.08%	87.35%	83.45%	75.18%	89.54%	85.89%	82.00%	84.91%
RV	55.56%	74.77%	58.56%	72.02%	68.13%	68.86%	45.74%	72.99%	76.89%	65.45%	69.34%
Flu	31.25%	49.54%	21.76%	44.04%	43.31%	25.30%	41.85%	38.93%	45.99%	23.11%	45.99%
Combination 2	63.66%	73.15%	65.51%	76.16%	70.80%	69.34%	60.34%	75.18%	73.72%	66.18%	75.18%
Combination 3	59.49%	71.30%	61.81%	74.21%	68.13%	65.45%	57.91%	71.78%	71.78%	63.02%	71.06%
Combination 4	58.56%	71.06%	61.81%	73.48%	67.64%	65.45%	57.66%	71.29%	71.53%	62.77%	67.96%
Combination 5	41.20%	62.27%	47.69%	60.34%	55.47%	57.42%	35.04%	59.12%	65.69%	52.55%	58.98%
Combination 6	26.39%	43.52%	17.59%	38.69%	35.52%	19.95%	33.82%	34.79%	41.12%	19.95%	39.14%
Combination 7	40.97%	62.04%	47.69%	60.10%	54.99%	57.42%	35.04%	58.64%	65.45%	52.31%	56.85%
Combination 8	26.39%	43.29%	17.59%	38.44%	35.28%	19.95%	33.82%	34.55%	41.12%	19.95%	38.20%
Combination 9	21.30%	39.35%	14.81%	32.85%	31.39%	18.25%	21.17%	29.93%	37.47%	16.79%	33.10%
Combination 10	21.30%	39.12%	14.81%	32.60%	31.14%	18.25%	21.17%	29.68%	37.47%	16.79%	32.64%
Immunization for Adolescents (IMA):										
Meningococcal	71.30%	70.83%	68.52%	71.53%	71.29%	71.05%	67.40%	65.45%	69.83%	68.13%	77.21%
Tdap/Td	83.10%	83.80%	81.25%	85.40%	84.67%	85.16%	77.62%	78.83%	83.70%	80.78%	86.14%
HPV*	12.73%	13.89%	10.19%	17.76%	13.38%	10.46%	11.19%	12.90%	16.30%	11.44%	22.30%
Combination 1	70.37%	69.91%	67.82%	71.05%	69.83%	70.80%	66.91%	64.72%	68.13%	67.40%	74.52%
Combination 2**	12.27%	13.19%	10.19%	16.55%	12.65%	10.46%	9.98%	11.92%	15.33%	10.95%	
Lead Screening in Children (LSC)	62.27%	73.15%	65.51%	75.67%	69.34%	66.18%	62.77%	77.62%	75.91%	65.21%	71.05%
Breast Cancer Screening (BCS)	34.89%	48.58%	43.68%	60.65%	56.93%	60.18%	60.18%	57.73%	51.59%	49.93%	58.08%
Cervical Cancer Screening (CCS)	35.58%	58.60%	49.07%	67.23%	59.61%	67.65%	28.47%	60.93%	67.78%	61.56%	55.94%

Table 5a. HEDIS 2017 Plan-Specific Medicaid Rates: Effectiveness of Care Measures											
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	HEDIS 2016 National Medicaid 50th Percentile
Chlamydia Screening in Women	(CHL):										
16–20 years	48.69%	48.69%	55.04%	44.31%	53.08%	51.30%	52.95%	45.94%	50.77%	49.83%	50.56%
21–24 years	55.77%	57.51%	63.42%	48.76%	56.76%	61.29%	38.65%	55.65%	59.02%	62.79%	61.37%
Total	52.12%	52.11%	59.25%	46.17%	54.85%	55.35%	52.12%	49.40%	53.93%	55.20%	55.16%
Respiratory Conditions											
Appropriate Testing for Children with Pharyngitis (CWP)	72.20%	79.73%	74.65%	84.41%	91.16%	85.03%	85.06%	79.08%	88.26%	82.13%	71.62%
Use of Spirometry Testing in the	Assessn	nent and									
Diagnosis of COPD (SPR)	26.42%	29.24%	46.67%	32.35%	33.72%	39.34%	NA	30.10%	27.72%	36.33%	30.26%
Pharmacotherapy Management	of COPD	Exacerba	tion (PCE	:):							
Systemic corticosteroid	51.53%	48.65%	59.00%	45.12%	42.52%	43.27%	NA	49.66%	46.13%	49.84%	70.39%
Bronchodilator	71.85%	75.03%	76.60%	72.05%	66.51%	75.40%	NA	74.00%	72.04%	73.46%	83.70%
Medication Management for Peo	ple With	Asthma ((MMA):								
Medication Compliance 50%***: 5–11 years	52.72%	50.78%	36.90%	58.47%	48.71%	46.83%	52.74%	48.53%	50.26%	45.41%	
12–18 years	51.81%	54.30%	43.49%	56.53%	48.78%	44.94%	61.75%	46.65%	49.64%	44.15%	
19–50 years	55.02%	55.65%	44.70%	58.04%	49.23%	53.24%	60.00%	61.36%	56.80%	48.09%	
51-64 years	NA	71.19%	51.11%	58.33%	85.71%	53.85%	NA	67.11%	74.51%	59.52%	
Total	53.39%	53.46%	40.88%	57.78%	49.61%	47.72%	57.27%	51.48%	52.28%	46.10%	
Medication Compliance 75% : 5-11 years	25.68%	26.16%	14.62%	32.13%	20.74%	20.29%	31.75%	22.27%	24.29%	19.51%	25.88%
12–18 years	23.68%	27.04%	17.81%	31.56%	22.45%	20.60%	38.65%	15.94%	27.82%	16.08%	25.00%
19–50 years	32.75%	33.06%	21.59%	30.65%	24.15%	29.58%	38.89%	36.81%	34.02%	20.99%	36.25%
51–64 years	47.37%	47.46%	31.11%	37.50%	57.14%	40.38%	50.00%	48.68%	62.75%	42.86%	49.48%
Total	26.78%	28.57%	17.64%	31.80%	22.67%	22.76%	35.38%	24.67%	28.55%	19.67%	31.28%

Table 5a. HEDIS 2017 Plan-Specific Medicaid Rates: Effectiveness of Care Measures											
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UНСМ	UHCW	HEDIS 2016 National Medicaid 50th Percentile
Asthma Medical Ratio (AMR):											
5–11 years	77.63%	78.53%	65.68%	86.10%	80.48%	82.83%	83.45%	83.33%	79.68%	74.21%	71.74%
12–18 years	68.64%	66.67%	68.13%	79.21%	71.32%	72.18%	76.41%	68.82%	64.66%	64.66%	60.50%
19–50 years	41.16%	44.95%	39.48%	50.24%	33.93%	41.32%	65.74%	51.59%	46.91%	41.99%	49.00%
51–64 years	38.46%	43.01%	47.62%	36.36%	45.83%	47.22%	NA	51.69%	52.63%	38.89%	52.03%
Total	65.01%	65.34%	58.08%	75.40%	64.94%	68.59%	78.70%	69.58%	66.05%	61.88%	61.26%
Cardiovascular Conditions											
Controlling High Blood Pressure (CBP)	48.49%	51.51%	45.94%	63.54%	60.98%	60.10%	64.47%	59.18%	47.56%	52.55%	54.78%
Persistence of Beta-Blocker Treatment after a Heart Attack (PBH)	60.76%	79.79%	54.17%	88.89%	62.50%	80.39%	NA	91.84%	88.73%	85.71%	83.06%
Statin Therapy for Patients with	Cardiova	ascular di	isease (S	PC)†:							
Received Statin Therapy: Males 21–75 years	67.77%	72.46%	74.15%	67.91%	68.03%	69.10%	NA	73.21%	69.02%	72.76%	
Females 40–75 years	69.89%	65.44%	68.91%	64.86%	65.79%	61.59%	NA	68.38%	65.41%	68.42%	
Total	68.66%	69.33%	71.79%	66.31%	66.93%	64.94%	NA	70.84%	67.13%	70.61%	
Statin Adherence 80%: Males 21–75 years	50.00%	61.73%	44.00%	54.07%	45.11%	44.73%	NA	65.99%	64.59%	56.28%	
Females 40–75 years	39.02%	55.28%	39.10%	47.71%	42.00%	34.22%	NA	66.57%	60.58%	55.92%	
Total	45.30%	59.02%	41.88%	50.80%	43.60%	39.20%	NA	66.26%	62.55%	56.11%	
Diabetes											
Comprehensive Diabetes Care (CDC):										
HbA1c Testing	78.11%	86.11%	80.92%	82.57%	81.09%	82.38%	70.81%	85.67%	80.97%	82.00%	85.95%
HbA1c Control (<7.0%)	36.03%	38.32%	35.06%	39.90%	34.31%	35.77%	36.05%	42.02%	35.29%	35.04%	33.82%
HbA1c Control (<8.0%)	40.63%	48.83%	41.49%	50.59%	47.36%	44.80%	42.44%	58.22%	50.67%	48.78%	46.76%
Retinal Eye Exam Performed	28.69%	43.86%	34.98%	48.56%	36.97%	53.86%	54.24%	55.11%	40.61%	43.44%	53.28%

Table 5a. HEDIS 2017 Plan-S	pecific I	Medicaid	Rates:	Effective	eness of	Care Me	asures				
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	ИНСМ	UHCW	HEDIS 2016 National Medicaid 50th Percentile
Medical Attention for Nephropathy	89.55%	88.16%	90.94%	90.02%	88.93%	87.92%	73.29%	90.00%	87.52%	90.00%	90.51%
BP Control (<140/90 mm Hg)	54.39%	59.80%	50.08%	66.16%	59.45%	55.03%	62.73%	60.89%	57.45%	52.78%	59.73%
Statin Therapy for Patients with	Diabetes	s (SPD)†:					•			•	
Received Statin Therapy: 40–75 yrs	52.95%	54.89%	56.63%	53.35%	50.84%	53.80%	48.00%	56.31%	52.10%	54.71%	
Statin Adherence 80%: 40–75 yrs.	45.31%	56.41%	38.99%	44.51%	41.29%	36.39%	83.33%	59.77%	60.34%	55.21%	
Musculoskeletal Conditions											
Disease-Modifying Anti-Rheuma	tic Drug	Therapy	for								
Rheumatoid Arthritis (ART)	65.41%	63.99%	57.42%	70.00%	53.21%	63.76%	NA	69.58%	58.17%	55.87%	72.22%
Behavioral Health											
Antidepressant Medication Mana	agement	(AMM):									
Effective Acute Phase Treatment	52.15%	50.28%	44.99%	45.53%	42.74%	38.00%	38.58%	51.47%	47.48%	44.56%	53.38%
Effective Continuation Phase Treatment	36.80%	36.13%	29.55%	28.00%	27.23%	21.98%	19.69%	34.59%	31.83%	28.72%	38.06%
Follow-Up Care for Children Pres	scribed A	DHD Med	lication (ADD):							
Initiation Phase	45.41%	48.51%	34.28%	47.25%	41.70%	38.79%	40.69%	55.09%	54.63%	41.34%	42.19%
Continuation and Maintenance Phase	60.81%	60.85%	48.84%	60.63%	57.87%	57.20%	50.00%	71.43%	64.48%	62.50%	52.47%
Follow-Up After Hospitalization	for Menta	al Illness	(FUH):								
7-Day Follow-Up	55.19%	50.48%	57.55%	65.01%	46.51%	66.58%	62.48%	64.02%	55.38%	65.48%	44.05%
30-Day Follow-Up	69.26%	68.58%	64.81%	76.80%	59.31%	77.26%	74.28%	77.26%	69.88%	75.19%	63.94%
Follow-Up After Emergency Dep	artment	Visit for N	Mental III	ness (FU	M)**:						
7-Day Follow-Up	25.09%	36.86%	19.18%	38.89%	33.02%	32.74%	48.24%	BR	BR	BR	
30-Day Follow-Up	40.94%	49.38%	38.36%	61.73%	51.14%	58.11%	69.84%	BR	BR	BR	
Follow-Up After Emergency Dep	artment		Alcohol a		Drug Dep	endence		:	ı	ı	
7-Day Follow-Up: 13-17 years	NA	2.22%	NA	6.12%	17.07%	NA	21.19%	BR	BR	BR	
18 years and older	2.83%	3.08%	5.90%	10.15%	11.81%	16.51%	9.86%	BR	BR	BR	
Total	2.71%	3.01%	5.74%	9.90%	12.07%	15.82%	16.93%	BR	BR	BR	

Table 5a. HEDIS 2017 Plan-S	pecific N	/ledicaid	Rates:	Effective	eness of	Care Me	asures				
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	HEDIS 2016 National Medicaid 50th Percentile
30-Day Follow-Up: 13-17 years	NA	6.67%	NA	14.29%	21.95%	NA	27.12%	BR	BR	BR	
18 years and older	4.16%	4.82%	6.94%	13.13%	14.82%	19.31%	11.27%	BR	BR	BR	
Total	4.15%	4.96%	6.76%	13.20%	15.17%	18.51%	21.16%	BR	BR	BR	
Diabetes Screening for People W	/ith Schiz	ophrenia	or Bipol	ar Disord	er Who A	re Using					
Antipsychotic Medication (SSD)	82.44%	82.71%	78.20%	83.12%	80.79%	81.01%	82.39%	86.04%	86.51%	78.99%	80.72%
Diabetes Monitoring for People V	With Diab	etes									
and Schizophrenia (SMD)	62.22%	78.45%	62.43%	70.85%	72.41%	64.48%	71.43%	75.00%	71.15%	69.59%	68.93%
Cardiovascular Monitoring for Pe	eople Wit	h		•		•					•
Schizophrenia (SMC)	NA	NA	NA	78.33%	NA	82.46%	NA	81.67%	75.41%	80.39%	80.00%
Adherence to Antipsychotic Med	ications f	for Indivi	duals	•			•				
With Schizophrenia (SAA)	52.30%	62.85%	44.85%	66.08%	49.07%	56.08%	72.24%	59.33%	71.01%	56.67%	59.79%
Metabolic Monitoring for Childre	n and Ad	olescents	on Anti	psychotic	s (APM):						•
1–5 Years	NA	NA	NA	14.29%	NA	NA	11.11%	NA	NA	NA	15.33%
6–11 Years	31.16%	31.46%	16.67%	33.56%	27.31%	17.22%	29.65%	27.53%	27.05%	21.26%	25.19%
12–17 Years	30.67%	35.20%	27.41%	36.11%	37.04%	29.38%	44.28%	38.81%	31.03%	22.61%	32.33%
Total	30.65%	33.73%	22.83%	34.49%	32.91%	24.37%	39.60%	34.19%	29.00%	22.00%	29.63%
Medication Management											
Annual Monitoring for Patients o	n Persist	tent Medi	cations (MPM):							
ACE Inhibitors or ARBs	90.25%	89.21%	90.11%	89.49%	85.65%	89.51%	84.71%	93.06%	90.60%	92.72%	87.43%
Digoxin	60.61%	44.19%	55.10%	52.00%	43.90%	65.43%	NA	59.12%	64.52%	67.26%	53.94%
Diuretics	90.42%	89.93%	89.28%	90.85%	86.63%	88.72%	88.89%	93.88%	91.85%	92.32%	87.52%
Total	90.13%	89.10%	89.43%	89.86%	85.87%	88.89%	86.00%	93.09%	90.88%	92.24%	87.23%
Overuse/Appropriateness											
Appropriate Treatment for Childs	ren with	Upper									
Respiratory Infection (URI)	76.90%		79.35%	79.16%	85.88%	74.06%	79.60%	77.22%	87.68%	81.53%	89.39%

Table 5a. HEDIS 2017 Plan-Specific Medicaid Rates: Effectiveness of Care Measures												
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	HEDIS 2016 National Medicaid 50th Percentile	
Avoidance of Antibiotic Treatme	nt in Adu	Its with A	Acute									
Bronchitis (AAB)	27.91%	29.69%	32.78%	30.88%	37.21%	33.74%	36.57%	33.18%	33.02%	36.00%	26.17%	
Use of Imaging Studies for Low Back Pain (LBP)	67.36%	68.40%	69.65%	58.29%	60.89%	62.57%	63.79%	57.42%	57.04%	58.29%	73.71%	
Measures Collected Through CA	HPS Heal	th Plan S	urvey									
Flu vaccinations for adults ages 18 to 64 (FVA)	35.62%	45.27%	31.29%	39.43%	40.00%	40.96%	36.13%	40.06%	44.69%	44.55%	38.03%	
Medical Assistance with Smokin	g and Tol	oacco Use	e Cessatio	on (MSC)	:							
Advising Smokers and Tobacco Users to Quit	70.94%	77.36%	74.53%	81.39%	77.27%	79.44%	NA	77.25%	81.14%	80.08%	76.59%	
Discussing Cessation Medications	37.97%	45.21%	37.50%	51.47%	42.35%	48.90%	NA	50.80%	45.07%	45.57%	48.31%	
Discussing Cessation Strategies	30.70%	42.37%	31.58%	44.44%	39.90%	46.15%	NA	38.34%	39.64%	38.79%	43.82%	
Supplemental Data - % Current Smokers††	50.49%	33.87%	36.30%	44.38%	42.45%	33.45%	18.54%	38.19%	35.20%	29.97%	31.68%	

^{*}For HEDIS 2017, the HPV measure was integrated into the IMA measure for reporting purposes and expanded to both genders.

†† A higher rate in Quality Compass is not intended to indicate good or poor performance, but rather indicate the percentages of plans who have higher rates of current smokers.

^{**}First-year measure.

^{***}Benchmarks are currently not reported by Quality Compass for this rate.

[†]Benchmarks are not reported by Quality Compass for 2016 first-year measures.

For the Effectiveness of Care Measures presented in **Table 5b**, a lower rate (particularly one below the national 50th percentile) is an indication of better performance. For example, a rate in the 10th percentile is better than a rate in the 90th percentile.

Table 5b. HEDIS 2017 Plan-Specific Medicaid Rates: Effectiveness of Care Measures Where Lower Rates Indicate Better Performance											
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	HEDIS 2016 National Medicaid 50th Percentile
Diabetes											
Comprehensive Diabetes Care	(CDC):										
HbA1c Poor Control (>9.0%)	49.09%	40.79%	50.56%	39.42%	44.63%	47.15%	53.21%	32.67%	40.85%	42.33%	43.80%
Overuse/Appropriateness											
Non-Recommended Cervical Ca	ncer Scre	ening in									
Adolescent Females (NCS)	2.75%	2.20%	4.25%	3.91%	3.99%	4.47%	3.36%	4.57%	3.89%	4.54%	2.42%
Use of Multiple Concurrent Anti	ipsychoti	cs in Chil	dren and	d Adolesc	ents (AF	PC):					
1–5 Years	NA	NA	NA	NA	NA	NA	2.56%	NA	NA	NA	0.00%
6-11 Years	0.97%	1.76%	0.00%	2.02%	1.18%	1.35%	2.54%	1.60%	0.63%	0.88%	1.56%
12-17 Years	2.27%	2.34%	2.31%	3.66%	2.57%	3.17%	3.71%	2.47%	2.45%	3.01%	2.53%
Total	1.82%	2.09%	1.33%	3.15%	2.02%	2.41%	3.36%	2.08%	1.76%	2.13%	1.99%

Table 6. HEDIS 2017 Plan-Specific Medicaid Rates: Access/Availability of Care Measures												
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	HEDIS 2016 National Medicaid 50th Percentile	
Adults' Access to Preventive/A	mbulator	y Health	Services	(AAP):								
20-44 years	67.03%	75.26%	70.77%	79.23%	75.60%	77.92%	42.79%	75.58%	77.90%	73.56%	79.48%	
45-64 years	78.63%	84.59%	81.03%	89.23%	85.85%	87.26%	44.57%	86.98%	87.21%	83.45%	86.83%	

Table 6. HEDIS 2017 Plan-Specific Medicaid Rates: Access/Availability of Care Measures											
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	HEDIS 2016 National Medicaid 50th Percentile
Children and Adolescents' Acce	ss to Pri	mary Care	e Practiti	oners (CA	AP):						
12–24 months	92.17%	95.60%	87.45%	96.63%	96.15%	92.03%	86.53%	95.33%	96.33%	89.62%	95.74%
25 months-6 years	81.10%	85.68%	81.93%	88.50%	86.93%	83.89%	78.70%	83.82%	86.79%	80.67%	87.69%
7–11 years	84.34%	88.92%	88.26%	92.14%	91.58%	90.01%	91.39%	88.22%	91.44%	87.66%	91.00%
12–19 years	80.78%	85.35%	83.37%	89.49%	88.37%	86.48%	87.69%	85.42%	88.72%	83.20%	89.37%
Initiation and Engagement of A	Alcohol ar	nd Other I	Drug (AO	D) Deper	ndence T	reatmen	t (IET):				
Initiation of AOD Treatment: 13-17 years	50.00%	43.11%	52.76%	43.32%	44.09%	54.55%	48.47%	47.03%	52.02%	51.45%	42.75%
≥ 18 years	35.21%	35.11%	41.81%	28.86%	33.50%	28.70%	41.73%	38.08%	41.73%	42.97%	37.78%
Total	35.70%	35.56%	42.27%	29.39%	33.86%	30.11%	44.88%	38.40%	42.28%	43.39%	38.07%
Engagement of AOD Treatment: 13–17 years	28.77%	25.78%	18.90%	27.94%	24.19 %	16.58%	27.61%	26.73%	30.65%	21.01%	13.53%
≥ 18 years	10.39%	12.66%	12.05%	6.78%	10.46%	8.48%	13.67%	9.35%	13.71%	11.59%	9.29%
Total	10.99%	13.39%	12.34%	7.55%	10.92%	8.93%	20.19%	9.98%	14.61%	12.05%	9.63%
Prenatal and Postpartum Care	(PPC):										
Timeliness of Prenatal Care	76.69%	80.93%	65.20%	88.51%	74.94%	74.21%	72.19%	79.75%	74.45%	68.13%	82.25%
Postpartum Care	53.61%	62.56%	51.28%	69.54%	53.53%	64.23%	51.69%	61.01%	59.61%	48.18%	60.98%
Use of First-Line Psychosocial (Care for C	Children a	nd Adole	scents o	n Antips	ychotics	(APP):				
1-5 Years	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	45.45%
6-11 Years	55.41%	70.31%	50.00%	48.37%	57.73%	53.04%	52.90%	48.89%	66.23%	47.12%	61.54%
12-17 Years	54.76%	64.12%	59.81%	56.60%	71.43%	63.80%	53.95%	60.14%	56.67%	53.17%	61.20%
Total	54.37%	65.67%	54.77%	51.71%	6 5.31%	58.66%	53.81%	55.69%	59.66%	49.58%	60.43%

Table 7 results are for utilization measures that are included in the Utilization and Risk-Adjusted Utilization Domain of Care.

Table 7. HEDIS 2017 Plan-Specific Medicaid Rates: Utilization Measures											
Measure	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	HEDIS 2016 National Medicaid 50th Percentile
Frequency of Ongoing Prenatal	Frequency of Ongoing Prenatal Care (FPC):										
≥ 81 percent	59.67%	57.21%	44.78%	81.03%	48.18%	52.07%	48.31%	68.86%	48.42%	37.96%	59.26%
Well-Child Visits in the First 15	Months o	f Life (W	/15):								
6 or More Visits	59.95%	73.38%	40.05%	70.40%	63.50%	55.72%	41.36%	66.84%	62.09%	45.50%	59.57%
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years											
of Life (W34)	62.50%	76.85%	69.21%	68.33%	70.06%	65.10%	62.84%	68.16%	74.71%	65.77%	71.42%
Adolescent Well-Care Visits (AWC)	50.00%	55.79%	53.01%	42.82%	46.47%	41.85%	45.74%	41.85%	48.66%	41.36%	48.41%

Individual Plan Performance—CAHPS

Table 8 details the color-coding and the rating scale, as well as any additional comments, used in **Tables 9** through **13** to indicate the rating achieved. **Tables 9** through **13** display the plan-specific performance rates for the CAHPS survey results. CAHPS measure results with an 'NA' indicate that there were

fewer than 100 valid responses and, hence, results are not presented. For all CAHPS survey results, performance is measured against the calculated statewide average. The 2016 National Medicaid CAHPS Benchmarking data were obtained from Quality Compass.

Table 8. 2017 CAHPS Rating Color and Measure Designations									
Color Designation	Rating Scale	Additional Comments							
	Greater than one standard deviation above the statewide average	No additional comments							
	Within one standard deviation above or below the statewide average	No additional comments							
	Greater than one standard deviation below the statewide average	No additional comments							

Table 8. 2017 CAHPS Rating Color and Measure Designations										
	No Rating Available Benchmarking data were not available									
Measure Designation		Definition								
NA	Not Applicable, there were fewer than 100 valid responses, hence results are not presented.									

Table 9. 2017 CAHPS 5.0H Adult Medicaid Survey Results												
AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Statewide Average	2016 National Medicaid CAHPS Benchmarking	
1. Getting	1. Getting Needed Care (Always + Usually)											
81.98%	86.52%	75.77%	86.59%	84.45%	85.30%	NA	88.25%	87.41%	84.24%	84.50%	80.43%	
2. Getting	2. Getting Care Quickly (Always + Usually)											
79.99%	86.53%	79.39%	90.27%	82.60%	86.87%	NA	88.20%	83.53%	83.46%	84.54%	80.06%	
3. How W	3. How Well Doctors Communicate (Always + Usually)											
88.53%	92.23%	92.21%	90.69%	89.23%	91.72%	NA	93.35%	92.41%	92.38%	91.42%	90.73%	
4. Custon	ner Servic	e (Always	+ Usually	/)								
NA	90.87%	NA	90.04%	NA	91.12%	NA	91.55%	87.52%	91.23%	90.39%	87.54%	
5. Shared	Decision	Making (Yes)									
82.70%	78.09%	NA	79.49%	NA	78.39%	NA	80.55%	75.67%	81.27%	79.45%	79.20%	
6. Rating	of All Hea	alth Care ((9+10)									
51.35%	57.62%	55.46%	56.79%	54.19%	57.87%	67.27%	57.52%	56.85%	59.03%	57.40%	53.64%	
7. Rating	of Persor	al Doctor	(9+10)									
62.08%	71.06%	65.24%	67.50%	60.00%	75.53%	68.75%	67.76%	71.86%	70.53%	68.03%	65.41%	
8. Rating	of Specia	list Seen I	Most Ofter	n (9+10)								
73.44%	70.39%	NA	64.52%	64.71%	70.09%	NA	67.70%	61.20%	66.01%	67.26%	65.97%	
9. Rating	of Health	Plan (9+	10)									
48.00%	62.20%	57.00%	62.97%	65.82%	68.40%	63.09%	66.00%	64.44%	65.98%	62.39%	57.69%	

Table 10. 2017 CAHPS 5.0H Child Medicaid Survey Results (General Population)												
AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Statewide Average	2016 National Medicaid CAHPS Benchmarking	
1. Getting	1. Getting Needed Care (Always + Usually)											
89.51%	88.50%	80.23%	91.48%	87.81%	87.67%	91.87%	89.95%	90.36%	82.73%	88.01%	83.66%	
2. Getting	2. Getting Care Quickly (Always + Usually)											
92.61%	91.10%	89.40%	95.27%	93.59%	93.10%	93.69%	91.73%	92.85%	89.01%	92.24%	88.54%	
3. How W	3. How Well Doctors Communicate (Always + Usually)											
93.29%	93.01%	89.74%	96.44%	93.93%	95.47%	94.51%	95.01%	95.62%	94.49%	94.15%	93.17%	
4. Custon	ner Servic	e (Always	+ Usually	<i>ı</i>)								
89.23%	87.60%	85.90%	93.38%	88.22%	89.41%	93.95%	91.94%	87.16%	90.78%	89.76%	87.98%	
5.Shared	Decision	Making (Yes)									
79.23%	80.79%	78.44%	81.85%	NA	80.72%	82.73%	79.31%	79.07%	NA	80.27%	78.41%	
6. Rating	of All Hea	alth Care ((9+10)									
73.57%	72.32%	70.73%	77.28%	76.36%	76.49%	73.51%	73.21%	72.50%	71.20%	73.72%	67.67%	
7. Rating	of Persor	nal Doctor	(9+10)									
76.79%	72.84%	75.49%	79.22%	79.69%	78.19%	76.53%	75.39%	79.69%	76.95%	77.08%	74.78%	
8. Rating	8. Rating of Specialist Seen Most Often (9+10)											
NA	NA	NA	78.95%	NA	NA	79.38%	NA	NA	NA	79.17%	71.10%	
9. Rating	of Health	Plan (9+	10)									
68.42%	74.38%	67.63%	80.95%	75.93%	78.90%	76.33%	77.29%	75.12%	76.99%	75.19%	69.00%	

Table 11	. 2017 C	AHPS 5.C	H Child I	Medicaid S	Survey Re	esults (Ch	nildren w	ith Chron	ic Condit	tions)		
AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	Statewide Average	2016 National Medicaid CAHPS Benchmarking	
1. Getting	1. Getting Needed Care (Always + Usually)											
86.55%	86.87%	84.19%	92.31%	90.94%	87.88%	91.56%	91.49%	92.30%	86.59%	89.07%	86.14%	
2. Getting Care Quickly (Always + Usually)												
94.80%	90.14%	92.04%	96.56%	95.25%	94.79%	93.66%	94.81%	95.74%	93.99%	94.18%	91.82%	
3. How W	ell Doctor	rs Commu	nicate (Al	ways + Us	ually)							
94.13%	93.05%	93.35%	96.33%	94.78%	96.43%	95.24%	95.70%	95.47%	95.77%	95.03%	93.92%	
4. Custom	ner Servic	e (Always	+ Usually	/)			•	ı	ı			
93.75%	NA	NA	95.59%	NA	90.87%	90.82%	93.10%	92.23%	NA	92.73%	89.43%	
5.Shared	Decision		es)		ı							
86.28%	83.39%	85.79%	88.63%	82.69%	82.39%	84.48%	85.99%	79.33%	83.76%	84.27%	84.95%	
6. Rating	of All Hea				T.	ı		I	ı			
61.98%	72.87%	64.95%	75.21%	72.98%	74.40%	70.48%	71.82%	72.45%	69.71%	70.69%	65.98%	
7. Rating	of Person	al Doctor	(9+10)	ı					ı			
73.26%	77.94%	72.12%		75.48%	80.20%	75.68%	80.10%	77.74%	78.71%	77.02%	74.67%	
8.Rating	of Special	ist Seen M	lost Often	(9+10)	ı			I				
70.00%	72.41%	NA	78.49%	78.90%	78.63%	75.00%	79.01%	73.43%	68.42%	74.92%	70.81%	
9. Rating					1			I				
60.19%	74.36%	59.50%		72.04%	77.40%	74.70%	76.20%	73.53%	73.43%	72.31%	65.80%	
	-			ways + Usu			1	I				
NA	NA	NA	NA	NA	NA	82.46%	NA	NA	NA	82.46%	77.06%	
				octor or Nu								
90.99%	91.25%	90.36%	91.57%	91.31%	91.19%	91.14%	91.64%	90.91%	92.39%	91.28%	90.55%	
				Vith Chron								
NA	NA	NA	78.60%	NA	NA	81.05%	78.29%	82.00%	NA	79.99%	77.11%	
				eded Inforr				·				
91.67%	90.87%	90.23%		93.93%	91.92%	92.75%	89.37%	92.15%	93.78%	92.22%	90.91%	
				Always + L								
90.49%	93.92%	92.00%	94.33%	92.03%	93.26%	91.87%	93.65%	94.16%	92.83%	92.85%	90.68%	

Medicaid HEDIS Trending—Statewide Weighted Rates

Each year of HEDIS reporting, Qsource has calculated the Medicaid statewide weighted averages for each measure by applying the size of the eligible population for each measure within a health plan to its reported rate. Using this methodology, plan-specific findings can be estimated from an overall TennCare statewide level, with each reporting health plan contributing to the statewide estimate proportionate to its eligible population size.


Trending for first-time measures—those reported for the first time in this year's HEDIS/CAHPS report—is not possible and, therefore, not presented in this section. Remaining measures are plotted to reflect the statewide performance of TennCare

MCOs since reporting began in 2006, except where measures were not reported for a particular year as stated in footnotes.

In 2008 new health plans were implemented in the Middle Grand Region that were not required to be NCQA accredited until December 2009. Similarly, new health plans were implemented in 2009 in the West Grand Region that were not required to be accredited until December 2010. The data would not have been reported by these MCOs for 2008 or 2009, respectively; hence, no 2008 or 2009 statewide weighted rates are presented. Beginning in January 2015, there were 400,000 TennCare enrollees transitioning to new MCOs. These factors should be considered while trending data.


Effectiveness of Care Measures: Prevention and Screening

Fig. 1. Adult BMI Assessment (ABA)




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). Measure specifications were revised in 2012 and for HEDIS 2016 the BMI and BMI percentile numerator age criteria was revised from 21 to 20 years; trending should be considered with caution.

Fig. 3. WCC—BMI Percentile: 12–17 years




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

Fig. 2. Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)—
BMI Percentile: 3–11 years




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.


Fig. 4. WCC—BMI Percentile: Total




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.



Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2012 measure specifications changed; trending between 2012 and prior years should be considered with caution.

Fig. 8. WCC—Counseling for Physical Activity: 3–11 years




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2016, changes were made to numerator criteria; trending with prior years should be considered with caution.




Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2016, changes were made to numerator criteria; trending with prior years should be considered with caution.

Fig. 11. Childhood Immunization Status (CIS): DTap




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.



Footnote: Data reporting began in 2009 (2008 and 2009 data are not reported in these graphs). In 2016, changes were made to numerator criteria; trending with prior years should be considered with caution.

Fig. 12. CIS: IPV




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


Medicaid HEDIS Trending-Effectiveness of Care Measures: Prevention and Screening

CIS: HiB


Fig. 14.




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.



between prior years' should be considered with caution.




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


Medicaid HEDIS Trending-Effectiveness of Care Measures: Prevention and Screening




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.



Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.




Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.




Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.


Medicaid HEDIS Trending-Effectiveness of Care Measures: Prevention and Screening




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.



Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.




Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.




Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

Fig. 25. CIS: Combination 6




Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

Fig. 27. CIS: Combination 8




Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

Fig. 26. CIS: Combination 7




Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

Fig. 28. CIS: Combination 9




Footnote: Data reporting began in 2010. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.




Footnote: Data reporting began in 2010. HepA dose requirements changed in 2013 from two doses to at least one dose; hence, trend with caution. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

Fig. 31. IMA: Tdap/Td




Footnote: Data reporting began in 2010.




Footnote: Data reporting began in 2010.

Fig. 32. HPV: Adolescents




Footnote: Data reporting began in 2012. In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution. Measure extended to males and females as of HEDIS 2017, was female only in prior years.

Fig. 33. IMA: Combination 1




Footnote: Data reporting began in 2010.

Fig. 35. Breast Cancer Screening (BCS)




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

Fig. 34. Lead Screening in Children (LSC)




Footnote: Data reporting began in 2008 (2008 and 2009 data are not reported in these graphs). Measure specifications changed in 2011; trending between 2011 and prior years should be considered with caution.


Fig. 36. Cervical Cancer Screening (CCS)




Footnote: Due to significant changes to the measure specification in 2014 CCS was identifies as having first-year status, results for this measure cannot be trended with previous years' results.

Medicaid HEDIS Trending—Effectiveness of Care Measures: Prevention and Screening





Footnote: Age stratification changed in 2009 (2008 and 2009 data are not reported in these graphs); as such, no comparative data are available from previous years.



Footnote: Age stratification changed in 2009 (2008 and 2009 data are not reported in these graphs); as such, no comparative data are available from previous years.

Effectiveness of Care Measures—Respiratory Conditions

Fig. 40. Appropriate Testing for Children With Pharyngitis (CWP)






Fig. 41. Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)



Footnote: For HEDIS 2016, the description and ages were changed from "2–18 years of age" to "3–18 years of age"; trending with prior years should be done with caution.


Footnote: Measure specifications changed in 2011; trending between 2011 and prior years should be considered with caution.

Fig. 42. Pharmacotherapy Management of COPD Exacerbation (PCE): Systemic Corticosteroid




Footnote: Data reporting began in 2008 (2008 and 2009 data are not reported in these graphs). For HEDIS 2017, the exclusion was deleted for Episode Dates when there was a readmission or an ED visit within 14 days.

Fig. 43. PCE: Bronchodilator




Footnote: Data reporting began in 2008 (2008 and 2009 data are not reported in these graphs). For HEDIS 2017, the exclusion was deleted for Episode Dates when there was a readmission or an ED visit within 14 days.

Fig. 44. Medication Management for People With Asthma (MMA)—Medication Compliance 50%: 5–11 years




Footnote: Data reporting began in 2012.

Fig. 46. MMA—Medication Compliance 50%: 19-50 years




Footnote: Data reporting began in 2012.

Fig. 45. MMA—Medication Compliance 50%: 12-18 years



Footnote: Data reporting began in 2012.

Fig. 47. MMA—Medication Compliance 50%: 51-64 years




Footnote: Data reporting began in 2012.

Medicaid HEDIS Trending—Effectiveness of Care Measures: Respiratory Conditions

Fig. 49.


100%




90% Rates 80% 70% Weighted 60% 50% 40% 29.90% 26.87% Statewide 23.64% 24.38% 30% 20% 10% 0% 2014 2015 2017 2016 **HEDIS Report Year**

MMA—Medication Compliance 75%: 5-11 years

Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.


Medicaid HEDIS Trending—Effectiveness of Care Measures: Respiratory Conditions




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.



Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.




Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.


Medicaid HEDIS Trending-Effectiveness of Care Measures: Respiratory Conditions



Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.



Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.



Footnote: Data reporting began in 2013. In 2015, an error was identified in the National Drug Code (NDC) list dosing requirement for one of the NDCs used when reporting the AMR measure. Trending between prior years' should be considered with caution.

Effectiveness of Care Measures—Cardiovascular Conditions

Fig. 59. Controlling High Blood Pressure (CBP)







Fig. 60. Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)



Footnote: In 2015, due to notable changes to the measure specification, results should be considered with caution.




Footnote: Data reporting began in 2015.




Footnote: Data reporting began in 2015.


Medicaid HEDIS Trending—Effectiveness of Care Measures: Cardiovascular Conditions




Footnote: Data reporting began in 2015.



Footnote: Data reporting began in 2015.




Footnote: Data reporting began in 2015.




Footnote: Data reporting began in 2015.


Effectiveness of Care Measures—Diabetes




Footnote: Trending between 2016 and prior years should be considered with caution due to conversion to ICD-10 codes. Also trending between 2015 and prior years' should be considered with caution due to revision to General Guideline 41 and ED visit requirement.



Footnote: Trending between 2016 and prior years should be considered with caution due to conversion to ICD-10 codes. Also trending between 2015 and prior years' should be considered with caution due to revision to General Guideline 41 and ED visit requirement.




Footnote: Trending between 2016 and prior years should be considered with caution due to conversion to ICD-10 codes. Also trending between 2015 and prior years' should be considered with caution due to revision to General Guideline 41 and ED visit requirement.



Footnote: Trending between 2016 and prior years should be considered with caution due to conversion to ICD-10 codes. Also trending between 2015 and prior years' should be considered with caution due to revision to General Guideline 41 and ED visit requirement.

Medicaid HEDIS Trending—Effectiveness of Care Measures: Diabetes



Footnote: Trending between 2016 and prior years should be considered with caution due to conversion to ICD-10 codes. Also trending between 2015 and prior vears' should be considered with caution due to revision to General Guideline 41 and ED visit requirement.

Fig. 73.

100%

90%

80%

70%

60%

50%

40%

30%

20%


10% 0%

2006

2007

2010

Statewide Weighted Rates



*Lower rates for this measure indicate better performance. Footnote: Trending between 2016 and prior years should be considered with caution due to conversion to ICD-10 codes. Also trending between 2015 and prior years' should be considered with caution due to revision to General Guideline 41 and ED visit requirement.

2012

2013

HEDIS Report Year


2014

2015

2016


2017

2011




Footnote: Trending between 2016 and prior years should be considered with caution due to conversion to ICD-10 codes. Also trending between 2015 and prior years' should be considered with caution due to revision to General Guideline 41 and ED visit requirement.

SPD—Received Statin Therapy: 40-75 years Fig. 74.




Footnote: Data reporting began in 2015.



Footnote: Data reporting began in 2015


Effectiveness of Care Measures—Musculoskeletal Conditions

Fig. 76. Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)




Effectiveness of Care Measures—Behavioral Health

Fig. 77. Antidepressant Medication Management (AMM): Effective Acute Phase Treatment




Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.

Fig. 79. Follow-Up Care for Children Prescribed ADHD Medication (ADD): Initiation Phase




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

Fig. 78. AMM: Effective Continuation Phase Treatment



Footnote: Due to significant changes to the measure specification in 2014, results for this measure cannot be trended with previous years' results.


Fig. 80. ADD: Continuation and Maintenance Phase



Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.


Medicaid HEDIS Trending-Effectiveness of Care Measures: Behavioral Health

Fig. 81. Follow-Up After Hospitalization for Mental Illness (FUH): 7-Day Follow-Up




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

Fig. 83. Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)




Footnote: Data reporting began in 2013.

Fig. 82. FUH: 30-Day Follow-Up




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

Fig. 84. Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)



Footnote: Data reporting began in 2013. In 2015, due to notable changes in the measure specification, trending between 2015 and prior years' should be considered with caution.

Fig. 85. Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)



Footnote: Data reporting began in 2013.

Fig. 87. Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM): 1-5 Years






Fig. 86. Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)





Footnote: Data reporting began in 2013. In 2016, changes were made to the timeframe when identifying the Index Prescription State Date (IPSD). Trending between 2016 and prior years should be considered with caution.

Fig. 88. APM: 6-11 Years




Medicaid HEDIS Trending—Effectiveness of Care Measures: Behavioral Health






Effectiveness of Care Measures—Medication Management

Fig. 91. Annual Monitoring for Patients on Persistent Medications (MPM): ACE Inhibitors or ARBs




Footnote: In 2015, due to significant changes to the measure specification, results for this measure cannot be trended to previous year's results.




Footnote: In 2015, due to significant changes to the measure specification, results for this measure cannot be trended to previous year's results.

Fig. 92. MPM: Digoxin




Footnote: In 2015, due to significant changes to the measure specification, results for this measure cannot be trended to previous year's results.



Footnote: The anticonvulsants rate was retired in 2015 and is no longer part of the total rate. In 2015, due to significant changes to the measure specification, results for this measure cannot be trended to previous year's results.


Effectiveness of Care Measures—Overuse/Appropriateness

Fig. 95. Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)*



^{*}Lower rates for this measure indicate better performance. Footnote: Data reporting began in 2014. In 2016, denied claims are no longer included when identifying the numerator of the measure. Trending between 2016 and prior years should be considered with caution.

Fig. 97. Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)



Footnote: The measure rate was inverted in 2008 (2008 and 2009 data are not reported in these graphs); as such, no comparative data are available from previous years.

Fig. 96. Appropriate Treatment for Children With Upper Respiratory Infection (URI)






Fig. 98. Use of Imaging Studies for Low Back Pain (LBP)




Footnote: Because United American Healthcare Corporation did not report this measure in 2007, it was excluded from the statewide weighted average calculation for that report year. In 2016, the conversion to ICD-10 codes affected how low back pain, recent trauma and intravenous drug abuse are identified in the event/diagnosis. Trending between 2016 and prior years should be considered with caution.

Medicaid HEDIS Trending—Effectiveness of Care Measures: Overuse/Appropriateness

Fig. 99. Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC): 1-5 Years*




^{*}Lower rates for this measure indicate better performance. Footnote: Data reporting began in 2014.




^{*}Lower rates for this measure indicate better performance. Footnote: Data reporting began in 2014.

Fig. 100. APC: 6-11 Years*



^{*}Lower rates for this measure indicate better performance. Footnote: Data reporting began in 2014.



^{*}Lower rates for this measure indicate better performance. Footnote: Data reporting began in 2014.

Access/Availability of Care Measures

Fig. 103. Adults' Access to Preventive/Ambulatory Health Services (AAP): 20–44 years




Fig. 104. AAP: 45-64 years




Fig. 105. Children and Adolescents' Access to Primary Care Practitioners (CAP): 12–24 months






Fig. 106. CAP: 25 months-6 years



Medicaid HEDIS Trending—Access/Availability of Care Measures








Fig. 109. Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET)—Initiation of AOD Treatment: 13–17 years




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.


Fig. 110. IET—Initiation of AOD Treatment: ≥18 years




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.




Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.



Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.



Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.



Footnote: Behavioral Health was carved out prior to HEDIS 2009; as such, no comparative data are available from previous years.

Fig. 115. Prenatal and Postpartum Care (PPC): Timeliness of Prenatal Care




Fig. 116. PPC: Postpartum Care




Fig. 117. Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP): 1-5 Years







Fig. 118. APP: 6-11 Years



Medicaid HEDIS Trending—Access/Availability of Care Measures





Utilization Measures

Fig. 121. Frequency of Ongoing Prenatal Care (FPC): ≥ 81%





Fig. 122. Well-Child Visits in the First 15 Months of Life (W15): 6 or More Visits



Footnote: In 2015, due to notable changes in the measure specification, trending between prior years' should be considered with caution.

Fig. 123. Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)





Fig. 124. Adolescent Well-Care Visits (AWC)



CHIP HEDIS/CAHPS Results

At HCFA's request, HEDIS measure and CAHPS results for CoverKids, Tennessee's CHIP, were added to this annual HEDIS/CAHPS report in 2017. <u>HEDIS definitions</u> for measures apply to all lines of business. For CoverKids, **BlueCare** (**CKBC**) is the only health plan administrator (HPA) and the only plan reporting HEDIS/CAHPS measures, so no comparative statewide data are available.

Table 12. HEDIS 2017 CHIP Rates	
Measure	Rate
Effectiveness of Care Measures	
Prevention and Screening	
Adult BMI Assessment (ABA)	NA
Weight Assessment and Counseling for Nutrition and Activity for Children/Adolescents (WCC):	Physical
BMI Percentile	63.26%
Counseling for Nutrition	50.36%
Counseling for Physical Activity	47.93%
Childhood Immunization Status (CIS):	
DTaP	81.51%
IPV	88.32%
MMR	88.08%
HiB	88.56%
Hepatitis B	84.67%
VZV	89.78%
Pneumococcal Conjugate	82.73%
Hepatitis A	86.62%
Rotavirus	75.91%
Influenza	54.26%
Combination #2	75.67%
Combination #3	74.21%
Combination #4	73.24%
Combination #5	65.45%

Table 12. HEDIS 2017 CHIP Rates						
Measure	Rate					
Combination #6	49.15%					
Combination #7	64.72%					
Combination #8	48.66%					
Combination #9	45.01%					
Combination #10	44.53%					
Immunizations for Adolescents (IMA):						
Meningococcal	66.18%					
Tdap	82.24%					
HPV						
Combination #1						
Combination #2	9.73%					
Lead Screening in Children (LSC)	64.48%					
Breast Cancer Screening (BCS)	NA					
Cervical Cancer Screening (CCS)	75.32%					
Chlamydia Screening in Women (CHL):						
16-20 Years	30.80%					
21-24 Years	80.56%					
Total	31.46%					
Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (CWP)	88.68%					
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	NA					

Table 12. HEDIS 2017 CHIP Rates		
Measure	Rate	
Pharmacotherapy Management of COPD Exacerbation	(PCE):	
Systemic Corticosteroid	NA	
Bronchodilator	NA	
Medication Management for People With Asthma (MM	IA):	
Medication Compliance 50%: 5-11 Years	59.92%	
12-18 Years	57.41%	
19-50 Years	NA	
51-64 Years	NA	
Total	58.87%	
Medication Compliance 75%: 5-11 Years	33.40%	
12-18 Years	29.11%	
19-50 Years	NA	
51-64 Years	NA	
Total	31.57%	
Asthma Medication Ratio (AMR):		
5-11 Years	79.48%	
12-18 Years	78.77%	
19-50 Years	NA	
51-64 Years	NA	
Total	79.23%	
Cardiovascular Conditions		
Controlling High Blood Pressure (CBP)	NA	
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	NA	
Statin Therapy for Patients With Cardiovascular Disease	e (SPC):	
Received Statin Therapy: 21-75 Years (Male)	NA	
40-75 Years (Female)	NA	
Total	NA	

Table 12. HEDIS 2017 CHIP Rates	
Measure	Rate
Statin Adherence 80%: 21-75 Years (Male)	NA
40-75 Years (Female)	NA
Total	NA
Diabetes	
Comprehensive Diabetes Care (CDC):	
Hemoglobin A1c (HbA1c) Testing	84.85%
HbA1c Control (<8.0%)	33.33%
HbA1c Control (<7.0%)	24.24%
Eye Exam (Retinal) Performed	42.42%
Medical Attention for Nephropathy	69.70%
Blood Pressure Control (<140/90 mm Hg)	63.64%
Statin Therapy for Patients With Diabetes (SPD):	
Received Statin Therapy	NA
Statin Adherence 80%	NA
Musculoskeletal Conditions	
Disease-Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (ART)	NA
Behavioral Health	
Antidepressant Medication Management (AMM):	
Effective Acute Phase Treatment	54.02%
Effective Continuation Phase Treatment	29.89%
Follow-Up Care for Children Prescribed ADHD Medication	n (ADD):
Initiation Phase	40.89%
Continuation and Maintenance (C&M) Phase	51.53%
Follow-Up After Hospitalization for Mental Illness (FU	IH):
7-Day Follow-Up	58.96%
30-Day Follow-Up	78.73%

CHIP Results

Measure								
Fallery Ha After Francisco B	Rate							
Follow-Up After Emergency Department Visit for Mental Illness (FUM):								
7-Day Follow-Up	35.88%							
30-Day Follow-Up	61.07%							
Follow-Up After Emergency Department Visit for Alco Other Drug Dependence (FUA):	hol and							
7-Day Follow-Up: 13-17 Years	11.43%							
18+ Years	NA							
Total	11.11%							
30-Day Follow-Up: 13-17 Years	17.14%							
18+ Years	NA							
Total	15.56%							
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)	62.50%							
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	NA							
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	NA							
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	NA							
Metabolic Monitoring for Children and Adolescents of Antipsychotics (APM):	1							
1-5 Years	NA							
	29.41%							
6-11 Years								
6-11 Years 12-17 Years	31.16%							
	31.16% 30.74%							
12-17 Years								
12-17 Years Total	30.74%							

Table 12. HEDIS 2017 CHIP Rates	
Measure	Rate
Digoxin	NA
Diuretics	NA
Total	NA
Overuse/Appropriateness	
Appropriate Treatment for Children With URI (URI)	79.75%
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (AAB)	NA
Use of Imaging Studies for Low Back Pain (LBP)	60.32%
Access/Availability of Care	
Adults' Access to Preventive/Ambulatory Health Service	es (AAP):
20-44 Years	77.44%
45-64 Years	NA
65+ Years	NA
Total	77.04%
Children and Adolescents' Access to Primary Care Practitioners (CAP):	
12-24 Months	94.89%
25 Months - 6 Years	85.97%
7-11 Years	89.56%
12-19 Years	85.75%
Initiation and Engagement of AOD Dependence Treatme	ent (IET):
Initiation of AOD Treatment: 13-17 Years	43.95%
18+ Years	50.00%
Total	46.27%
Engagement of AOD Treatment: 13-17 Years	22.93%
18+ Years	19.39%
Total	21.57%

CHIP Results

Table 12. HEDIS 2017 CHIP Rates							
Measure	Rate						
Prenatal and Postpartum Care (PPC):							
Timeliness of Prenatal Care	69.27%						
Postpartum Care	64.88%						
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)							
1-5 Years	NA						
6-11 Years	NA						
12-17 Years	57.50%						
Total	55.14%						
Utilization							
Frequency of Ongoing Prenatal Care (FPC):							
81+ Percent	59.76%						
Well-Child Visits in the First 15 Months of Life (W15):	;						
6+ Visits	75.22%						
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	66.58%						
Adolescent Well-Care Visits (AWC)	38.93%						

Table 13. HEDIS 2017 CHIP Rates Where Lower Findicate Better Performance	Rates					
Measure	Rate					
Effectiveness of Care Measures						
Diabetes						
Comprehensive Diabetes Care (CDC):						
HbA1c Poor Control (>9.0%)	60.61%					
Overuse/Appropriateness						
Non-Recommended Cervical Cancer Screening in Adolescent						
Use of Multiple Concurrent Antipsychotics in Children a Adolescents (APC):	and					
1-5 Years	NA					
6-11 Years	1.64%					
12-17 Years	0.00%					
Total	0.44%					

 $\textbf{Table 14} \text{ and } \textbf{Table 15} \text{ show the CAHPS results for the CoverKids HPA.} \\ \underline{\textbf{CAHPS definitions}} \text{ for measures apply to all lines of business.} \\$

Table 14. 2017 CAHPS 5.0H Child CHIP Survey Results (General Population)									
Question	СКВС								
1. Getting Needed Care (Always + Usually)	93.05%								
2. Getting Care Quickly (Always + Usually)	95.96%								
3. How Well Doctors Communicate (Always + Usually)	95.98%								
4. Customer Service (Always + Usually)	94.95%								
5.Shared Decision Making (Yes)	81.97%								
6. Rating of All Health Care (9+10)	75.75%								
7. Rating of Personal Doctor (9+10)	78.89%								
8. Rating of Specialist Seen Most Often (9+10)	NA								
9. Rating of Health Plan (9+10)	80.77%								

Table 15. 2017 CAHPS 5.0H Child CHIP Survey Results (Children with Chronic	Conditions)
Question	СКВС
1. Getting Needed Care (Always + Usually)	91.05%
2. Getting Care Quickly (Always + Usually)	96.67%
3. How Well Doctors Communicate (Always + Usually)	96.83%
4. Customer Service (Always + Usually)	94.36%
5. Shared Decision Making (Yes)	83.05%
6. Rating of All Health Care (9+10)	72.49%
7. Rating of Personal Doctor (9+10)	77.30%
8.Rating of Specialist Seen Most Often (9+10)	68.42%
9. Rating of Health Plan (9+10)	77.33%
10. Coordination of Care (Always + Usually)	81.82%
11. Access to Specialized Services (Always + Usually)	NA
12. Family-Centered Care: Personal Doctor Who Knows Child (Yes)	93.00%
13. Coordination of Care for Children With Chronic Conditions (Yes)	75.78%
14. Family-Centered Care: Getting Needed Information (Always + Usually)	95.27%
15. Access to Prescription Medicines (Always + Usually)	97.38%

APPENDIX A | Utilization Measure Medicaid Results and Benchmarks

Utilization Additional Measure Descriptions

Frequency of Selected Procedure (FSP)

FSP summarizes the utilization of frequently performed procedures that often show wide regional variation and have generated concern regarding potentially inappropriate utilization.

Ambulatory Care (AMB)

AMB summarizes utilization of ambulatory care in the following categories:

- Outpatient Visits
- ♦ ED Visits

<u>Inpatient Utilization – General Hospital/Acute Care (IPU)</u>

IPU summarizes utilization of acute IP care and services in the following categories:

- Total IP
- Medicine

- Surgery
- Maternity

Identification of Alcohol and Other Drug Services (IAD)

IAD summarizes the number and percentage of members with an AOD claim who received the following chemical dependency services during the measurement year:

- Any services
- ♦ IP

- Outpatient or ED
- Intensive outpatient or partial hospitalization

Mental Health Utilization (MPT)

MPT summarizes the number and percentage of members receiving the following mental health services during the measurement year:

- Any services
- ♦ IP

- Outpatient or ED
- Intensive outpatient or partial hospitalization

Antibiotic Utilization (ABX)

ABX summarizes the following data on outpatient utilization of antibiotic prescriptions during the MY, stratified by age and gender:

- Total number of and average (Avg.) number of antibiotic prescription per member per year (PMPY)
- Total and avg. days supplied for all antibiotic prescriptions

APPENDIX A | Utilization Measure Medicaid Results and Benchmarks

- Total number of prescriptions and avg. number of prescriptions PMPY for antibiotic of concern
- Percentage of antibiotic of concern for all antibiotic prescriptions
- Avg. number of antibiotics PMPY reported by drug class:
 - For selected 'antibiotics of concern'
 - For all other antibiotics

Standardized Healthcare-Associated Infection Ratio (HAI)

HAI reports the percentages of total discharges summarizes the hospital-reported standard infection ratios (SIR) for four different healthcare-associated infections (HAIs), adjusted for the proportion of members discharged from each MCO's contracted acute care hospital. The measure reports the percentage of total discharges from hospitals with a high,

moderate, low or unavailable SIR, next to a total plan-weighted SIR for each of the following infections during the MY, stratified by age and gender:

- Total number of and avg. number of antibiotic PMPY
- Total and avg. days supplied for all antibiotic prescriptions
- Total number of prescriptions and avg. number of prescriptions PMPY for antibiotic of concern
- Percentage of antibiotic of concern for all antibiotic prescriptions
- Avg. number of antibiotics PMPY reported by drug class:
 - For selected 'antibiotics of concern'
 - For all other antibiotics

Utilization Measures: Medicaid Plan-Specific Rates/National Benchmarks

In **Table A**, cells are shaded gray for those measures that were not calculated or for which data were not reported.

Table A	. HE	DIS 201	7 Medi	caid Pla	n-Spec	ific Rat	es with	HEDIS	2016 N	ational	Benchi	marks:	Utilizati	ion Mea	sures			
Measure	C	405	0.004	0.004	DOE	DOM.	DOM	TOC	111105	LIGE LILIONA	LILIOVA	2016 National Medicaid Means and Percentiles						
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90	
Frequen	cy of	Ongoing	Prenat	al Care ((FPC):													
<21%	NA	8.39%	7.21%	11.83%	3.74%	11.19%	12.17%	9.55%	7.85%	13.14%	13.63%	11.96%	2.87%	4.87%	8.22%	14.69%	23.60%	
21–40%	NA	7.46%	6.74%	14.39%	2.59%	13.14%	10.46%	10.96%	5.32%	9.73%	10.71%	7.26%	2.33%	3.95%	5.82%	9.02%	13.93%	
41–60%	NA	8.39%	8.84%	11.83%	4.60%	12.41%	9.98%	13.48%	4.81%	13.14%	14.60%	8.59%	4.65%	6.03%	7.92%	10.46%	12.99%	
61–80%	NA	16.08%	20.00%	17.17%	8.05%	15.09%	15.33%	17.70%	13.16%	15.57%	23.11%	15.23%	10.48%	12.58%	14.95%	17.95%	20.45%	
≥81%	NA	59.67%	57.21%	44.78%	81.03%	48.18%	52.07%	48.31%	68.86%	48.42%	37.96%	56.61%	32.79%	45.72%	59.26%	69.54%	75.77%	
Well-Ch	ild Vis	sits in th	e First 1	5 Month	ns of Life	(W15):												
0 Visits	NA	2.31%	2.31%	5.32%	1.44%	0.49%	2.92%	11.92%	3.16%	2.74%	4.14%	2.62%	0.44%	0.93%	1.71%	3.24%	5.77%	
1 Visits	NA	3.24%	1.85%	4.86%	1.15%	2.19%	5.11%	4.14%	1.58%	2.24%	5.35%	2.30%	0.70%	1.26%	1.95%	2.92%	4.12%	
2 Visits	NA	4.86%	2.78%	7.18%	1.15%	4.14%	5.60%	3.65%	3.16%	2.74%	6.08%	3.45%	1.23%	2.06%	3.19%	4.62%	5.84%	
3 Visits	NA	6.48%	3.70%	12.96%	4.02%	4.38%	6.57%	7.79%	3.95%	3.49%	10.46%	5.54%	2.66%	3.72%	5.42%	6.98%	8.57%	
4 Visits	NA	9.26%	6.71%	12.73%	6.32%	10.22%	9.98%	13.38%	9.74%	7.23%	11.19%	9.64%	6.01%	7.54%	9.16%	11.30%	13.40%	
5 Visits	NA	13.89%	9.26%	16.90%	15.52%	15.09%	14.11%	17.76%	11.58%	19.45%	17.27%	17.11%	12.02%	14.29%	16.49%	19.23%	23.72%	
6 or More Visits	NA	59.95%	73.38%	40.05%	70.40%	63.50%	55.72%	41.36%	66.84%	62.09%	45.50%	59.35%	45.38%	53.49%	59.57%	67.76%	73.88%	
						Fre	quency	of Selec	ted Prod	edures	(FSP)							
Bariatrio	c weig	ght loss	surgery:	Proced	ures /1,	000 Men	nber Yea	ars										
0–19		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
20-44	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.01	0.00	0.00	0.01	0.02	0.03	
45-64		0.00	0.04	0.00	0.01	0.02	0.00	0.00	0.01	0.03	0.00	0.01	0.00	0.00	0.01	0.02	0.04	
0–19		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
20-44	F	0.01	0.02	0.01	0.04	0.02	0.00	0.00	0.04	0.03	0.02	0.06	0.00	0.01	0.05	0.09	0.13	
45-64		0.01	0.04	0.03	0.03	0.06	0.01	0.00	0.05	0.05	0.01	0.08	0.00	0.01	0.05	0.10	0.16	
Tonsille	ctomy	: Proce	dures /1	,000 Me	mber Ye	ears												
0–9	N 4 0 E	0.95	0.80	0.49	1.19	0.78	0.58	0.96	1.22	0.81	0.56	0.62	0.24	0.45	0.62	0.80	0.95	
10–19	M&F	0.47	0.32	0.29	0.51	0.37	0.28	0.31	0.51	0.40	0.27	0.28	0.07	0.19	0.27	0.36	0.45	
Hystere	ctomy	/—Abdoi	minal (A) and Va	iginal (V): Proce	dures /	1,000 M	ember Y	ears								
A 15–44	_	0.08	0.12	0.08	0.11	0.14	0.15	0.01	0.10	0.14	0.14	0.13	0.05	0.09	0.13	0.17	0.21	
A 45–64	F	0.20	0.18	0.31	0.11	0.22	0.31	0.00	0.12	0.15	0.37	0.31	0.11	0.20	0.27	0.34	0.48	

Table A	. HEC	DIS 201	7 Medio	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizati	ion Mea	sures			
Measure		4.05	0.004	0.004	DOE	DOM	DOM	T00			1111014	2016 National Medicaid Means and Percentiles						
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90	
V 15–44	F	0.21	0.19	0.07	0.25	0.20	0.08	0.04	0.28	0.17	0.07	0.14	0.03	0.06	0.12	0.20	0.30	
V 45–64	F	0.26	0.20	0.10	0.31	0.23	0.09	0.00	0.19	0.23	0.08	0.22	0.05	0.12	0.19	0.27	0.42	
Cholecy	stecto	my—Op	en (0) a	nd Clos	ed (C)/L	.aparosc	opic: Pr	ocedure	s /1,000	Membe	r Years							
O 30–64	М	0.02	0.02	0.07	0.03	0.00	0.04	0.03	0.05	0.00	0.05	0.03	0.00	0.01	0.02	0.04	0.05	
O 15–44	F	0.00	0.01	0.02	0.00	0.01	0.01	0.01	0.02	0.01	0.01	0.01	0.00	0.00	0.01	0.01	0.02	
O 45–64	F	0.06	0.01	0.08	0.01	0.03	0.08	0.00	0.02	0.02	0.05	0.03	0.00	0.00	0.03	0.05	0.07	
C 30-64	M	0.41	0.38	0.28	0.50	0.48	0.33	0.10	0.50	0.42	0.29	0.29	0.12	0.19	0.28	0.37	0.51	
C 15-44	Е	0.82	0.71	0.48	0.80	0.74	0.55	0.35	0.86	0.78	0.46	0.67	0.36	0.49	0.63	0.80	1.02	
C 45-64	Г	0.71	0.69	0.47	0.73	0.60	0.39	0.12	0.94	0.75	0.49	0.65	0.33	0.45	0.62	0.82	1.00	
Back Su	rgery	: Proced	ures /1,	000 Mei	mber Ye	ars												
20–44	M	0.24	0.26	0.17	0.36	0.22	0.21	0.01	0.24	0.23	0.23	0.27	0.04	0.12	0.24	0.34	0.49	
20-44	F	0.12	0.21	0.11	0.26	0.18	0.13	0.01	0.26	0.27	0.10	0.22	0.04	0.10	0.16	0.24	0.30	
45–64	М	0.47	0.76	0.63	0.71	0.70	0.35	0.00	0.82	0.82	0.27	0.62	0.19	0.38	0.57	0.80	0.94	
45-04	F	0.32	0.85	0.24	0.75	0.87	0.29	0.12	0.92	0.95	0.59	0.53	0.08	0.31	0.49	0.67	0.85	
Mastect	omy:	Procedu	res /1,0	00 Mem	ber Yea	rs												
15–44	F	0.01	0.02	0.01	0.05	0.04	0.02	0.01	0.05	0.02	0.01	0.03	0.00	0.01	0.02	0.03	0.05	
45-64	F	0.11	0.24	0.06	0.38	0.18	0.30	0.00	0.35	0.33	0.14	0.19	0.00	0.10	0.14	0.21	0.38	
Lumpec	tomy:	Procedi	ures /1,	000 Men	nber Yea	ars												
15–44	_	0.11	0.08	0.13	0.09	0.10	0.14	0.06	0.10	0.11	0.08	0.11	0.04	0.09	0.12	0.14	0.16	
45–64	F	0.18	0.30	0.33	0.53	0.26	0.55	0.00	0.32	0.39	0.39	0.38	0.17	0.27	0.38	0.44	0.54	
							Ambu	latory Ca	are: Tota	al (AMB))							
Outpatie	ent Vi	sits: Visi	its/1,00	0 Memb	er Month	าร												
<1	NA	765.43	743.34	579.83	848.64	759.45	682.04	889.58	764.61	745.96	610.34							
1–9	NA	249.72	285.18	215.93	341.65	285.37	275.46	348.28	291.35	310.56	257.02							
10–19	NA	197.71	219.21	175.52	278.44	227.33	224.25	243.89	247.52	242.38	205.54							
20–44	NA	230.70	306.83	242.25	342.65	311.39	332.39	96.57	329.34	346.19	301.98							
45–64	NA	464.24	624.28	453.55	681.36	626.52	631.68	175.29	674.42	716.85	587.29							
65–74	NA	412.09	660.38	378.81	85.50	121.37	159.80	296.30	738.47	680.08	591.74							
75–84	NA	308.67	596.08	399.71	25.00	166.23	62.24	583.33	557.38	365.19	379.63							
≥85	NA	266.67	504.95	359.79	21.98	139.72	71.43		260.05	179.54	139.23							
Total	NA	267.77	327.48	249.53	382.57	325.11		259.20	366.15			357.17	258.19	303.40	350.23	389.30	450.33	

Table A	. HEI	DIS 201	7 Medi	caid Pla	n-Spec	ific Rat	es with	HEDIS	2016 N	ational	Benchr	marks:	Utilizati	ion Mea	sures		
Measure												2016	National	Medicaio	l Means a	nd Perce	entiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
ED Visits	s: Vis	its/1,00	0 Memb	er Month	าร												
<1	NA	114.37	82.06	117.41	109.35	94.16	118.77	97.82	116.92	84.28	117.68						
1–9	NA	63.72	41.67	43.06	61.71	49.18	56.13	50.15	57.41	44.43	51.52						
10–19	NA	55.81	40.25	37.59	60.21	42.86	42.96	50.06	54.13	45.26	39.87						
20–44	NA	118.91	89.35	103.49	110.00	112.18	92.97	33.51	110.65	103.42	94.75						
45–64	NA	96.22	83.19	89.04	97.97	96.34	86.12	20.92	103.57	105.19	93.16						
65–74	NA	40.61	52.29	56.17	9.21	13.46	16.83	40.74	77.28	70.80	72.79						
75–84	NA	33.41	57.46	58.57	2.81	11.04	1.57	0.00	58.96	46.51	38.05						
≥85	NA	23.19	34.94	35.27	3.30	4.62	1.88		28.13	25.11	29.72						
Total	NA	84.74	60.55	67.97	81.23	72.51	68.35	47.13	79.09	68.73	66.81	64.38	42.89	53.23	62.75	73.29	87.57
					Inpatio	ent Utiliz	zation—	General	Hospital	/Acute	Care: To	tal (IPU)				
Total In	patie	nt															
Discharg	ges: D	Discharg	es/1,00	0 Membe	er Month	ıs											
<1	NA	11.52	7.61	7.11	8.53	7.02	6.98	27.67	9.21	6.67	6.19						
1–9	NA	0.97	0.85	0.81	0.98	0.80	0.93	6.12	0.75	0.93	0.67						
10–19	NA	1.89	1.64	1.69	2.39	1.83	2.16	3.74	1.75	2.04	1.67						
20–44	NA	10.38	10.02	10.90	12.90	11.51	11.78	3.91	8.89	10.88	8.88						
45–64	NA	20.16	16.77	19.19	16.77	18.70	15.75	5.34	16.60	15.47	12.36						
65–74	NA	19.38	21.00	18.24	2.48	1.42	5.71	25.93	21.48	19.29	16.20						
75–84	NA	23.87	26.53	25.62	0.51	7.14	3.14	0.00	19.38	14.07	9.51						
≥85	NA	17.39	23.88	28.22	1.10	2.31	9.40		10.61	6.46	4.85						
Total	NA	6.65	5.64	6.21	6.89	6.12	6.01	4.95	6.27	5.94	4.83	8.59	5.14	5.83	6.81	8.51	13.78
Days: Da	ays/1	,000 Me	mber M	onths													
<1	NA	112.89	59.90	55.89	53.57	36.01	48.00	255.99	106.61	52.92	80.43						
1–9	NA	3.48	3.57	3.26	2.89	2.47	3.25	34.18	2.64	3.01	2.71						
10–19	NA	6.90	5.61	6.38	7.05	5.61	7.10	19.38	6.18	7.03	6.83						
20–44	NA	40.35	34.81	39.26	42.59	37.01	39.01	18.11	32.99	39.65	37.23						
45–64	NA	111.51	94.19	119.50	86.64	93.50	88.19	34.68	93.43	84.16	81.66						
65–74	NA	122.75	120.31	91.01	12.97	4.49	37.21	140.74	123.85	111.65	126.76						
75–84	NA	134.45	174.41	187.41	1.53	46.10	30.86	0.00	115.41	82.27	63.97						
≥85	NA	104.35	157.83	153.44	2.20	18.48	69.55		53.73	31.05	32.41						
Total	NA	31.25	24.97	28.28	26.87	22.95	24.20	28.00	30.76	25.97	26.06	38.86	18.26	22.47	27.92	35.47	70.10

Table A	. HEC	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizat	ion Mea	sures		
Measure		4.05	4.014	0.014	DOE	DOM	DOM	TOC		1111004	1111014	2016	National	Medicaio	d Means a	nd Perce	entiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
Average	Leng	th of St	ay: Aver	age # of	Days												
<1	NA	9.80	7.87	7.86	6.28	5.13	6.88	9.25	11.57	7.93	13.00						
1–9	NA	3.59	4.21	4.03	2.95	3.07	3.50	5.59	3.53	3.25	4.05						
10–19	NA	3.66	3.42	3.78	2.94	3.07	3.29	5.18	3.54	3.45	4.09						
20–44	NA	3.89	3.47	3.60	3.30	3.22	3.31	4.63	3.71	3.65	4.19						
45–64	NA	5.53	5.62	6.23	5.17	5.00	5.60	6.49	5.63	5.44	6.60						
65–74	NA	6.33	5.73	4.99	5.23	3.17	6.51	5.43	5.77	5.79	7.83						
75–84	NA	5.63	6.57	7.31	3.00	6.45	9.83		5.96	5.85	6.72						
≥85	NA	6.00	6.61	5.44	2.00	8.00	7.40		5.07	4.81	6.69						
Unknown	NA																
Total	NA	4.70	4.42	4.55	3.90	3.75	4.03	5.65	4.91	4.37	5.40	4.18	3.29	3.67	4.10	4.55	5.28
Medicine	е																
Discharg	ges: D	ischarg	es/1,00	0 Membe	er Month	าร											
<1	NA	9.95	6.29	5.54	7.66	6.11	5.79	22.07	8.12	5.78	4.95						
1–9	NA	0.75	0.58	0.56	0.83	0.62	0.75	4.72	0.59	0.73	0.49						
10-19	NA	0.61	0.53	0.41	0.67	0.56	0.54	2.50	0.53	0.73	0.46						
20–44	NA	2.99	2.34	2.61	3.11	3.03	3.02	2.05	2.63	2.72	2.10						
45–64	NA	13.29	11.51	12.41	12.12	13.80	11.51	4.29	11.44	10.62	8.17						
65–74	NA	14.77	14.88	14.04	1.84	1.18	4.63	18.52	15.27	13.41	10.70						
75–84	NA	19.09	23.15	21.96	0.51	6.49	2.62	0.00	14.64	10.74	6.59						
≥85	NA	14.49	22.13	26.46	1.10	1.15	7.52		8.46	5.31	3.12						
Total	NA	3.05	2.47	2.48	2.97	2.68	2.53	3.48	3.29	2.67	2.04	4.45	1.66	2.27	3.05	4.26	8.62
Days: Da	ays/1	,000 Me	mber M	onths													
<1	NA	91.59	36.08	26.37	46.56	25.77	26.08	148.95	91.51	43.50	38.22						
1–9	NA	2.09	1.49	1.72	2.21	1.65	2.29	20.70	1.86	2.35	1.82						
10–19	NA	2.11	1.69	1.32	2.27	1.79	2.05	12.88	2.13	2.52	2.06						
20–44	NA	11.07	8.80	9.82	13.33	11.96	12.62	9.45	11.63	11.27	11.33						
45–64	NA	55.91	52.04	51.77	57.54	62.23	56.65	21.20	59.11	53.73	48.22						
65–74	NA	70.60	79.72	58.73	8.89	3.54	27.79	103.70	77.93	69.89	69.54						
75–84	NA	97.85	126.75	153.73	1.53	40.91	27.72	0.00	72.41	57.32	38.88						
≥85	NA	85.51	146.19	137.57	2.20	4.62	58.27		42.51	26.05	17.34						
Total	NA	13.52	10.64	9.93	13.37	10.95	11.13	17.12	17.20	12.72	11.66	18.47	5.19	8.35	12.05	16.86	37.45

Table A	. HEC	DIS 201	7 Medi	caid Pla	n-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizati	ion Mea	sures		
Measure		4.05	0.004	0.014	DOE	D014	DOM	T00			1111014	2016	National	Medicaio	l Means a	and Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
Average	Leng	th of Sta	ay: Aver	age # of	Days	•				•	•			•	-		
<1	NA	9.20	5.74	4.76	6.08	4.22	4.50	6.75	11.27	7.52	7.72						
1–9	NA	2.78	2.58	3.07	2.67	2.64	3.05	4.39	3.15	3.24	3.70						
10–19	NA	3.44	3.20	3.24	3.37	3.17	3.82	5.16	3.99	3.46	4.53						
20–44	NA	3.70	3.75	3.77	4.29	3.95	4.18	4.62	4.42	4.15	5.38						
45–64	NA	4.21	4.52	4.17	4.75	4.51	4.92	4.94	5.17	5.06	5.90						
65–74	NA	4.78	5.36	4.18	4.83	3.00	6.00	5.60	5.10	5.21	6.50						
75–84	NA	5.13	5.47	7.00	3.00	6.30	10.60		4.95	5.34	5.90						
≥85	NA	5.90	6.61	5.20	2.00	4.00	7.75		5.03	4.90	5.55						
Unknown	NA																
Total	NA	4.43	4.30	4.00	4.50	4.09	4.41	4.91	5.22	4.76	5.70	3.94	3.32	3.57	3.89	4.26	4.62
Surgery	,																
Discharg	ges: D	ischarg	es/1,00	0 Membe	er Month	าร											
<1	NA	1.56	1.33	1.57	0.86	0.83	1.17	5.60	1.05	0.86	1.24						
1–9	NA	0.22	0.27	0.25	0.15	0.18	0.18	1.40	0.16	0.20	0.18						
10–19	NA	0.32	0.30	0.30	0.29	0.28	0.30	0.72	0.29	0.25	0.23						
20–44	NA	1.90	1.35	1.45	1.34	1.14	1.19	0.50	1.44	1.16	1.16						
45–64	NA	6.85	5.19	6.72	4.64	4.87	4.21	1.05	5.15	4.81	4.16						
65–74	NA	4.61	6.12	4.19	0.64	0.24	1.08	7.41	6.21	5.88	5.50						
75–84	NA	4.77	3.38	3.66	0.00	0.65	0.52	0.00	4.74	3.33	2.92						
≥85	NA	2.90	1.75	1.76	0.00	1.15	1.88		2.15	1.15	1.72						
Total	NA	1.52	1.13	1.28	1.05	0.92	0.91	0.99	1.42	1.04	1.00	1.86	0.77	1.08	1.43	1.90	3.02
Days: Da	ays/1	,000 Me	mber M	onths													
<1	NA	21.30	23.82	29.52	6.87	10.11	21.88	107.04	14.95	9.36	42.20						
1–9	NA	1.38	2.08	1.54	0.66	0.82	0.96	13.47	0.78	0.66	0.89						
10–19	NA	2.12	1.64	2.37	1.10	1.13	1.53	5.06	1.42	1.13	1.58						
20–44	NA	14.92	8.86	11.35	7.59	6.00	7.19	4.74	7.55	6.00	7.94						
45–64	NA	55.51	41.99	67.23	29.06	31.18	31.48	13.49	34.27	30.33	33.33						
65–74	NA	52.15	40.59	32.28	4.08	0.94	9.42	37.04	45.92	41.75	57.22						
75–84	NA	36.60	47.66	33.67	0.00	5.19	3.14	0.00	43.00	24.95	25.09						
≥85	NA	18.84	11.65	15.87	0.00	13.86	11.28		11.22	5.00	15.07						
Total	NA	12.24	8.78	11.84	6.13	5.43	6.50	9.51	9.11	6.14	8.68	14.21	4.72	6.65	9.30	13.07	25.02

Table A	. HE	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizat	ion Mea	sures		
Measure												2016	National	Medicaio	d Means a	nd Perce	entiles
by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
Average	Leng	th of St	ay: Aver	age # of	Days	-				-				-	-		
<1	NA	13.62	17.95	18.79	8.00	12.13	18.74	19.12	14.18	10.87	34.11						
1–9	NA	6.43	7.74	6.18	4.45	4.57	5.41	9.65	4.94	3.30	5.06						
10–19	NA	6.69	5.38	7.83	3.86	4.08	5.11	7.02	4.94	4.56	6.79						
20–44	NA	7.85	6.57	7.83	5.65	5.28	6.03	9.40	5.25	5.19	6.87						
45–64	NA	8.10	8.08	10.00	6.27	6.40	7.47	12.89	6.65	6.30	8.02						
65–74	NA	11.30	6.63	7.70	6.38	4.00	8.71	5.00	7.39	7.10	10.41						
75–84	NA	7.67	14.10	9.20		8.00	6.00		9.07	7.50	8.59						
≥85	NA	6.50	6.67	9.00		12.00	6.00		5.21	4.36	8.75						
Total	NA	8.06	7.79	9.22	5.86	5.89	7.17	9.65	6.42	5.89	8.72	7.01	4.85	6.01	6.88	7.96	9.01
Maternit	ty (ca	lculated	l using n	nember l	months	for mem	bers 10	-64 year	s)								
Discharg	ges: D	ischarg	es/1,00	0 Membe	er Month	าร											
10–19	NA	0.96	0.81	0.98	1.43	0.99	1.32	0.51	0.93	1.06	0.98						
20-44	NA	5.48	6.33	6.85	8.45	7.34	7.57	1.36	4.82	7.00	5.62						
45–64	NA	0.02	0.06	0.05	0.01	0.02	0.02	0.00	0.01	0.04	0.04						
Total	NA	3.00	3.29	3.75	4.43	3.85	3.98	0.73	2.40	3.62	2.89	3.69	0.88	2.15	2.99	4.52	6.93
Days: Da	ays/1	,000 Me	mber M	onths													
10–19	NA	2.68	2.28	2.69	3.68	2.68	3.52	1.34	2.63	3.38	3.18						
20–44	NA	14.36	17.16	18.10	21.68	19.03	19.20	3.92	13.81	22.38	17.97						
45–64	NA	0.09	0.16	0.51	0.03	0.08	0.04	0.00	0.05	0.09	0.11						
Total	NA	7.93	8.94	10.01	11.37	10.04	10.16	2.01	6.88	11.57	9.25	9.90	2.46	5.99	8.06	11.63	18.54
Average	Leng	th of St	ay: Aver	age # of	f Days												
10–19	NA	2.79	2.82	2.76	2.57	2.72	2.67	2.63	2.84	3.18	3.24						
20–44	NA	2.62	2.71	2.64	2.57	2.59	2.54	2.89	2.86	3.19	3.20						
45–64	NA	4.33	2.55	9.43	2.67	4.33	2.00		5.50	2.43	2.83						
Unknown	NA																
Total	NA	2.64	2.72	2.67	2.57	2.61	2.55	2.76	2.86	3.19	3.20	2.73	2.34	2.52	2.67	2.83	3.07
					Ident	ification	of Alcor	nol and (Other Dr	ug Servi	ices: Tot	al (IAD)					
Any Serv	vices																
	М	0.17%	0.01%	0.03%	0.18%	0.04%	0.06%	0.25%	0.14%	0.03%	0.02%						
0–12	F	0.15%	0.02%	0.04%	0.14%	0.03%	0.02%	0.23%	0.13%	0.04%	0.03%						
	M&F	0.16%	0.02%	0.04%	0.16%	0.04%	0.04%	0.24%	0.13%	0.03%	0.03%						

APPENDIX A | Utilization Measure Medicaid Results and Benchmarks

Table A	. HEC	DIS 201	7 Medi	caid Pla	in-Spec	ific Rate	es with	HEDIS	2016 N	ational	Benchr	marks:	Utilizat	ion Mea	sures		
Measure		4.05	4014	0.0107	DOE	DOM	DOM	T00			11110144	2016	National	Medicaio	d Means a	and Perce	entiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	М	2.09%	2.50%	1.86%	2.13%	1.99%	1.85%	6.61%	2.35%	2.60%	1.96%						
13–17	F	1.65%	1.63%	1.08%	1.67%	1.31%	1.22%	6.75%	1.69%	1.79%	1.16%						
	M&F	1.87%	2.07%	1.47%	1.90%	1.65%	1.53%	6.66%	2.02%	2.20%	1.55%						
	М	5.79%	4.27%	4.13%	4.24%	4.88%	2.77%	3.71%	3.98%	4.81%	3.62%						
18–24	F	7.32%	4.83%	3.92%	5.80%	5.57%	3.06%	3.37%	5.74%	4.87%	3.03%						
	M&F	6.68%	4.63%	4.00%	5.28%	5.32%	2.96%	3.58%	5.06%	4.85%	3.25%						
	M	11.63%	9.41%	9.32%	9.83%	11.61%	8.20%	2.01%	9.97%	11.41%	8.98%						
25–34	F	11.11%	8.50%	5.32%	11.33%	10.83%	6.24%	2.48%	10.60%	9.37%	5.71%						
	M&F	11.25%	8.69%	5.94%	11.06%	10.99%	6.53%	2.32%	10.45%	9.76%	6.26%						
	М	14.50%	12.77%	13.47%	14.58%	18.13%	13.82%	1.63%	15.79%	15.35%	11.98%						
35–64	F	10.29%	9.13%	6.42%	12.70%	13.70%	8.57%	1.55%	11.42%	12.39%	6.81%						
	M&F	11.99%	10.43%	8.88%	13.32%	15.19%	9.94%	1.58%	13.04%	13.42%	8.49%						
	М	6.07%	8.75%	6.40%	1.13%	1.07%	0.96%	0.00%	7.32%	7.26%	4.94%						
≥65	F	2.76%	4.03%	1.93%	0.60%	0.27%	0.56%	0.00%	4.39%	3.76%	2.78%						
	M&F	4.01%	5.76%	3.40%	0.76%	0.54%	0.67%	0.00%	5.27%	4.79%	3.42%						
	М																
Unknown	F																
	M&F																
	M	4.73%	3.45%	3.22%	3.77%	4.08%	2.70%	2.69%	4.84%	4.06%	2.99%						
Total	F	5.55%	4.18%	2.99%	5.92%	5.58%	3.54%	2.42%	5.55%	5.10%	2.96%						
	M&F	5.19%	3.87%	3.08%	5.04%	4.95%	3.21%	2.58%	5.25%	4.66%	2.97%	6.08%	1.41%	2.87%	5.05%	7.33%	12.91%
Inpatier	nt																
	М	0.01%	0.00%	0.00%	0.00%	0.00%	0.01%	0.06%	0.01%	0.01%	0.00%						
0–12	F	0.01%	0.01%	0.00%	0.00%	0.01%	0.00%	0.02%	0.00%	0.01%	0.00%						
	M&F	0.01%	0.00%	0.00%	0.00%	0.00%	0.01%	0.05%	0.01%	0.01%	0.00%						
	М	0.49%	0.42%	0.62%	0.45%	0.33%	0.60%	1.01%	0.42%	0.41%	0.31%						
13–17	F	0.55%	0.28%	0.45%	0.34%	0.30%	0.52%	0.99%	0.40%	0.45%	0.52%						
	M&F	0.52%	0.35%	0.54%	0.40%	0.32%	0.56%	1.00%	0.41%	0.43%	0.42%						
	М	2.02%	1.30%	1.49%	1.03%	1.48%	0.89%	1.14%	1.40%	1.70%	1.17%						
18–24	F	3.32%	1.95%	1.19%	2.35%	1.91%	0.87%	1.04%	2.41%	1.84%	0.95%						
	M&F	2.78%	1.72%	1.31%	1.92%	1.75%	0.88%	1.10%	2.02%	1.79%	1.03%						
	М	4.58%	2.76%	4.41%	3.09%	3.69%	2.94%	1.25%	3.17%	4.49%	3.36%						
25–34	F	5.08%	2.97%	1.91%	4.38%	3.80%	1.69%	1.14%	3.97%	3.21%	1.71%						
	M&F	4.95%	2.92%	2.30%	4.15%	3.78%	1.87%	1.18%	3.79%	3.46%	1.98%						

Measure												2016	National	Medicaio	d Means a	and Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	М	5.52%	4.32%	5.64%	3.92%	6.10%	4.01%	0.95%	4.82%	4.69%	4.08%						
35-64	F	3.21%	2.59%	2.00%	2.73%	3.26%	1.82%	0.84%	2.83%	2.91%	1.62%						
	M&F	4.14%	3.21%	3.27%	3.12%	4.21%	2.39%	0.89%	3.57%	3.53%	2.42%						
	M	3.04%	2.73%	1.48%	0.68%	0.53%	0.00%	0.00%	2.54%	2.36%	1.91%						
≥65	F	0.61%	0.71%	0.48%	0.10%	0.00%	0.19%	0.00%	0.83%	0.77%	0.33%						
	M&F	1.53%	1.45%	0.81%	0.28%	0.18%	0.13%	0.00%	1.35%	1.24%	0.80%						
	M																
Unknown	F																
	M&F																
	M	1.73%	1.06%	1.32%	0.99%	1.29%	0.82%	0.60%	1.45%	1.26%	0.97%						
Total	F	2.18%	1.33%	0.99%	1.75%	1.64%	0.87%	0.56%	1.65%	1.45%	0.80%						
	M&F	1.98%	1.21%	1.12%	1.44%	1.49%	0.85%	0.58%	1.57%	1.37%	0.87%	1.81%	0.37%	0.79%	1.25%	2.05%	3.82%
Intensiv	re Out	patient	/Partial	Hospital	ization	•	•	•	•	•	•		•	•	•	•	
	М	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.03%	0.00%	0.00%	0.00%						
0–12	F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.00%	0.00%	0.00%						
0	M&F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.02%	0.00%	0.00%	0.00%						
	М	0.69%	0.68%	0.30%	0.86%	0.69%	0.51%	2.24%	0.79%	0.92%	0.40%						
13–17	F	0.15%	0.39%	0.06%	0.46%	0.33%	0.14%	2.78%	0.28%	0.39%	0.21%						
	M&F	0.42%	0.54%	0.18%	0.66%	0.51%	0.32%	2.44%	0.54%	0.66%	0.30%						
	М	0.60%	0.68%	0.38%	0.75%	1.47%	0.58%	0.81%	0.56%	0.83%	0.43%						
18–24	F	1.09%	0.84%	0.56%	1.12%	1.67%	0.50%	0.52%	0.88%	0.63%	0.42%						
	M&F	0.89%	0.78%	0.49%	1.00%	1.60%	0.52%	0.70%	0.75%	0.70%	0.43%						
	M	1.42%	0.98%	1.09%	1.81%	2.96%	1.05%	0.42%	1.03%	2.00%	1.24%						
25-34	F	2.05%	1.33%	0.86%	2.58%	2.98%	1.21%	0.28%	1.78%	1.61%	0.92%						
	M&F	1.88%	1.26%	0.89%	2.44%	2.97%	1.18%	0.33%	1.60%	1.69%	0.97%						
	M	0.74%	0.93%	1.04%	1.34%	2.89%	1.28%	0.17%	0.64%	1.00%	0.76%						
35-64	F	0.83%	0.69%	0.52%	1.39%	2.04%	0.71%	0.23%	0.71%	0.80%	0.47%						
	M&F	0.79%	0.78%	0.70%	1.37%	2.33%	0.86%	0.20%	0.68%	0.87%	0.56%						
	M	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.10%	0.25%	0.26%						
≥65	F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%						
	M&F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.03%	0.07%	0.08%						
	М																
Unknown	F																
	M&F																

Table A	. HE	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	ational	Benchr	marks:	Utilizat	ion Mea	sures		
Measure		105	0.004	0.014	DOE	DOM	DOM	T 00			1111014	2016	National	Medicaio	l Means a	and Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	М	0.43%	0.37%	0.30%	0.52%	0.85%	0.35%	0.77%	0.36%	0.49%	0.28%						
Total	F	0.74%	0.52%	0.37%	0.97%	1.22%	0.44%	0.71%	0.56%	0.55%	0.32%						
	M&F	0.60%	0.45%	0.34%	0.79%	1.06%	0.41%	0.75%	0.48%	0.53%	0.30%	0.25%	0.00%	0.02%	0.11%	0.31%	0.68%
Outpatie	ent/E	D*															
	М	0.16%	0.01%	0.03%	0.18%	0.04%	0.05%	0.20%	0.13%	0.02%	0.02%						
0–12	F	0.13%	0.01%	0.04%	0.14%	0.03%	0.02%	0.22%	0.12%	0.03%	0.03%						
	M&F	0.14%	0.01%	0.04%	0.16%	0.03%	0.04%	0.21%	0.13%	0.03%	0.03%						
	М	1.59%	2.01%	1.42%	1.80%	1.60%	1.50%	5.65%	1.97%	2.23%	1.74%						
13–17	F	1.38%	1.38%	0.90%	1.52%	1.08%	0.94%	6.10%	1.53%	1.46%	1.04%						
	M&F	1.48%	1.69%	1.16%	1.66%	1.35%	1.21%	5.82%	1.75%	1.85%	1.38%						
	М	4.63%	3.35%	3.40%	3.53%	3.89%	2.31%	3.49%	3.18%	3.61%	3.07%						
18–24	F	5.39%	3.74%	3.19%	4.19%	4.47%	2.54%	2.76%	4.43%	4.03%	2.47%						
	M&F	5.08%	3.60%	3.27%	3.97%	4.25%	2.46%	3.20%	3.95%	3.88%	2.68%						
	М	9.58%	7.95%	7.41%	8.17%	9.52%	6.81%	2.32%	8.51%	9.22%	7.43%						
25–34	F	8.70%	7.04%	4.26%	9.29%	9.14%	5.31%	2.12%	8.84%	7.96%	4.87%						
	M&F	8.93%	7.22%	4.75%	9.09%	9.22%	5.53%	2.17%	8.76%	8.21%	5.30%						
	М		10.70%	10.74%	12.89%	15.23%	11.88%	1.42%	13.68%		10.34%						
35–64	F	8.66%	7.98%	5.53%	11.41%	12.19%	7.70%	0.94%	10.21%		6.10%						
	M&F	9.81%	8.96%	7.35%	11.89%	13.21%	8.79%	1.11%	11.50%		7.48%						
	М	3.54%	7.11%	5.42%	0.45%	0.53%	0.96%	0.00%	5.71%	6.42%	3.73%						
≥65	F	2.46%	3.48%	1.69%	0.70%	0.27%	0.56%	0.00%	4.07%	3.41%	2.52%						
	M&F	2.87%	4.81%	2.91%	0.62%	0.36%	0.67%	0.00%	4.57%	4.30%	2.88%						
	M																
Unknown	F																
	M&F																
	M	3.79%	2.86%	2.58%	3.28%	3.38%	2.29%	2.37%	4.14%	3.43%	2.56%						
Total	F	4.43%	3.52%	2.48%	5.03%	4.79%	3.08%	2.11%	4.81%	4.46%	2.59%	E 4404	4.4007	2.450/	4.4007	/ 70 0/	44 4404
	M&F	4.15%	3.24%	2.52%	4.32%	4.20%	2.77%		4.52%			5.44%	1.18%	2.45%	4.40%	6.79%	11.11%
						M	ental He	alth Uti	ization:	Total (N	MPT)						
Any Ser			ı														
	М	9.55%	7.64%	4.11%	9.81%	8.05%		26.37%		7.99%	4.30%						
0–12	F	6.04%	4.90%	2.38%	6.18%	4.90%	3.10%	18.52%		4.85%	2.55%						
	M&F	7.84%	6.29%	3.25%	8.02%	6.49%	3.99%	23.12%	7.13%	6.44%	3.44%						

Measure												2016	National	Medicaio	l Means a	nd Perce	entiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	M	13.58%	12.60%	7.11%	15.39%	11.25%	8.52%	37.72%	12.75%	12.27%	7.17%						
13–17	F	14.10%	14.67%	6.93%	16.68%	12.68%	8.74%	36.93%	14.63%	13.54%	6.87%						
	M&F	13.84%	13.63%	7.02%	16.03%	11.96%	8.63%	37.43%	13.70%	12.90%	7.01%						
	М	9.95%	11.97%	6.72%	11.13%	8.36%	8.43%	11.60%	12.97%	11.77%	9.62%						
18–64	F	11.92%	14.64%	5.74%	14.43%	10.99%	8.58%	7.75%	15.78%	13.87%	8.84%						
	M&F	11.21%	13.81%	6.03%	13.48%	10.19%	8.54%	9.81%	14.83%	13.22%	9.07%						
	М	9.11%	6.70%	3.45%	0.91%	2.13%	3.83%	16.22%	6.23%	7.94%	6.32%						
≥65	F	10.74%	9.25%	5.78%	2.20%	1.91%	3.74%	0.00%	9.85%	9.67%	5.89%						
	M&F	10.13%	8.31%	5.02%	1.80%	1.99%	3.77%	7.84%	8.76%	9.16%	6.02%						
	М																
Unknown	F																
	M&F																
	М	10.25%	9.71%	5.36%	11.01%	8.58%	6.45%	25.16%	10.91%	9.77%	6.36%						
Total	F	10.08%	10.88%	4.63%	11.64%	8.81%	6.61%	18.70%	11.87%	10.37%	6.26%						
	M&F	10.15%	10.39%	4.93%	11.38%	8.71%	6.55%	22.45%	11.46%	10.12%	6.30%	12.84%	4.82%	7.21%	10.94%	15.74%	21.73%
Inpatier	nt																
•	М	0.12%	0.08%	0.14%	0.10%	0.07%	0.11%	0.85%	0.07%	0.07%	0.10%						
0–12	F	0.09%	0.06%	0.09%	0.05%	0.05%	0.08%	0.47%	0.09%	0.05%	0.08%						
	M&F	0.11%	0.07%	0.12%	0.08%	0.06%	0.10%	0.69%	0.08%	0.06%	0.09%						
	М	0.88%	0.74%	0.92%	0.88%	0.63%	1.06%	3.13%	0.73%	0.70%	0.83%						
13–17	F	1.61%	1.16%	1.37%	1.30%	1.05%	1.52%	4.53%	1.24%	1.40%	1.15%						
	M&F	1.24%	0.95%	1.14%	1.08%	0.84%	1.30%	3.64%	0.99%	1.05%	0.99%						
	М	2.15%	1.85%	2.60%	1.44%	1.91%	1.70%	1.75%	2.04%	2.07%	2.51%						
18–64	F	1.65%	1.43%	1.28%	1.37%	1.49%	1.12%	1.35%	1.59%	1.67%	1.39%						
	M&F	1.83%	1.56%	1.67%	1.39%	1.62%	1.27%	1.56%	1.74%	1.79%	1.73%						
	М	5.57%	1.50%	0.00%	0.45%	2.13%	1.44%	0.00%	2.34%	3.55%	3.47%						
≥65	F	7.98%	1.82%	2.41%	0.80%	1.37%	1.50%	0.00%	3.62%	3.83%	2.56%						
	M&F	7.07%	1.70%	1.62%	0.69%	1.63%	1.48%	0.00%	3.23%	3.75%	2.83%						
	М				,,,,,,			,,,,,,	3120.0	31.2.0							
Unknown	F																
	M&F																
		1.049/	0.74%	1.05%	0.64%	0.73%	0.71%	1.68%	0.94%	0.83%	1.00%						
	М	1 ()4%						1.00/0	J. / T / U	0.00/0	1.00/0						
Total	M F	1.04% 1.13%	0.74%	0.86%	0.89%	0.90%	0.80%	1.61%	1.16%	1.11%	0.94%						

Measure												2016	National	Medicaio	d Means a	nd Perce	entiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
Intensiv	re Out	tpatient.	/Partial	Hospital	lization	•				•	•	•	-		•	•	•
	М	0.04%	0.00%	0.04%	0.02%	0.00%	0.08%	0.14%	0.04%	0.01%	0.03%						
0–12	F	0.01%	0.00%	0.06%	0.02%	0.00%	0.06%	0.14%	0.02%	0.00%	0.03%						
	M&F	0.03%	0.00%	0.05%	0.02%	0.00%	0.07%	0.14%	0.03%	0.00%	0.03%						
	M	0.23%	0.12%	0.53%	0.14%	0.11%	0.53%	0.67%	0.26%	0.04%	0.36%						
13–17	F	0.11%	0.13%	0.48%	0.13%	0.18%	0.54%	1.47%	0.14%	0.05%	0.48%						
	M&F	0.17%	0.13%	0.51%	0.13%	0.15%	0.53%	0.96%	0.20%	0.05%	0.43%						
	M	0.06%	0.09%	0.31%	0.06%	0.62%	0.29%	0.33%	0.10%	0.13%	0.36%						
18–64	F	0.12%	0.14%	0.22%	0.15%	0.53%	0.29%	0.28%	0.19%	0.15%	0.36%						
	M&F	0.10%	0.12%	0.25%	0.12%	0.56%	0.29%	0.31%	0.16%	0.14%	0.36%						
	M	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.08%	0.09%						
≥65	F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.07%	0.00%						
	M&F	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.07%	0.03%						
	M																
Unknown	F																
	M&F																
	M	0.07%	0.05%	0.19%	0.05%	0.21%	0.21%	0.33%	0.09%	0.05%	0.18%						
Total	F	0.08%	0.08%	0.19%	0.10%	0.29%	0.23%	0.46%	0.12%	0.08%	0.24%						
	M&F	0.08%	0.07%	0.19%	0.08%	0.26%	0.22%	0.38%	0.11%	0.07%	0.22%	0.44%	0.01%	0.04%	0.15%	0.36%	1.55%
Outpatie	ent/El	D															
_	М	9.54%	7.63%	4.07%	9.79%	8.04%	4.82%	26.16%	9.02%	7.98%	4.27%						
0–12	F	6.03%	4.88%	2.36%	6.17%	4.89%	3.09%	18.43%		4.85%	2.54%						
	M&F	7.83%	6.28%	3.22%	8.01%	6.48%	3.96%	22.96%	7.13%	6.43%	3.42%						
	M	13.41%	12.46%	6.72%	15.26%	11.07%	8.29%	36.97%	12.62%	12.14%	6.82%						
13–17	F	13.91%	14.53%	6.51%	16.59%	12.44%	8.44%	36.12%	14.56%	13.25%	6.62%						
	M&F	13.66%	13.49%	6.61%	15.92%	11.75%	8.37%	36.66%	13.59%	12.68%	6.72%						
	M	9.35%	11.37%	5.63%	10.80%	7.46%	7.93%	14.40%	12.48%	11.12%	8.90%						
18–64	F	11.40%	14.29%	5.21%	14.12%	10.30%	8.24%	8.46%	15.44%	13.41%	8.40%						
	M&F	10.65%	13.38%	5.34%	13.17%	9.44%	8.16%	11.45%	14.43%	12.71%	8.55%						
	M	3.54%	5.47%	3.45%	0.45%	0.00%	2.87%	17.78%	4.31%	4.73%	3.29%						
≥65	F	3.38%	7.82%	3.37%	1.50%	0.55%	2.62%	0.00%	6.66%	6.30%	3.70%						
	M&F	3.44%	6.96%	3.40%	1.18%	0.36%	2.69%	8.70%	5.95%	5.83%	3.58%						
	M																
Unknown																	

Table A	. HEC	DIS 201	7 Medio	caid Pla	an-Spec	ific Rat	es with	HEDIS	2016 N	ational	Benchi	marks:	Utilizat	ion Mea	sures		
Measure	C	465	0.004	0.0107	DOE	DOM	DOM	TOC	LILIOE	LULIONA	LULIOVA	2016	National	Medicaio	d Means a	nd Perce	entiles
by Age	Sex	AGE	AGM	AGW	BCE	ВСМ	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	М	9.97%	9.48%	4.94%	10.87%	8.26%	6.25%	26.45%	10.65%	9.49%	6.02%						
Total	F	9.73%	10.66%	4.29%	11.46%	8.42%	6.39%	19.21%	11.52%	10.00%	5.93%						
	M&F	9.84%	10.16%	4.55%	11.22%	8.35%	6.33%	23.38%	11.15%	9.79%	5.96%	12.11%	4.44%	6.76%	10.69%	14.61%	20.87%
							Antibio	tic Utiliz	ation: To	otal (AB)	X)						
Antibiot	ic Uti	lization															
Average	Scrip	ots PMP	for Ant	ibiotics													
_	М	1.10	1.00	0.73	1.46	1.05	1.02	1.30	1.12	1.12	0.86						
0–9	F	1.15	1.04	0.76	1.51	1.10	1.08	1.38	1.17	1.16	0.87						
	M&F	1.13	1.02	0.75	1.48	1.07	1.05	1.33	1.15	1.14	0.86						
	M	0.68	0.60	0.46	0.87	0.58	0.59	0.73	0.68	0.62	0.52						
10–17	F	0.89	0.84	0.63	1.16	0.75	0.81	1.07	0.94	0.87	0.67						
	M&F	0.78	0.72	0.54	1.01	0.66	0.70	0.85	0.81	0.74	0.59						
	M	0.64	0.62	0.57	0.69	0.55	0.59	0.47	0.62	0.63	0.55						
18–34	F	1.48	1.44	1.54	1.56	1.48	1.57	0.85	1.34	1.40	1.36						
	M&F	1.20	1.21	1.28	1.34	1.22	1.32	0.64	1.12	1.19	1.14						
	M	0.82	0.88	0.91	0.96	0.82	0.93	0.29	0.87	0.91	0.86						
35–49	F	1.43	1.49	1.48	1.60	1.46	1.62	0.33	1.44	1.49	1.42						
	M&F	1.21	1.31	1.32	1.41	1.28	1.48	0.31	1.25	1.31	1.28						
	M	0.96	1.16	0.90	1.05	1.00	0.97	0.44	1.10	1.13	0.96						
50–64	F	1.40	1.79	1.36	1.59	1.46	1.52	0.74	1.71	1.72	1.52						
	M&F	1.19	1.50	1.16	1.39	1.26	1.31	0.57	1.44	1.47	1.26						
	M	1.63	1.82	1.08	0.15	0.53	0.40	0.87	1.52	1.07	1.10						
65–74	F	2.28	2.59	1.75	0.30	0.38	0.39	0.49	2.05	1.67	1.46						
	M&F	2.00	2.28	1.51	0.26	0.44	0.39	0.67	1.85	1.46	1.32						
	M	2.02	1.74	1.63	0.01	0.60	0.00	0.00	1.20	0.88	0.54						
75–84	F	1.94	2.34	1.66	0.09	0.39	0.11	0.00	1.54	0.96	0.75						
	M&F	1.97	2.16	1.65	0.07	0.45	0.09	0.00	1.45	0.93	0.70						
	М	1.68	1.42	1.02	0.60	1.11	1.12		0.77	0.44	0.47						
≥85	F	1.22	2.49	1.02	0.38	0.21	0.24		0.70	0.48	0.36						
	M&F	1.29	2.28	1.02	0.42	0.40	0.38		0.71	0.47	0.38						
	М																
Unknown	F																
	M&F																

Table A	. HEC	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizat	ion Mea	sures		
Measure		4.05	0.004	0.014	DOE	DOM	DOM	T00			11110144	2016	National	Medicaio	l Means a	nd Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	M	0.86	0.86	0.66	1.11	0.81	0.82	0.84	0.92	0.91	0.74	0.81	0.57	0.65	0.75	0.92	1.09
Total	F	1.27	1.25	1.15	1.47	1.22	1.29	1.07	1.29	1.27	1.10	1.19	0.82	0.95	1.11	1.31	1.60
	M&F	1.09	1.09	0.95	1.33	1.05	1.11	0.94	1.13	1.12	0.95	1.02	0.72	0.81	0.96	1.13	1.33
Average	Days	Supplie	ed per Ai	ntibiotic	Script												
	M	9.20	9.44	9.39	9.30	9.49	9.39	10.69	9.26	9.53	9.49						
0–9	F	9.34	9.51	9.45	9.44	9.55	9.47	10.92	9.34	9.60	9.49						
	M&F	9.27	9.47	9.42	9.37	9.52	9.43	10.79	9.30	9.56	9.49						
	M	9.52	9.86	9.45	10.26	9.45	9.88	11.27	10.18	9.87	10.00						
10–17	F	9.32	9.29	8.86	10.09	9.57	9.66	11.13	9.77	9.32	9.47						
	M&F	9.41	9.53	9.11	10.17	9.52	9.75	11.21	9.94	9.56	9.70						
	M	9.16	9.61	8.85	9.93	9.18	9.55	12.11	10.03	9.76	9.40						
18–34	F	8.17	8.17	7.64	8.80	8.76	8.48	10.05	8.51	8.29	7.92						
	M&F	8.35	8.37	7.78	8.95	8.81	8.60	10.89	8.77	8.50	8.11						
	M	8.98	10.05	9.92	10.02	10.27	10.54	12.22	9.55	9.80	10.13						
35–49	F	8.69	8.66	8.53	9.16	9.08	9.08	11.06	8.85	8.69	8.69						
	M&F	8.76	8.95	8.80	9.34	9.30	9.27	11.51	9.00	8.93	8.93						
	M	9.39	9.82	9.62	10.95	10.80	10.84	15.18	9.81	10.14	9.99						
50–64	F	8.68	9.17	8.54	9.62	9.20	9.90	15.24	9.15	9.32	8.66						
	M&F	8.95	9.40	8.91	9.99	9.74	10.15	15.21	9.37	9.59	9.12						
	M	9.22	9.29	12.24	10.54	14.47	11.85	8.00	9.69	8.89	9.41						
65–74	F	8.95	8.29	8.49	9.47	9.35	9.26	7.33	9.19	8.41	8.89						
	M&F	9.04	8.62	9.43	9.68	11.73	10.06	7.73	9.34	8.54	9.05						
	M	11.85	9.05	10.49	7.00	6.55			9.20	9.80	8.48						
75–84	F	12.52	8.82	9.85	8.05	10.64	7.93		9.40	9.57	8.48						
	M&F	12.30	8.88	10.03	8.00	9.09	7.93		9.35	9.63	8.48						
	M	9.07	5.98	10.10	8.25	9.71	3.88		7.36	7.20	7.78						
≥85	F	13.17	9.18	7.16	5.79	7.67	6.67		9.47	8.85	7.51						
	M&F	12.39	8.79	7.77	6.41	8.86	5.35		9.13	8.61	7.56						
	M																
Unknown	F																
	M&F																
	М	9.25	9.61	9.40	9.71	9.60	9.69	11.12	9.60	9.68	9.66	9.95	9.29	9.50	9.74	10.10	10.55
Total	F	8.74	8.83	8.30	9.29	9.14	9.08	10.86	9.06	8.95	8.69	9.11	8.49	8.79	8.99	9.26	9.68
	M&F	8.92	9.09	8.61	9.43	9.29	9.26	10.99	9.24	9.20	9.00	9.42	8.80	9.06	9.29	9.55	10.01

Table A.	. HEC	DIS 201	7 Media	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	ational	Benchr	narks:	Utilizati	ion Mea	sures		
Measure	Carr	۸۵۶	0.004	0.0707	DOE	DCM	DCM	TOC	шсг	LULIONA	LILICIA	2016	National	Medicaio	l Means a	nd Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
Average	Scrip	ts PMP	for Ant	ibiotics	of Conce	ern											
	М	0.53	0.44	0.31	0.74	0.45	0.50	0.63	0.55	0.49	0.38						
0–9	F	0.52	0.44	0.31	0.71	0.45	0.49	0.61	0.55	0.50	0.36						
	M&F	0.53	0.44	0.31	0.73	0.45	0.49	0.62	0.55	0.49	0.37						
	М	0.33	0.27	0.22	0.42	0.26	0.28	0.31	0.34	0.28	0.25						
10–17	F	0.40	0.36	0.27	0.53	0.32	0.37	0.43	0.45	0.38	0.29						
	M&F	0.36	0.32	0.25	0.47	0.29	0.32	0.36	0.40	0.33	0.27						
	М	0.32	0.30	0.28	0.32	0.26	0.27	0.20	0.30	0.30	0.27						
18–34	F	0.64	0.60	0.61	0.66	0.59	0.61	0.33	0.60	0.60	0.56						
	M&F	0.53	0.52	0.52	0.57	0.50	0.52	0.25	0.51	0.52	0.48						
	М	0.42	0.44	0.46	0.50	0.40	0.47	0.11	0.46	0.47	0.44						
35–49	F	0.73	0.72	0.69	0.82	0.70	0.74	0.11	0.75	0.73	0.68						
	M&F	0.62	0.63	0.63	0.72	0.62	0.69	0.11	0.66	0.65	0.62						
	М	0.54	0.59	0.46	0.53	0.48	0.48	0.15	0.59	0.58	0.47						
50–64	F	0.78	0.95	0.70	0.84	0.76	0.77	0.23	0.95	0.95	0.80						
	M&F	0.66	0.79	0.59	0.73	0.64	0.66	0.18	0.79	0.80	0.65						
-	М	0.98	1.01	0.44	0.08	0.21	0.22	0.48	0.89	0.62	0.62						
65–74	F	1.34	1.35	0.93	0.15	0.21	0.22	0.16	1.14	0.95	0.76						
	M&F	1.19	1.21	0.76	0.13	0.21	0.22	0.31	1.05	0.83	0.71						
-	М	1.31	1.01	0.74	0.00	0.35	0.00	0.00	0.66	0.53	0.31						
75–84	F	0.87	1.46	0.75	0.03	0.24	0.07	0.00	0.82	0.52	0.41						
	M&F	1.01	1.33	0.75	0.02	0.27	0.05	0.00	0.78	0.52	0.39						
-	M	1.08	0.85	0.61	0.38	0.39	0.70		0.48	0.28	0.35						
≥85	F	0.55	1.41	0.51	0.19	0.14	0.11		0.36	0.26	0.19						
	M&F	0.63	1.30	0.53	0.22	0.19	0.20		0.38	0.26	0.21						
	M F																
Unknown																	
	M&F M	0.43	0.40	0.30	0.55	0.37	0.40	0.38	0.46	0.42	0.34	0.35	0.21	0.27	0.32	0.40	0.53
Total	F	0.43	0.40	0.30	0.69	0.52	0.56	0.38	0.48	0.42	0.34	0.50	0.21	0.27	0.32	0.40	0.53
_	г M&F	0.52	0.38	0.41	0.63	0.32	0.49	0.44	0.56	0.51	0.43	0.30	0.32	0.33	0.40	0.37	0.63
Percenta									2.30	0.01	0.10	5.10	J. _ ,	0.00	0.10	J. 17	0.30
Crociita	M M		44.05%					48.77%	49.29%	43.93%	43.88%						
0–9	F		41.85%		47.43%			44.02%									
_			42.95%														

Measure	Sex	AGE	AGM	AGW	BCE	всм				UHCM	UHCW	2016 National Medicaid Means and Percentiles						
by Age							BCW	TCS	UHCE			Mean	P10	P25	P50	P75	P90	
	М	48.98%	45.69%	48.15%	48.05%	45.58%	47.43%	42.95%	50.12%	45.79%	47.65%							
10–17	F	44.41%	43.27%	43.68%	45.99%	42.44%	45.09%	40.38%	48.14%	44.14%	43.69%							
	M&F	46.41%	44.28%	45.55%	46.88%	43.82%	46.05%	41.76%	48.98%	44.84%	45.39%							
	М	49.01%	48.21%	49.21%	46.32%	47.22%	45.25%	41.51%	49.19%	48.22%	49.08%							
18–34	F	43.23%	41.71%	39.43%	42.22%	39.85%	38.54%	38.44%	44.76%	42.76%	41.47%							
	M&F	44.28%	42.64%	40.58%	42.75%	40.78%	39.30%	39.70%	45.51%	43.54%	42.46%							
	М	51.12%	49.18%	50.39%	51.55%	48.95%	50.36%	39.50%	53.28%	51.81%	51.69%							
35–49	F	51.26%	48.30%	46.77%	51.19%	48.17%	45.82%	34.99%	52.11%	49.35%	47.76%							
	M&F							36.74%	52.37%	49.89%	48.43%							
	М	56.04%	50.63%	50.66%	50.51%	48.13%	49.29%	33.75%	53.52%	51.85%	48.64%							
50–64	F			51.61%				31.56%										
								32.53%										
	M							55.56%										
65–74	F							33.33%										
	M&F			49.93%		48.39%	55.87%	46.67%		57.19%								
	М			45.28%		59.09%				60.78%								
75–84	F			45.19%						54.40%								
	M&F			45.21%						56.14%								
	M	64.29%	60.00%	60.00%	62.50%	35.29%	62.50%		62.30%	63.64%	74.51%							
≥85	F			50.00%						53.87%								
	M&F	48.65%	57.06%	52.08%	53.13%	48.28%	52.94%		53.37%	55.29%	55.67%							
	М																	
Unknown	F																	
	M&F																	
											46.60%							
Total											44.45%							
	M&F	47.31%	45.00%	43.11%	47.67%	43.45%	44.74%	43.62%	49.62%	45.79%	45.14%	42.10%	36.01%	38.83%	41.73%	45.40%	48.90%	
Antibiot	ics of	Concer	า Utiliza	tion														
Average	Scrip	ts PMP	for Qui	nolones														
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00							
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00							
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00							
	М	0.00	0.01	0.00	0.01	0.00	0.01	0.01	0.01	0.01	0.00							
10–17	F	0.01	0.02	0.01	0.02	0.01	0.02	0.03	0.02	0.02	0.01							
	M&F	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.01							

Table A	. HEC	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	narks:	Utilizat	ion Mea	sures		
Measure	Sex	AGE	ACNA	4.0)4/	BCE	всм	2014	T00		1111004	UHCW	2016 National Medicaid Means and Percentiles					
by Age			AGM	AGW			BCW	TCS	UHCE	UHCM		Mean	P10	P25	P50	P75	P90
	M	0.04	0.04	0.04	0.04	0.04	0.04	0.03	0.04	0.05	0.04						
18–34	F	0.11	0.11	0.11	0.12	0.12	0.12	0.07	0.11	0.11	0.10						
	M&F	0.09	0.09	0.09	0.10	0.09	0.10	0.05	0.09	0.09	0.08						
	M	0.09	0.10	0.12	0.11	0.11	0.11	0.04	0.10	0.11	0.10						
35–49	F	0.17	0.17	0.16	0.20	0.17	0.19	0.03	0.18	0.17	0.16						
	M&F	0.14	0.14	0.15	0.17	0.15	0.17	0.03	0.15	0.15	0.15						
	M	0.16	0.19	0.14	0.16	0.16	0.15	0.05	0.18	0.18	0.15						
50–64	F	0.24	0.28	0.22	0.27	0.27	0.25	0.13	0.29	0.28	0.26						
	M&F	0.20	0.24	0.18	0.22	0.22	0.21	0.08	0.24	0.24	0.21						
	M	0.36	0.40	0.09	0.03	0.08	0.10	0.19	0.31	0.20	0.22						
65–74	F	0.49	0.51	0.37	0.07	0.11	0.08	0.00	0.43	0.35	0.27						
	M&F	0.43	0.47	0.28	0.05	0.10	0.09	0.09	0.38	0.30	0.25						
	M	0.66	0.54	0.34	0.00	0.08	0.00	0.00	0.24	0.18	0.12						
75–84	F	0.35	0.69	0.42	0.01	0.12	0.04	0.00	0.34	0.23	0.19						
	M&F	0.45	0.64	0.40	0.01	0.11	0.03	0.00	0.31	0.21	0.17						
	M	0.96	0.50	0.31	0.30	0.07	0.14		0.21	0.11	0.19						
≥85	F	0.24	0.84	0.21	0.06	0.09	0.05		0.15	0.11	0.09						
	M&F	0.35	0.77	0.23	0.11	0.08	0.07		0.16	0.11	0.11						
	M																
Unknown	F																
	M&F																
	М	0.03	0.03	0.03	0.03	0.03	0.02	0.02	0.04	0.03	0.03	0.04	0.01	0.02	0.03	0.04	0.09
Total	F	0.08	0.08	0.07	0.09	0.08	0.09	0.03	0.10	0.08	0.08	0.09	0.04	0.06	0.08	0.10	0.15
	M&F	0.06	0.06	0.06	0.07	0.06	0.06	0.02	0.08	0.06	0.06	0.07	0.03	0.04	0.06	0.08	0.13
Average	Scrip	ts PMP	for Cer	halospo	rins 2nd	-4th Ge	eneratio	n					-		-	•	
J	М	0.19	0.19	0.10	0.29	0.20	0.18	0.24	0.20	0.21	0.12						
0–9	F	0.20	0.20	0.11	0.30	0.21	0.18	0.24	0.22	0.23	0.13						
0 /	M&F	0.19	0.19	0.10	0.29	0.20	0.18	0.24	0.21	0.22	0.12						
	M	0.06	0.06	0.10	0.27	0.26	0.05	0.06	0.06	0.06	0.04						
10–17	F	0.08	0.09	0.05	0.12	0.08	0.07	0.10	0.10	0.08	0.05						
.5 1,	M&F	0.07	0.07	0.03	0.12	0.07	0.06	0.08	0.08	0.07	0.04						
	M	0.07	0.02	0.02	0.03	0.07	0.00	0.02	0.03	0.02	0.02						
18–34	F	0.05	0.05	0.03	0.06	0.05	0.04	0.03	0.05	0.05	0.02						
10-34	M&F	0.03	0.05	0.03	0.05	0.03	0.04	0.03	0.05	0.05	0.03						
	MAI	0.04	0.03	0.03	0.03	0.04	0.04	0.02	0.03	0.03	0.03						

Table A	Table A. HEDIS 2017 Medicaid Plan-Specific Rates with HEDIS 2016 National Benchmarks: Utilization Measures																
Measure	Sex	AGE	AGM	AGW	ВСЕ	всм	BCW	TCS	UHCE	UHCM	UHCW	2016 National Medicaid Means and Percentiles					
by Age												Mean	P10	P25	P50	P75	P90
	M	0.03	0.03	0.03	0.04	0.03	0.04	0.01	0.03	0.04	0.02						
35–49	F	0.06	0.07	0.04	0.07	0.06	0.04	0.01	0.07	0.06	0.04						
	M&F	0.05	0.05	0.04	0.06	0.05	0.04	0.01	0.06	0.06	0.03						
	M	0.04	0.04	0.02	0.05	0.04	0.03	0.02	0.05	0.04	0.02						
50–64	F	0.06	0.07	0.04	0.08	0.06	0.05	0.00	0.09	0.10	0.05						
	M&F	0.05	0.06	0.03	0.07	0.05	0.04	0.01	0.07	0.07	0.04						
	M	0.06	0.10	0.07	0.00	0.01	0.01	0.00	0.11	0.09	0.05						
65–74	F	0.10	0.12	0.09	0.02	0.01	0.02	0.08	0.15	0.11	0.07						
	M&F	0.09	0.11	0.09	0.02	0.01	0.02	0.04	0.14	0.10	0.06						
	M	0.21	0.04	0.00	0.00	0.03	0.00	0.00	0.09	0.08	0.05						
75–84	F	0.15	0.21	0.07	0.00	0.01	0.00	0.00	0.13	0.08	0.03						
	M&F	0.17	0.16	0.05	0.00	0.02	0.00	0.00	0.12	0.08	0.03						
	M	0.00	0.14	0.00	0.00	0.13	0.56		0.09	0.02	0.05						
≥85	F	0.16	0.15	0.05	0.05	0.00	0.00		0.08	0.04	0.03						
	M&F	0.14	0.15	0.04	0.04	0.03	0.09		0.08	0.04	0.03						
	M																
Unknown	F																
	M&F																
	M	0.09	0.11	0.06	0.16	0.11	0.10	0.11	0.10	0.12	0.07	0.06	0.01	0.02	0.05	0.08	0.12
Total	F	0.10	0.11	0.06	0.14	0.10	0.09	0.12	0.11	0.12	0.06	0.06	0.02	0.03	0.05	0.08	0.12
	M&F	0.10	0.11	0.06	0.15	0.10	0.09	0.12	0.11	0.12	0.07	0.06	0.01	0.03	0.05	0.08	0.12
Average	Scrip	ts PMP	for Azi	thromyc	ins and	Clarithro	omycins										
	М	0.20	0.13	0.09	0.26	0.12	0.16	0.18	0.20	0.13	0.12						
0–9	F	0.18	0.12	0.09	0.23	0.12	0.15	0.17	0.19	0.13	0.11						
	M&F	0.19	0.12	0.09	0.25	0.12	0.15	0.18	0.19	0.13	0.11						
	М	0.15	0.12	0.09	0.18	0.11	0.12	0.11	0.17	0.13	0.11						
10–17	F	0.18	0.16	0.13	0.23	0.13	0.16	0.15	0.21	0.17	0.13						
	M&F	0.17	0.14	0.11	0.20	0.12	0.14	0.13	0.19	0.15	0.12						
	M	0.11	0.12	0.11	0.10	0.08	0.09	0.06	0.11	0.12	0.11						
18–34	F	0.24	0.24	0.26	0.24	0.22	0.22	0.13	0.23	0.24	0.24						
	M&F	0.20	0.21	0.22	0.20	0.18	0.19	0.09	0.19	0.20	0.20						
	M	0.12	0.14	0.13	0.14	0.11	0.14	0.02	0.14	0.16	0.14						
35-49	F	0.24	0.25	0.24	0.26	0.23	0.25	0.05	0.25	0.26	0.23						
	M&F	0.20	0.22	0.21	0.23	0.20	0.22	0.04	0.21	0.23	0.21						

Table A	. HEC	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizat	ion Mea	sures		
Measure	C	405	A CNA	0.004	DOE	DOM	DOW	TOC	шог	LULIONA	1111014	2016	National	Medicaio	l Means a	and Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	M	0.14	0.17	0.13	0.13	0.13	0.12	0.03	0.17	0.19	0.13						
50–64	F	0.25	0.31	0.23	0.25	0.22	0.22	0.05	0.30	0.31	0.26						
	M&F	0.20	0.25	0.18	0.20	0.18	0.18	0.04	0.24	0.26	0.20						
	M	0.24	0.24	0.10	0.02	0.02	0.06	0.10	0.25	0.15	0.15						
65–74	F	0.52	0.41	0.29	0.04	0.04	0.05	0.00	0.31	0.28	0.22						
	M&F	0.40	0.34	0.22	0.03	0.03	0.05	0.04	0.29	0.24	0.20						
	M	0.21	0.25	0.15	0.00	0.16	0.00	0.00	0.16	0.15	0.06						
75–84	F	0.17	0.34	0.18	0.01	0.08	0.02	0.00	0.18	0.13	0.10						
	M&F	0.18	0.31	0.18	0.01	0.10	0.02	0.00	0.17	0.14	0.09						
	M	0.00	0.14	0.00	0.08	0.07	0.00		0.11	0.09	0.06						
≥85	F	0.04	0.26	0.11	0.02	0.00	0.03		0.05	0.06	0.02						
	M&F	0.03	0.24	0.08	0.03	0.01	0.02		0.06	0.06	0.03						
	M																
Unknown	F																
	M&F																
	М	0.16	0.13	0.10	0.19	0.11	0.13	0.12	0.17	0.13	0.12	0.14	0.08	0.11	0.13	0.15	0.19
Total	F	0.21	0.20	0.18	0.24	0.17	0.19	0.15	0.22	0.20	0.18	0.20	0.12	0.15	0.18	0.22	0.27
	M&F	0.19	0.17	0.15	0.22	0.15	0.17	0.13	0.20	0.17	0.15	0.17	0.11	0.13	0.16	0.19	0.23
Average	Scrip	ts PMP	for Am	oxicillin	/Clavula	nates	-	•	•					•		•	
	М	0.13	0.10	0.08	0.17	0.11	0.13	0.16	0.14	0.13	0.11						
0–9	F	0.12	0.10	0.08	0.16	0.11	0.13	0.15	0.13	0.12	0.10						
	M&F	0.13	0.10	0.08	0.17	0.11	0.13	0.16	0.14	0.13	0.10						
	М	0.09	0.07	0.06	0.11	0.07	0.07	0.08	0.09	0.07	0.06						
10–17	F	0.09	0.08	0.06	0.12	0.07	0.08	0.10	0.10	0.09	0.06						
	M&F	0.09	0.07	0.06	0.12	0.07	0.08	0.09	0.10	0.08	0.06						
	М	0.08	0.07	0.06	0.08	0.07	0.07	0.05	0.07	0.07	0.06						
18–34	F	0.12	0.12	0.11	0.14	0.12	0.13	0.06	0.12	0.12	0.12						
	M&F	0.11	0.11	0.10	0.13	0.10	0.11	0.05	0.11	0.11	0.10						
	М	0.10	0.10	0.11	0.12	0.09	0.11	0.04	0.11	0.10	0.11						
35–49	F	0.15	0.15	0.15	0.17	0.14	0.16	0.02	0.15	0.15	0.15						
/	M&F	0.13	0.13	0.14	0.15	0.13	0.15	0.03	0.14	0.13	0.14						
	M	0.10	0.11	0.09	0.12	0.09	0.11	0.04	0.11	0.11	0.10						
50–64	F	0.15	0.18	0.15	0.16	0.14	0.16	0.04	0.17	0.17	0.15						
	M&F	0.13	0.15	0.12	0.14	0.12	0.14	0.04	0.14	0.15	0.13						
	WAF	0.13	0.15	0.12	0.14	0.12	0.14	0.04	0.14	0.15	0.13						

Table A	. HEC	DIS 201	7 Medio	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	ational	Benchr	marks:	Utilizati	ion Mea	sures		
Measure	Sex	405	0.004	0.0707	DOE	DOM	DOM	TOC	111105	LULIONA	11110)4/	2016	National	Medicaio	l Means a	nd Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	M	0.17	0.13	0.08	0.03	0.04	0.04	0.10	0.13	0.10	0.12						
65–74	F	0.15	0.21	0.10	0.02	0.03	0.06	0.08	0.18	0.12	0.14						
	M&F	0.16	0.18	0.10	0.02	0.03	0.05	0.09	0.16	0.11	0.13						
	M	0.03	0.13	0.18	0.00	0.00	0.00	0.00	0.10	0.09	0.06						
75–84	F	0.08	0.16	0.07	0.00	0.02	0.00	0.00	0.10	0.06	0.05						
	M&F	0.07	0.15	0.11	0.00	0.02	0.00	0.00	0.10	0.07	0.05						
	M	0.12	0.07	0.31	0.00	0.00	0.00		0.05	0.05	0.04						
≥85	F	0.04	0.10	0.05	0.00	0.05	0.00		0.04	0.03	0.04						
	M&F	0.05	0.09	0.11	0.00	0.04	0.00		0.04	0.04	0.04						
	M																
Unknown	F																
	M&F																
	M	0.10	0.09	0.08	0.13	0.09	0.10	0.10	0.11	0.10	0.09	0.08	0.05	0.06	0.08	0.10	0.12
Total	F	0.12	0.12	0.10	0.15	0.11	0.13	0.10	0.13	0.12	0.11	0.10	0.06	0.08	0.09	0.11	0.14
	M&F	0.11	0.11	0.09	0.14	0.10	0.12	0.10	0.12	0.11	0.10	0.09	0.06	0.07	0.09	0.10	0.13
Average	Scrip	ts PMPY	for Ket	olides													
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18-34	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35–49	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50–64	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
65–74	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						

Table A	. HEC	DIS 201	7 Medi	caid Pla	n-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizat	ion Mea	sures		
Measure	C	405	A CN4	0.004/	DOE	DOM	DOW	TOC	шог	LILLONA	11110)4/	2016	National	Medicaio	d Means a	and Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
75–84	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
≥85	F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	M																
Unknown	F																
	M&F																
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Average	Scrip	ts PMP	for Clir	ndamyci	ns	•	•	•	•	•	-		•	•	•	•	
J	М	0.02	0.02	0.04	0.02	0.02	0.03	0.04	0.01	0.02	0.03						
0–9	F	0.02	0.02	0.04	0.02	0.02	0.03	0.03	0.01	0.02	0.03						
	M&F	0.02	0.02	0.04	0.02	0.02	0.03	0.03	0.01	0.02	0.03						
	М	0.02	0.02	0.03	0.03	0.02	0.03	0.04	0.02	0.02	0.03						
10–17	F	0.02	0.03	0.03	0.03	0.03	0.04	0.05	0.03	0.03	0.04						
	M&F	0.02	0.02	0.03	0.03	0.02	0.04	0.04	0.02	0.02	0.03						
	М	0.06	0.04	0.05	0.06	0.05	0.04	0.03	0.05	0.05	0.04						
18–34	F	0.12	0.08	0.10	0.10	0.09	0.09	0.04	0.09	0.08	0.08						
	M&F	0.10	0.07	0.08	0.09	0.08	0.08	0.04	0.08	0.07	0.07						
	М	0.08	0.06	0.07	0.09	0.07	0.07	0.01	0.08	0.07	0.06						
35–49	F	0.11	0.09	0.10	0.12	0.10	0.10	0.01	0.10	0.09	0.10						
	M&F	0.10	0.08	0.09	0.11	0.09	0.09	0.01	0.09	0.09	0.09						
	M	0.07	0.06	0.06	0.07	0.05	0.07	0.01	0.07	0.05	0.06						
50-64	F	0.08	0.09	0.07	0.08	0.07	0.08	0.02	0.09	0.08	0.08						
	M&F	0.07	0.08	0.07	0.08	0.06	0.08	0.01	0.08	0.07	0.07						
	M	0.13	0.08	0.09	0.00	0.04	0.01	0.10	0.06	0.05	0.05						
65–74	F	0.08	0.08	0.07	0.01	0.02	0.01	0.00	0.06	0.08	0.05						
	M&F	0.10	0.08	0.07	0.01	0.03	0.01	0.04	0.06	0.07	0.05						
	M	0.03	0.06	0.06	0.00	0.05	0.00	0.00	0.06	0.02	0.02						
75–84	F	0.11	0.04	0.00	0.00	0.01	0.00	0.00	0.04	0.02	0.04						
	M&F	0.09	0.05	0.02	0.00	0.02	0.00	0.00	0.04	0.02	0.03						

Table A	. HEC	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	narks:	Utilizat	ion Mea	sures		
Measure	C	405	0.004	0.004/	DOE	DOM	DOW	TOC	LILIOE	LULIONA	11110)4/	2016	National	Medicaio	d Means a	and Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	M	0.00	0.00	0.00	0.00	0.13	0.00		0.02	0.02	0.00						
≥85	F	0.00	0.03	0.08	0.00	0.00	0.03		0.02	0.01	0.01						
	M&F	0.00	0.03	0.06	0.00	0.03	0.02		0.02	0.02	0.01						
	M																
Unknown	F																
	M&F																
	M	0.04	0.03	0.04	0.04	0.03	0.04	0.04	0.04	0.03	0.04	0.03	0.02	0.02	0.03	0.04	0.05
Total	F	0.07	0.05	0.07	0.07	0.06	0.07	0.04	0.06	0.05	0.06	0.05	0.03	0.04	0.05	0.06	0.07
	M&F	0.06	0.04	0.06	0.05	0.05	0.05	0.04	0.05	0.04	0.05	0.04	0.02	0.03	0.04	0.05	0.06
Average	Scrip	ts PMP	for Mis	c. Antib	iotics of	Concerr))		•	•	•			•	•	•	
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18–34	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01						
35-49	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.02	0.02	0.01	0.00	0.01	0.00	0.00	0.01	0.01	0.01						
50–64	F	0.01	0.02	0.00	0.01	0.00	0.00	0.00	0.00	0.01	0.01						
	M&F	0.01	0.02	0.00	0.01	0.01	0.00	0.00	0.01	0.01	0.01						
	M	0.01	0.05	0.00	0.00	0.02	0.00	0.00	0.03	0.04	0.02						
65–74	F	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.00	0.01						
	M&F	0.01	0.02	0.00	0.00	0.01	0.00	0.00	0.02	0.02	0.01						
	М	0.18	0.00	0.00	0.00	0.03	0.00	0.00	0.01	0.01	0.01						
75–84	F	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00						
	M&F	0.06	0.02	0.00	0.00	0.01	0.00	0.00	0.02	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
≥85	F	0.06	0.03	0.00	0.06	0.00	0.00		0.02	0.00	0.00						
	M&F	0.05	0.03	0.00	0.05	0.00	0.00		0.01	0.00	0.00						

Measure	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	2016	National	Medicaio	d Means a	and Perce	entiles
by Age	Sex	AGE	AGIVI	AGW	BCE	BCIVI	BCW	105	UHCE	OHCIVI	UHCW	Mean	P10	P25	P50	P75	P90
	M																
Unknown	F																
	M&F																
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
Total	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
All Othe	r Anti	biotics (Utilizatio	on													
Average	Scrip	ts PMP\	for Abs	orbable	Sulfona	mides											
	M	0.04	0.03	0.04	0.06	0.04	0.05	0.10	0.04	0.03	0.04						
)_9	F	0.08	0.06	0.06	0.09	0.06	0.08	0.13	0.07	0.06	0.07						
	M&F	0.06	0.04	0.05	0.07	0.05	0.07	0.12	0.06	0.05	0.06						
	M	0.04	0.03	0.03	0.06	0.04	0.04	0.07	0.04	0.04	0.03						
10–17	F	0.08	0.08	0.06	0.11	0.07	0.07	0.14	0.09	0.08	0.06						
	M&F	0.06	0.05	0.05	0.08	0.05	0.06	0.09	0.07	0.06	0.05						
	М	0.08	0.07	0.06	0.07	0.06	0.05	0.05	0.07	0.07	0.05						
18–34	F	0.16	0.14	0.13	0.15	0.15	0.13	0.10	0.13	0.14	0.12						
	M&F	0.13	0.12	0.11	0.13	0.13	0.11	0.07	0.11	0.12	0.10						
	M	0.11	0.12	0.10	0.11	0.10	0.10	0.02	0.11	0.11	0.09						
35–49	F	0.16	0.15	0.14	0.16	0.16	0.14	0.04	0.15	0.16	0.14						
	M&F	0.14	0.14	0.13	0.14	0.14	0.13	0.03	0.13	0.14	0.13						
	M	0.12	0.16	0.12	0.13	0.12	0.09	0.06	0.13	0.16	0.10						
50–64	F	0.14	0.19	0.13	0.14	0.15	0.13	0.07	0.16	0.18	0.13						
	M&F	0.13	0.18	0.12	0.13	0.14	0.11	0.07	0.15	0.17	0.12						
	M	0.14	0.21	0.09	0.02	0.04	0.02	0.29	0.15	0.11	0.08						
65–74	F	0.22	0.30	0.15	0.02	0.03	0.03	0.16	0.19	0.16	0.14						
	M&F	0.19	0.26	0.13	0.02	0.03	0.02	0.22	0.17	0.14	0.12						
	M	0.15	0.18	0.12	0.00	0.00	0.00	0.00	0.10	0.07	0.05						
75–84	F	0.22	0.22	0.21	0.00	0.07	0.01	0.00	0.13	0.10	0.06						
	M&F	0.20	0.21	0.18	0.00	0.05	0.01	0.00	0.12	0.09	0.05						
	M	0.12	0.07	0.10	0.23	0.00	0.00		0.03	0.04	0.04						
≥85	F	0.18	0.23	0.11	0.05	0.02	0.00		0.08	0.04	0.03						
	M&F	0.17	0.20	0.11	0.08	0.01	0.00		0.07	0.04	0.03						

Table A		JIS EU	7 IVICAI	eara r la	п эрсс	mo Rat	OS WILL	TIEDI S		ectorial	BCHCIII					and Dorse	matilaa
Measure by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW					and Perce	P90
by Age	M											Mean	P10	P25	P50	P75	P90
Jnknown	F																
OTIKITOWIT	M&F																
	M	0.06	0.06	0.05	0.07	0.05	0.05	0.07	0.06	0.06	0.05	0.07	0.03	0.04	0.05	0.06	0.09
Total	F	0.12	0.11	0.10	0.13	0.11	0.11	0.12	0.12	0.11	0.10	0.11	0.06	0.07	0.09	0.12	0.15
	M&F	0.10	0.09	0.08	0.10	0.09	0.09	0.09	0.09	0.09	0.08	0.09	0.05	0.06	0.07	0.09	0.12
Average	Scrin				sides												
/ wer age	М	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
,	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18–34	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35–49	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00						
50–64	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
65–74	F	0.04	0.01	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.01						
	M&F	0.02	0.01	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.01						
75–84	F	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
. 05	M	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
≥85	F	0.00	0.03	0.00	0.00	0.00	0.00		0.00	0.01	0.00						
	M&F	0.00	0.02	0.00	0.00	0.00	0.00		0.00	0.01	0.00						
l lalea	M																
Unknown	F																
	M&F																

Table A		л <u>Ј</u>	7 IVICUI	calu Pla	m-spec	HIC Kat	CS WILLI	TILDIS	201010	ational	Dericiii						
Measure	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW					and Perce	
by Age												Mean	P10	P25	P50	P75	P90
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Average	Scrip	ts PMP	for 1st	Genera	tion Cep	halospo	rins										
	M	0.04	0.06	0.03	0.06	0.06	0.05	0.06	0.05	0.07	0.04						
0–9	F	0.06	0.07	0.04	0.07	0.08	0.06	0.07	0.06	0.07	0.04						
	M&F	0.05	0.07	0.04	0.06	0.07	0.05	0.06	0.05	0.07	0.04						
	M	0.05	0.06	0.04	0.06	0.06	0.05	0.06	0.05	0.06	0.04						
10–17	F	0.06	0.07	0.04	0.08	0.07	0.06	0.07	0.06	0.07	0.05						
	M&F	0.06	0.06	0.04	0.07	0.06	0.05	0.06	0.05	0.07	0.04						
	M	0.05	0.06	0.05	0.06	0.06	0.05	0.04	0.05	0.06	0.05						
18–34	F	0.11	0.12	0.10	0.12	0.12	0.11	0.06	0.10	0.11	0.09						
	M&F	0.09	0.10	0.08	0.10	0.10	0.10	0.05	0.08	0.10	0.08						
	M	0.07	0.09	0.07	0.08	0.08	0.07	0.02	0.07	0.08	0.08						
35–49	F	0.09	0.12	0.09	0.11	0.12	0.10	0.02	0.10	0.11	0.09						
	M&F	0.09	0.11	0.09	0.10	0.11	0.10	0.02	0.09	0.11	0.09						
	M	0.09	0.12	0.09	0.08	0.09	0.09	0.04	0.10	0.11	0.10						
50-64	F	0.10	0.15	0.10	0.12	0.12	0.12	0.04	0.13	0.13	0.13						
	M&F	0.09	0.14	0.09	0.10	0.11	0.10	0.04	0.12	0.12	0.11						
	M	0.17	0.21	0.10	0.01	0.05	0.02	0.10	0.11	0.09	0.10						
65–74	F	0.08	0.32	0.10	0.02	0.03	0.08	0.00	0.17	0.15	0.14						
	M&F	0.12	0.28	0.10	0.01	0.04	0.06	0.04	0.15	0.13	0.13						
	M	0.18	0.21	0.28	0.00	0.00	0.00	0.00	0.08	0.11	0.09						
75–84	F	0.21	0.21	0.20	0.04	0.00	0.01	0.00	0.11	0.09	0.06						
	M&F	0.20	0.21	0.22	0.03	0.00	0.01	0.00	0.10	0.09	0.07						
	M	0.00	0.21	0.00	0.00	0.72	0.42		0.09	0.03	0.03						
≥85	F	0.14	0.24	0.00	0.08	0.00	0.03		0.08	0.05	0.06						
	M&F	0.12	0.24	0.00	0.07	0.15	0.09		0.09	0.05	0.06						
	М																
Unknown	F																
	M&F																
	М	0.05	0.07	0.04	0.06	0.06	0.05	0.05	0.06	0.07	0.05	0.06	0.04	0.04	0.06	0.07	0.09
Total	F	0.08	0.10	0.07	0.10	0.10	0.08	0.06	0.09	0.09	0.07	0.09	0.05	0.06	0.08	0.10	0.13
	M&F	0.07	0.09	0.06	0.08	0.08	0.07	0.06	0.07	0.08	0.06	0.07	0.04	0.05	0.07	0.08	0.11

Table A	. HEL	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr						
Measure	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW		T .	1		and Perce	l .
by Age												Mean	P10	P25	P50	P75	P90
Average	Scrip				_			_									
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18–34	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35–49	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50–64	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
65–74	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
75–84	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
≥85	F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	M																
Unknown	F																
	M&F																
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Average	Scrip	ts PMP	for Mad	crolides	(not azi	th. or cla	arith.)										
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.03	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00	0.00						

Table A	. HEC	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	narks:	Utilizati	on Mea	sures		
Measure	C	405	0.004	0.0707	DOE	DOM	DOW	TOC	111105	LULIONA	1111014	2016	National	Medicaio	Means a	nd Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
10–17	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
18–34	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
35–49	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
50–64	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
65–74	F	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00						
1	M&F	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.08	0.00	0.00						
75–84	F	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.00	0.00						
	М	0.00	0.00	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
≥85	F	0.00	0.02	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	M&F	0.00	0.01	0.00	0.00	0.00	0.00		0.00	0.00	0.00						
	М																
Unknown	F																
	M&F																
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total	F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Average	Scrip	ts PMP	for Per	nicillins													
	М	0.48	0.47	0.35	0.60	0.49	0.43	0.47	0.47	0.52	0.40						
0–9	F	0.49	0.47	0.35	0.62	0.50	0.44	0.51	0.48	0.52	0.39						
	M&F	0.48	0.47	0.35	0.61	0.50	0.43	0.49	0.47	0.52	0.40						
	M	0.21	0.19	0.14	0.26	0.19	0.17	0.21	0.19	0.20	0.15						
10–17	F	0.27	0.24	0.18	0.31	0.23	0.21	0.27	0.24	0.25	0.18						
	M&F	0.24	0.21	0.16	0.28	0.21	0.19	0.23	0.21	0.22	0.16						

Table A	. HEC	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	ational	Benchr	marks:	Utilizati	ion Mea	sures		
Measure	C	405	0.004	0.0707	DOE	DOM	DOW	TOC	111105	LULIONA	11110)4/	2016	National	Medicaio	d Means a	nd Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	BCM	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	M	0.14	0.12	0.11	0.15	0.12	0.13	0.10	0.12	0.12	0.10						
18–34	F	0.24	0.22	0.22	0.27	0.24	0.26	0.14	0.21	0.22	0.20						
	M&F	0.20	0.20	0.19	0.24	0.21	0.23	0.12	0.18	0.19	0.17						
	M	0.13	0.13	0.16	0.17	0.16	0.17	0.09	0.14	0.15	0.14						
35–49	F	0.19	0.20	0.20	0.23	0.21	0.26	0.09	0.18	0.20	0.20						
	M&F	0.17	0.18	0.19	0.22	0.20	0.24	0.09	0.17	0.18	0.18						
	M	0.10	0.15	0.13	0.18	0.19	0.19	0.07	0.13	0.14	0.16						
50–64	F	0.15	0.21	0.18	0.22	0.20	0.23	0.16	0.17	0.16	0.21						
	M&F	0.13	0.18	0.16	0.21	0.19	0.21	0.11	0.15	0.15	0.19						
	M	0.18	0.23	0.31	0.04	0.13	0.10	0.00	0.14	0.13	0.16						
65–74	F	0.28	0.29	0.26	0.04	0.05	0.03	0.08	0.18	0.14	0.18						
	M&F	0.24	0.27	0.28	0.04	0.08	0.05	0.04	0.16	0.13	0.17						
	M	0.12	0.08	0.09	0.00	0.00	0.00	0.00	0.12	0.03	0.03						
75–84	F	0.08	0.18	0.16	0.01	0.04	0.01	0.00	0.12	0.08	0.08						
	M&F	0.10	0.15	0.14	0.01	0.03	0.01	0.00	0.12	0.07	0.07						
	M	0.12	0.21	0.10	0.00	0.00	0.00		0.06	0.02	0.01						
≥85	F	0.04	0.09	0.19	0.06	0.05	0.05		0.05	0.03	0.02						
	M&F	0.05	0.11	0.17	0.05	0.04	0.05		0.05	0.03	0.02						
	M																
Unknown	F																
	M&F																
	M	0.27	0.29	0.23	0.38	0.30	0.28	0.27	0.27	0.32	0.25	0.28	0.17	0.22	0.26	0.33	0.39
Total	F	0.30	0.30	0.25	0.37	0.31	0.30	0.31	0.27	0.31	0.25	0.30	0.20	0.25	0.29	0.35	0.41
	M&F	0.29	0.30	0.24	0.37	0.30	0.29	0.28	0.27	0.31	0.25	0.29	0.19	0.24	0.28	0.34	0.40
Average	Scrip	ts PMP	for Tet	racyclin	es												
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
0–9	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00						
	M	0.03	0.04	0.03	0.06	0.02	0.04	0.06	0.05	0.04	0.04						
10–17	F	0.04	0.04	0.03	0.07	0.03	0.05	0.05	0.05	0.04	0.04						
	M&F	0.04	0.04	0.03	0.06	0.03	0.05	0.06	0.05	0.04	0.04						
	M	0.04	0.05	0.04	0.06	0.04	0.06	0.07	0.06	0.05	0.05						
18–34	F	0.07	0.06	0.07	0.08	0.06	0.08	0.05	0.07	0.07	0.07						
	M&F	0.06	0.06	0.06	0.07	0.05	0.08	0.06	0.07	0.06	0.06						

Table A	. HEC	DIS 201	7 Medi	caid Pla	ın-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizat	ion Mea	sures		
Measure	Sex	AGE	0.004	AGW	BCE	всм	BCW	TOC	LUICE	LULICNA	UHCW	2016	National	Medicaio	d Means a	nd Perce	ntiles
by Age	Sex	AGE	AGM	AGW	BCE	BCIVI	BCW	TCS	UHCE	UHCM	UHCW	Mean	P10	P25	P50	P75	P90
	М	0.06	0.06	0.07	0.07	0.05	0.08	0.04	0.06	0.06	0.07						
35–49	F	0.09	0.09	0.09	0.10	0.08	0.11	0.01	0.10	0.09	0.09						
	M&F	0.08	0.08	0.08	0.09	0.07	0.10	0.02	0.09	0.08	0.08						
	M	0.07	0.09	0.07	0.09	0.07	0.09	0.09	0.10	0.10	0.09						
50–64	F	0.10	0.12	0.09	0.13	0.10	0.11	0.09	0.15	0.13	0.10						
	M&F	0.08	0.10	0.08	0.11	0.09	0.10	0.09	0.13	0.11	0.10						
	M	0.13	0.11	0.09	0.01	0.01	0.02	0.00	0.14	0.06	0.10						
65–74	F	0.15	0.17	0.16	0.02	0.02	0.01	0.08	0.18	0.13	0.09						
	M&F	0.14	0.15	0.13	0.02	0.02	0.01	0.04	0.17	0.11	0.09						
	M	0.18	0.18	0.40	0.01	0.00	0.00	0.00	0.13	0.06	0.03						
75–84	F	0.25	0.10	0.07	0.01	0.01	0.00	0.00	0.15	0.06	0.05						
	M&F	0.23	0.12	0.17	0.01	0.01	0.00	0.00	0.15	0.06	0.04						
	M	0.36	0.07	0.20	0.00	0.00	0.00		0.07	0.04	0.03						
≥85	F	0.10	0.18	0.21	0.00	0.00	0.00		0.05	0.02	0.02						
	M&F	0.14	0.16	0.21	0.00	0.00	0.00		0.05	0.02	0.02						
	M																
Unknown	F																
	M&F																
	M	0.03	0.03	0.02	0.04	0.02	0.03	0.04	0.04	0.03	0.03	0.04	0.02	0.03	0.03	0.04	0.06
Total	F	0.05	0.05	0.05	0.06	0.04	0.06	0.03	0.07	0.05	0.05	0.06	0.03	0.04	0.05	0.07	0.08
	M&F	0.04	0.04	0.04	0.05	0.03	0.05	0.04	0.06	0.04	0.04	0.05	0.02	0.03	0.04	0.06	0.07
Average	Scrip	ts PMP	for Mis	c. Antibi	iotics												
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
0–9	F	0.01	0.01	0.00	0.01	0.01	0.00	0.02	0.01	0.01	0.00						
	M&F	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.00						
	M	0.01	0.00	0.00	0.01	0.00	0.00	0.01	0.01	0.00	0.00						
10–17	F	0.04	0.05	0.04	0.06	0.04	0.06	0.09	0.05	0.04	0.04						
	M&F	0.02	0.03	0.02	0.03	0.02	0.03	0.04	0.03	0.02	0.02						
	M	0.01	0.01	0.02	0.02	0.02	0.02	0.01	0.01	0.01	0.02						
18–34	F	0.27	0.29	0.41	0.28	0.31	0.38	0.17	0.22	0.27	0.32						
	M&F	0.19	0.21	0.31	0.22	0.23	0.29	0.08	0.16	0.20	0.24						
	М	0.03	0.04	0.04	0.03	0.03	0.03	0.01	0.02	0.03	0.03						
35–49	F	0.16	0.21	0.27	0.17	0.19	0.27	0.05	0.15	0.20	0.22						
	M&F	0.11	0.16	0.20	0.13	0.14	0.22	0.03	0.11	0.15	0.17						

Table A	. HEC	DIS 201	7 Medi	caid Pla	in-Spec	ific Rat	es with	HEDIS	2016 N	lational	Benchr	marks:	Utilizat	i <mark>on</mark> Mea	sures		
Measure	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	2016	National	Medicaio	d Means a	and Perce	ntiles
by Age	Sex	AGE	AGIVI	AGW	BCE	BCIVI	BCW	165	UHCE	UHCIVI	UHCW	Mean	P10	P25	P50	P75	P90
	М	0.04	0.05	0.03	0.04	0.04	0.04	0.03	0.03	0.04	0.04						
50–64	F	0.12	0.16	0.15	0.14	0.13	0.16	0.14	0.14	0.17	0.14						
	M&F	0.08	0.11	0.10	0.10	0.09	0.12	0.08	0.09	0.11	0.10						
	M	0.03	0.03	0.05	0.00	0.08	0.02	0.00	0.08	0.05	0.04						
65–74	F	0.17	0.14	0.14	0.05	0.04	0.02	0.00	0.18	0.14	0.14						
	M&F	0.11	0.10	0.11	0.03	0.05	0.02	0.00	0.14	0.11	0.10						
	M	0.09	0.07	0.00	0.00	0.24	0.00	0.00	0.04	0.07	0.01						
75–84	F	0.30	0.15	0.27	0.00	0.03	0.02	0.00	0.19	0.10	0.10						
	M&F	0.23	0.12	0.19	0.00	0.09	0.02	0.00	0.15	0.09	0.07						
	M	0.00	0.00	0.00	0.00	0.00	0.00		0.04	0.02	0.02						
≥85	F	0.20	0.30	0.00	0.00	0.00	0.05		0.07	0.07	0.04						
	M&F	0.17	0.24	0.00	0.00	0.00	0.05		0.07	0.06	0.04						
	M																
Unknown	F																
	M&F	0.01		0.04	0.01	0.04	0.04	0.01	0.04	0.04	0.04	0.04	0.04	0.01	0.04		
T-4-1	M F	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.02	0.03
Total	M&F	0.13 0.08	0.14	0.20 0.12	0.14 0.09	0.14	0.18 0.11	0.09 0.04	0.11 0.07	0.13 0.08	0.14 0.09	0.13 0.08	0.08	0.09	0.12 0.07	0.15 0.09	0.19 0.11
								0.04	0.07	0.06	0.09	0.08	0.05	0.06	0.07	0.09	0.11
Standar						-		APCI). I	JAI 2. C	atheter	accaciat	od urina	ry tract	infoctio	n (CAUT	T); HAI-	E.
MRSA bi													пу паст	mecno	II (CAUI	1 <i>),</i> паі-	5.
Percenta	age of	f Total D	ischarge	es From	High SI	R Hospit	als										
CLABSI		0.22	0.33	0.39	0.29	0.40	0.36	0.32	0.33	0.33	0.46						
CAUTI		0.15	0.21	0.19	0.30	0.33	0.13	0.35	0.35	0.25	0.47						
MRSA		0.13	0.09	0.17	0.28	0.09	0.13	0.11	0.28	0.23	0.46						
CDIFF		0.12	0.09	0.24	0.28	0.09	0.27			0.56	0.48						
Percenta	ane of							0.11	0.25	0.56	0.09						
CLABSI	age of	0.01	0.17	0.01	0.00	0.16	0.01	0.02	0.01	0.15	0.00						
CAUTI		0.01	0.09	0.25	0.01	0.11	0.32	0.04	0.02	0.14	0.00						
MRSA		0.01	0.09	0.23	0.01	0.11	0.00	0.04	0.02	0.14	0.00						
CDIFF		0.22	0.02	0.11	0.34	0.03	0.14	0.09	0.29	0.07	0.00						

APPENDIX A | Utilization Measure Medicaid Results and Benchmarks

Table A	Table A. HEDIS 2017 Medicaid Plan-Specific Rates with HEDIS 2016 National Benchmarks: Utilization Measures																
Measure	Sex	AGE	AGM	AGW	BCE	всм	BCW	TCS	UHCE	инсм	UHCW	2016	National	Medicaio	d Means a	and Perce	ntiles
by Age	Sex	AGE	AGIVI	AGW	BCE	BCIVI	BCVV	103	UNCE	OHCIVI	OHCW	Mean	P10	P25	P50	P75	P90
Percent	Percentage of Total Discharges From Low SIR Hospitals																
CLABSI		0.31	0.19	0.23	0.41	0.22	0.36	0.20	0.38	0.40	0.24						
CAUTI		0.46	0.43	0.21	0.48	0.37	0.32	0.18	0.51	0.54	0.33						
MRSA		0.37	0.37	0.36	0.39	0.40	0.41	0.40	0.36	0.36	0.02						
CDIFF		0.27	0.27	0.34	0.32	0.31	0.29	0.36	0.35	0.32	0.81						
Percent	age of	f Total D	ischarg	es From	Hospita	ls With l	Jnavaila	ble SIR									
CLABSI		0.46	0.30	0.37	0.30	0.22	0.28	0.46	0.28	0.12	0.29						
CAUTI		0.38	0.27	0.35	0.22	0.20	0.23	0.44	0.12	0.07	0.20						
MRSA		0.49	0.39	0.40	0.32	0.31	0.32	0.47	0.36	0.27	0.51						
CDIFF		0.37	0.27	0.32	0.21	0.17	0.19	0.43	0.11	0.05	0.09						

APPENDIX B | HEDIS 2016 National Medicaid Means and Percentiles

Table B. HEDIS 2016 National Medicaid Means and Percentiles											
Measure	Mean			Percentile							
ivieasui e	Mean	10th	25th	50th	75th	90th					
HEDIS Effectiveness	of Care M	easures									
Prevention and Screening											
Adult BMI Assessment (ABA)	80.77%	69.47%	77.13%	84.54%	89.35%	92.54%					
Weight Assessment and Counseling for Nutrition and Physical Ac	tivity for (Children/A	dolescents	(WCC):							
BMI Percentile: 3-11 years	64.83%	41.32%	55.03%	68.22%	78.38%	86.30%					
12–17 years	63.19%	39.16%	51.63%	65.74%	76.76%	85.16%					
Total	64.37%	40.14%	54.50%	67.54%	77.78%	86.37%					
Counseling for Nutrition: 3-11 years	61.62%	43.53%	53.03%	63.33%	73.36%	80.22%					
12–17 years	57.30%	40.15%	47.83%	57.35%	68.39%	78.69%					
Total	60.22%	42.92%	51.84%	62.65%	70.88%	79.52%					
Counseling for Physical Activity: 3-11 years	52.40%	35.59%	43.61%	53.99%	62.19%	71.30%					
12–17 years	55.24%	37.04%	46.51%	55.75%	65.36%	74.62%					
Total	53.44%	35.90%	45.09%	55.38%	63.47%	71.58%					
Childhood Immunization Status (CIS):											
DTaP/DT	76.33%	66.89%	72.51%	77.97%	82.24%	85.15%					
IPV	87.70%	81.02%	86.09%	89.78%	92.46%	93.79%					
MMR	89.21%	83.76%	87.86%	90.47%	92.70%	94.25%					
HiB	87.62%	81.01%	85.95%	89.37%	91.97%	93.67%					
НерВ	87.70%	79.16%	85.64%	90.05%	93.19%	94.81%					
VZV	88.79%	83.56%	87.27%	89.97%	92.49%	93.95%					
PCV	76.53%	66.24%	72.75%	78.59%	82.64%	85.40%					
НерА	83.70%	74.51%	79.69%	84.91%	88.89%	91.85%					
RV	67.94%	54.50%	63.46%	69.34%	74.25%	79.12%					

Table B. HEDIS 2016 National Medicaid Means and Percentiles										
Measure	Mean			Percentile						
wedsui e	Ivieari	10th	25th	50th	75th	90th				
Influenza	45.74%	28.32%	36.34%	45.99%	54.01%	63.09%				
Combination 2	72.46%	62.86%	68.03%	75.18%	78.59%	82.88%				
Combination 3	68.99%	57.84%	64.30%	71.06%	75.60%	79.81%				
Combination 4	65.91%	54.30%	60.81%	67.96%	72.54%	78.06%				
Combination 5	57.21%	43.27%	52.55%	58.98%	63.77%	69.06%				
Combination 6	39.01%	22.87%	30.61%	39.14%	46.47%	54.50%				
Combination 7	55.17%	41.28%	49.82%	56.85%	61.92%	67.88%				
Combination 8	38.01%	21.65%	29.36%	38.20%	45.99%	53.01%				
Combination 9	33.86%	18.73%	25.78%	33.10%	41.57%	46.89%				
Combination 10	33.24%	18.00%	25.99%	32.64%	40.91%	46.47%				
Immunizations for Adolescents (IMA):										
Meningococcal	74.79%	58.48%	67.26%	77.21%	84.47%	88.52%				
Tdap/Td	83.36%	73.48%	81.28%	86.14%	89.92%	91.75%				
HPV*	22.71%	13.64%	17.66%	22.30%	27.09%	32.25%				
Combination 1	72.66%	56.90%	66.03%	74.52%	82.09%	86.57%				
Combination 2**										
Lead Screening in Children (LSC)	66.50%	40.28%	56.44%	71.05%	79.50%	84.77%				
Breast Cancer Screening (BCS)	58.50%	47.21%	52.24%	58.08%	65.30%	71.52%				
Cervical Cancer Screening (CCS)	55.85%	41.12%	48.18%	55.94%	63.88%	69.95%				
Chlamydia Screening in Women (CHL):										
16–20 years	51.49%	39.57%	43.87%	50.56%	58.45%	66.67%				
21–24 years	60.65%	48.51%	54.76%	61.37%	67.95%	72.06%				
Total	55.27%	43.07%	48.83%	55.16%	61.63%	68.92%				
Respiratory Conditions										
Appropriate Testing for Children With Pharyngitis (CWP)	71.12%	55.08%	63.24%	71.62%	81.01%	86.59%				

Table B. HEDIS 2016 National Medicaid Means and Percentiles											
Mogeries	Mean			Percentile							
Measure	Mean	10th	25th	50th	75th	90th					
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	30.96%	21.59%	25.81%	30.26%	35.43%	40.54%					
Pharmacotherapy Management of COPD Exacerbation (PCE):											
Systemic Corticosteroid	67.10%	48.84%	61.44%	70.39%	75.48%	79.07%					
Bronchodilator	79.92%	66.11%	77.05%	83.70%	86.75%	88.78%					
Medication Management for People With Asthma (MMA):											
Medication Compliance 50%***: 5–11 years											
12–18 years											
19–50 years											
51–64 years											
Total											
Medication Compliance 75%: 5-11 years	28.33%	17.13%	20.98%	25.88%	34.24%	41.18%					
12–18 years	26.33%	14.84%	19.20%	25.00%	30.65%	37.63%					
19–50 years	37.72%	25.18%	31.26%	36.25%	43.08%	50.98%					
51–64 years	50.01%	39.66%	43.14%	49.48%	55.56%	62.75%					
Total	32.67%	19.64%	25.08%	31.28%	37.50%	46.72%					
Asthma Medical Ratio (AMR):											
5–11 years	70.15%	56.36%	65.00%	71.74%	76.39%	82.70%					
12–18 years	59.13%	46.77%	53.67%	60.50%	65.45%	69.65%					
19–50 years	48.90%	38.05%	44.13%	49.00%	55.09%	58.96%					
51–64 years	51.72%	40.64%	45.35%	52.03%	59.18%	63.64%					
Total	59.67%	46.83%	54.55%	61.26%	65.36%	70.00%					
Cardiovascular Conditions											
Controlling High Blood Pressure (CBP)	54.74%	39.41%	46.87%	54.78%	63.99%	70.69%					
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	80.43%	64.04%	76.92%	83.06%	88.30%	91.67%					

Manazina	D/I = = ···			Percentile		
Measure	Mean	10th	25th	50th	75th	90th
Statin Therapy for Patients with Cardiovascular disease (SP	C)†:	•	•			
Received Statin Therapy: Males 21-75 years						
Received Statin Therapy: Females 40 -75 years						
Received Statin Therapy: Total						
Statin Adherence 80%: Males 21-75 years						
Statin Adherence 80%: Females 40 -75 years						
Statin Adherence 80%: Total						
Diabetes						
Comprehensive Diabetes Care (CDC):						
HbA1c Testing	85.94%	79.56%	82.98%	85.95%	89.42%	92.88%
HbA1c Control (<7.0%)	32.36%	23.52%	29.27%	33.82%	38.31%	40.43%
HbA1c Control (<8.0%)	45.54%	31.16%	39.80%	46.76%	52.55%	58.39%
Retinal Eye Exam Performed	52.68%	35.64%	44.53%	53.28%	61.50%	68.11%
Medical Attention for Nephropathy	90.01%	85.94%	88.32%	90.51%	91.97%	93.56%
Blood Pressure Control (<140/90 mm Hg)	59.04%	43.75%	52.26%	59.73%	68.61%	75.73%
Statin Therapy for Patients with Diabetes (SPD)†:			•			
Received Statin Therapy: 40 -75 years						
Statin Adherence 80%: 40 -75 years						
Musculoskeletal Conditions						
Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)	71.69%	57.36%	65.67%	72.22%	79.20%	85.71%
Behavioral Health					-	
Antidepressant Medication Management (AMM):						
Effective Acute Phase Treatment	54.45%	44.00%	48.32%	53.38%	59.52%	67.57%
Effective Continuation Phase Treatment	39.44%	28.11%	32.77%	38.06%	43.39%	54.30%
Follow-Up Care for Children Prescribed ADHD Medication (A	DD):	•	,	•	•	
Initiation Phase	42.20%	28.77%	34.16%	42.19%	49.55%	55.48%
Continuation and Maintenance Phase	50.93%	33.96%	40.91%	52.47%	62.50%	67.239

Table B. HEDIS 2016 National Medicaid Means and Percen	tiles					
Managema	Mann			Percentile		
Measure	Mean	10th	25th	50th	75th	90th
Follow-Up After Hospitalization for Mental Illness (FUH):						
7-Day Follow-Up	43.71%	24.71%	34.23%	44.05%	55.34%	64.23%
30-Day Follow-Up	61.29%	41.31%	54.58%	63.94%	72.56%	78.52%
Follow-Up After Emergency Department Visit for Mental Illness ((FUM) * *:					
7-Day Follow-Up						
30-Day Follow-Up						
Follow-Up After Emergency Department Visit for Alcohol and Oth	er Drug D	ependence	(FUA)**:			
7-Day Follow-Up: 13–17 years						
18 years and older						
Total						
30-Day Follow-Up: 13–17 years						
18 years and older						
Total						
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	80.37%	72.35%	76.99%	80.72%	84.01%	87.17%
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	68.20%	57.45%	62.69%	68.93%	74.55%	78.26%
Cardiovascular Monitoring for People With Cardio-vascular Disease and Schizophrenia (SMC)	78.47%	65.38%	73.89%	80.00%	83.75%	88.37%
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	57.88%	42.86%	52.80%	59.79%	65.44%	70.88%
Metabolic Monitoring for Children and Adolescents on Antipsycho	otics (APM):	·	•		
1–5 Years	16.70%	6.06%	10.26%	15.33%	20.00%	31.25%
6–11 Years	26.16%	17.02%	21.21%	25.19%	29.73%	36.67%
12–17 Years	32.05%	20.42%	26.39%	32.33%	37.31%	43.48%
Total	29.84%	18.57%	23.89%	29.63%	34.93%	42.33%

Table B. HEDIS 2016 National Medicaid Means and Percentiles										
Managema	24			Percentile						
Measure	Mean	10th	25th	50th	75th	90th				
Medication Management	•									
Annual Monitoring for Patients on Persistent Medications (MPM)):									
ACE Inhibitors or ARBs	87.51%	83.31%	85.63%	87.43%	89.92%	92.13%				
Digoxin	54.01%	46.15%	49.57%	53.94%	58.55%	61.98%				
Diuretics	87.49%	83.33%	85.18%	87.52%	90.00%	92.28%				
Total	87.28%	83.16%	85.19%	87.23%	89.56%	91.84%				
Overuse/Appropriateness										
Appropriate Treatment for Children With Upper Respiratory Infection (URI)	87.76%	76.23%	84.92%	89.39%	93.38%	96.08%				
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)	28.09%	19.38%	22.12%	26.17%	32.51%	38.91%				
Use of Imaging Studies for Low Back Pain (LBP)	73.57%	66.04%	69.88%	73.71%	77.09%	81.42%				
Measures Collected Though CAHPS										
Flu vaccinations for adults ages 18 to 64 (FVA)	38.46%	28.70%	33.79%	38.03%	43.54%	48.01%				
Medical Assistance With Smoking Cessation (MSC):										
Advising Smokers and Tobacco Users to Quit	75.89%	67.83%	73.14%	76.59%	79.36%	81.85%				
Discussing Cessation Medications	48.12%	36.67%	43.01%	48.31%	53.85%	58.39%				
Discussing Cessation Strategies	43.28%	34.00%	38.86%	43.82%	47.83%	51.75%				
Supplemental Data - % Current Smokers	31.02%	17.50%	22.97%	31.68%	39.01%	43.79%				
HEDIS Effectiveness of Care Measures Where	Lower Ra	tes Indicat	ed Better F	Performand	:e					
Diabetes										
Comprehensive Diabetes Care (CDC):										
HbA1c Poor Control (>9.0%)	45.35%	61.31%	52.31%	43.80%	36.87%	29.23%				
Overuse/Appropriateness										
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)	2.71%	5.35%	3.77%	2.42%	1.42%	0.85%				

Table B. HEDIS 2016 National Medicaid Means and Percentiles										
Mogazire	Mean			Percentile						
Measure	Mean	10th	25th	50th	75th	90th				
Use of Multiple Concurrent Antipsychotics in Children and Adoles	scents (AP	C):								
1-5 Years	0.66%	2.86%	1.96%	0.00%	0.00%	0.00%				
6-11 Years	1.82%	3.75%	2.74%	1.56%	0.63%	0.00%				
12-17 Years	3.00%	6.29%	3.97%	2.53%	1.41%	0.00%				
Total	2.49%	5.30%	3.14%	1.99%	1.17%	0.00%				
HEDIS Access/Availabi	lity of Care	e Measures	:							
Adults' Access to Preventive/Ambulatory Health Services (AAP):										
20–44 years	77.27%	63.73%	73.35%	79.48%	83.42%	86.04%				
45–64 years	85.52%	76.95%	82.49%	86.83%	89.78%	91.57%				
Children and Adolescents' Access to Primary Care Practitioners ((CAP):									
12–24 months	94.69%	89.89%	93.14%	95.74%	97.28%	97.85%				
25 months–6 years	87.24%	81.16%	84.83%	87.69%	90.98%	93.34%				
7-11 years	90.23%	84.16%	87.91%	91.00%	93.25%	96.10%				
12–19 years	88.60%	83.13%	85.84%	89.37%	92.67%	94.69%				
Initiation and Engagement of Alcohol and Other Drug (AOD) Dep	endence T	reatment ((IET):							
Initiation of AOD Treatment: 13–17 years	42.25%	27.49%	35.94%	42.75%	50.00%	52.99%				
≥18 years	37.94%	30.00%	34.17%	37.78%	42.67%	46.16%				
Total	38.23%	30.21%	34.37%	38.07%	42.82%	46.56%				
Engagement of AOD Treatment: 13-17 years	15.44%	7.43%	9.18%	13.53%	21.46%	26.70%				
≥18 years	9.69%	4.16%	6.33%	9.29%	12.32%	16.65%				
Total	10.23%	4.42%	6.92%	9.63%	13.20%	16.93%				
Prenatal and Postpartum Care (PPC):										
Timeliness of Prenatal Care	80.03%	66.91%	74.21%	82.25%	87.56%	91.00%				
Postpartum Care	60.93%	48.94%	55.47%	60.98%	67.53%	73.61%				

Table B. HEDIS 2016 National Medicaid Means and Percent	tiles					
Measure	Mean			Percentile		
weasure	iviean	10th	25th	50th	75th	90th
Use of First-Line Psychosocial Care for Children and Adolescents	on Antipsy	ychotics (A	PP):			
1-5 Years	49.04%	33.33%	40.48%	45.45%	62.99%	66.67%
6-11 Years	58.83%	36.03%	47.96%	61.54%	68.35%	77.78%
12-17 Years	59.12%	39.84%	50.57%	61.20%	68.25%	76.47%
Total	57.44%	36.73%	48.83%	60.43%	68.57%	74.34%
HEDIS Utilization and Relativ	ve Resourc	e Use Mea	sures			
Utilization						
Frequency of Ongoing Prenatal Care (FPC):						
<21%	11.96%	2.87%	4.87%	8.22%	14.69%	23.60%
21–40%	7.26%	2.33%	3.95%	5.82%	9.02%	13.93%
41–60%	8.59%	4.65%	6.03%	7.92%	10.46%	12.99%
61–80%	15.23%	10.48%	12.58%	14.95%	17.95%	20.45%
≥81%	56.61%	32.79%	45.72%	59.26%	69.54%	75.77%
Well-Child Visits in the First 15 Months of Life (W15):						
0 Visits	2.62%	0.44%	0.93%	1.71%	3.24%	5.77%
1 Visits	2.30%	0.70%	1.26%	1.95%	2.92%	4.12%
2 Visits	3.45%	1.23%	2.06%	3.19%	4.62%	5.84%
3 Visits	5.54%	2.66%	3.72%	5.42%	6.98%	8.57%
4 Visits	9.64%	6.01%	7.54%	9.16%	11.30%	13.40%
5 Visits	17.11%	12.02%	14.29%	16.49%	19.23%	23.72%
6 or More Visits	59.35%	45.38%	53.49%	59.57%	67.76%	73.88%
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)	71.27%	60.64%	64.72%	71.42%	77.57%	82.97%
Adolescent Well-Care Visits (AWC)	48.89%	32.26%	40.88%	48.41%	57.66%	66.04%

^{*}For HEDIS 2017, the HPV measure was integrated into the IMA measure for reporting purposes and expanded to both genders.

†Benchmarks are not reported by Quality Compass for 2016 first-year measures.

^{**}First-year measure.

^{***}Benchmarks are currently not reported by Quality Compass for this rate.

APPENDIX C | MCO Medicaid Population in Member Months

Table C1. HEDIS 2017 MCO Medicaid Population Reported in Member Months by Age and Sex—AG											
A C		AGE			AGM			AGW			
Age Group	Male	Female	Total	Male	Female	Total	Male	Female	Total		
<1	24,463	22,860	47,323	37,943	36,655	74,598	27,484	25,991	53,475		
1–4	93,348	87,156	180,504	152,175	145,968	298,143	104,614	100,080	204,694		
5–9	118,823	114,341	233,164	168,907	164,673	333,580	125,679	126,475	252,154		
10–14	122,898	117,959	240,857	119,236	118,151	237,387	105,541	106,015	211,556		
15–17	43,325	43,277	86,602	75,338	74,823	150,161	41,396	41,985	83,381		
18–19	33,513	31,438	64,951	36,986	42,086	79,072	30,829	31,683	62,512		
0–19	436,370	417,031	853,401	590,585	582,356	1,172,941	435,543	432,229	867,772		
Subtotal	65.33%	49.24%	56.33%	72.15%	52.27%	60.69%	71.95%	49.21%	58.48%		
20–24	48,624	84,095	132,719	38,676	90,149	128,825	48,242	89,064	137,306		
25–29	30,795	98,381	129,176	21,882	94,398	116,280	18,406	124,726	143,132		
30–34	31,163	69,978	101,141	27,617	96,900	124,517	18,059	73,645	91,704		
35–39	27,994	52,285	80,279	29,735	82,943	112,678	17,276	42,446	59,722		
40–44	21,836	39,031	60,867	25,495	53,550	79,045	12,674	32,340	45,014		
20–44	160,412	343,770	504,182	143,405	417,940	561,345	114,657	362,221	476,878		
Subtotal	24.02%	40.59%	33.28%	17.52%	37.51%	29.04%	18.94%	41.24%	32.14%		
45–49	18,559	29,250	47,809	21,114	33,595	54,709	10,718	26,393	37,111		
50–54	19,027	23,929	42,956	20,276	26,347	46,623	12,950	21,789	34,739		
55–59	19,065	18,385	37,450	19,647	22,073	41,720	16,746	19,106	35,852		
60–64	12,086	10,653	22,739	14,334	16,064	30,398	12,239	11,630	23,869		
45–64	68,737	82,217	150,954	75,371	98,079	173,450	52,653	78,918	131,571		
Subtotal	10.29%	9.71%	9.96%	9.21%	8.80%	8.97%	8.70%	8.98%	8.87%		

Table C1. HEDIS 2017 MCO Medicaid Population Reported in Member Months by Age and Sex—AG											
A C		AGE			AGM		AGW				
Age Group	Male	Female	Total	Male	Female	Total	Male	Female	Total		
65–69	1,419	1,760	3,179	4,400	6,157	10,557	1,472	2,482	3,954		
70–74	467	721	1,188	2,551	3,839	6,390	492	1,098	1,590		
75–79	309	472	781	1,315	2,485	3,800	250	677	927		
80–84	117	405	522	561	1,739	2,300	159	327	486		
85–89	67	326	393	277	1,025	1,302	57	211	268		
≥90	48	317	365	91	515	606	82	261	343		
≥65	2,427	4,001	6,428	9,195	15,760	24,955	2,512	5,056	7,568		
Subtotal	0.36%	0.47%	0.42%	1.12%	1.41%	1.29%	0.41%	0.58%	0.51%		
Total	667,946	847,019	1,514,965	818,556	1,114,135	1,932,691	605,365	878,424	1,483,789		

Table C2	Table C2. HEDIS 2017 MCO Medicaid Population Reported in Member Months by Age and Sex—BC and TCS												
Age		BCE		всм				BCW		TCS			
Group	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	
<1	48,796	46,671	95,467	37,198	36,001	73,199	33,660	32,283	65,943	5,918	6,264	12,182	
1–4	162,214	154,231	316,445	126,684	123,425	250,109	122,279	117,821	240,100	53,959	46,447	100,406	
5–9	172,045	167,643	339,688	155,050	151,919	306,969	133,918	131,853	265,771	91,313	61,373	152,686	
10–14	139,184	136,041	275,225	152,345	151,570	303,915	111,825	115,481	227,306	102,929	60,111	163,040	
15–17	79,990	79,066	159,056	52,305	50,791	103,096	64,708	68,320	133,028	73,993	43,346	117,339	
18–19	43,506	52,694	96,200	35,648	40,655	76,303	35,001	41,756	76,757	49,666	26,544	76,210	
0–19	645,735	636,346	1,282,081	559,230	554,361	1,113,591	501,391	507,514	1,008,905	377,778	244,085	621,863	
Subtotal	72.70%	49.20%	58.77%	72.83%	51.57%	60.43%	77.08%	51.00%	61.31%	83.03%	74.39%	79.41%	

Table C2	Table C2. HEDIS 2017 MCO Medicaid Population Reported in Member Months by Age and Sex—BC and TCS												
Age	BCE				всм			BCW			TCS		
Group	Male	Female	Total	Male	Female	Total	Male	Female	Total	Male	Female	Total	
20–24	41,502	118,561	160,063	50,182	106,280	156,462	37,866	89,125	126,991	41,282	28,732	70,014	
25–29	19,629	117,713	137,342	25,294	118,819	144,113	12,104	77,428	89,532	7,039	15,515	22,554	
30–34	28,870	107,716	136,586	27,032	85,857	112,889	16,459	88,808	105,267	7,326	14,027	21,353	
35–39	31,933	90,945	122,878	24,962	65,065	90,027	16,409	80,822	97,231	6,691	10,852	17,543	
40–44	29,801	63,107	92,908	17,980	44,977	62,957	14,112	49,332	63,444	4,949	6,349	11,298	
20–44	151,735	498,042	649,777	145,450	420,998	566,448	96,950	385,515	482,465	67,287	75,475	142,762	
Subtotal	17.08%	38.50%	29.78%	18.94%	39.16%	30.74%	14.91%	38.74%	29.32%	14.79%	23.00%	18.23%	
45–49	25,270	46,369	71,639	16,399	35,086	51,485	12,479	31,793	44,272	3,207	3,545	6,752	
50–54	23,216	41,145	64,361	16,603	26,998	43,601	12,883	25,334	38,217	2,891	2,377	5,268	
55–59	21,503	33,417	54,920	16,754	20,585	37,339	13,455	21,784	35,239	2,403	1,419	3,822	
60–64	15,377	25,936	41,313	11,069	12,401	23,470	10,722	16,647	27,369	1,270	1,076	2,346	
45–64	85,366	146,867	232,233	60,825	95,070	155,895	49,539	95,558	145,097	9,771	8,417	18,188	
Subtotal	9.61%	11.35%	10.64%	7.92%	8.84%	8.46%	7.62%	9.60%	8.82%	2.15%	2.57%	2.32%	
65–69	2,516	5,386	7,902	1,136	1,888	3,024	1,472	2,868	4,340	109	87	196	
70–74	1,592	3,120	4,712	520	752	1,272	552	1655	2,207	32	59	91	
75–79	781	1,683	2,464	309	581	890	278	802	1,080	24	12	36	
80–84	320	1,198	1,518	159	586	745	174	693	867	0	0	0	
85–89	114	536	650	102	419	521	84	304	388	0	0	0	
≥90	58	286	344	102	346	448	2	161	163	0	0	0	
≥65	5,381	12,209	17,590	2,328	4,572	6,900	2,562	6,483	9,045	165	158	323	
Subtotal	0.61%	0.94%	0.81%	0.30%	0.43%	0.37%	0.39%	0.65%	0.55%	0.04%	0.05%	0.04%	
Total	888,217	1,293,464	2,181,681	767,833	1,075,001	1,842,834	650,442	995,070	1,645,512	455,001	328,135	783,136	

Table C3. H	Table C3. HEDIS 2017 MCO Medicaid Population Reported in Member Months by Age and Sex—UHC									
Ago Croup		UHCE			UHCM			UHCW		
Age Group	Male	Female	Total	Male	Female	Total	Male	Female	Total	
<1	24,549	22,878	47,427	37,273	35,880	73,153	26,290	25,434	51,724	
1–4	121,480	116,400	237,880	148,550	144,341	292,891	115,750	111,303	227,053	
5–9	146,083	141,688	287,771	161,500	158,038	319,538	134,452	131,987	266,439	
10–14	114,191	110,672	224,863	117,453	114,847	232,300	98,567	98,804	197,371	
15–17	70,709	71,962	142,671	72,832	70,665	143,497	58,891	62,010	120,901	
18–19	36,885	40,580	77,465	36,773	42,157	78,930	31,422	36,293	67,715	
0–19	513,897	504,180	1,018,077	574,381	565,928	1,140,309	465,372	465,831	931,203	
Subtotal	65.79%	47.55%	55.29%	72.23%	51.09%	59.92%	72.87%	50.82%	59.87%	
20–24	37,801	77,258	115,059	34,397	84,622	119,019	35,464	82,374	117,838	
25–29	21,789	75,040	96,829	19,189	90,763	109,952	14,507	68,534	83,041	
30–34	23,601	77,040	100,641	25,195	93,877	119,072	12,608	65,855	78,463	
35–39	29,327	78,660	107,987	29,394	80,108	109,502	16,911	68,399	85,310	
40–44	28,994	58,575	87,569	25,114	52,344	77,458	16,240	45,757	61,997	
20–44	141,512	366,573	508,085	133,289	401,714	535,003	95,730	330,919	426,649	
Subtotal	18.12%	34.57%	27.59%	16.76%	36.26%	28.11%	14.99%	36.10%	27.43%	
45–49	27,143	41,210	68,353	21,794	34,640	56,434	14,816	28,277	43,093	
50–54	26,122	36,241	62,363	20,112	28,200	48,312	16,783	22,934	39,717	
55–59	27,480	32,068	59,548	17,587	24,596	42,183	17,504	20,548	38,052	
60–64	21,857	26,742	48,599	13,867	18,536	32,403	14,608	15,367	29,975	
45-64	102,602	136,261	238,863	73,360	105,972	179,332	63,711	87,126	150,837	
Subtotal	13.14%	12.85%	12.97%	9.22%	9.57%	9.42%	9.98%	9.50%	9.70%	
65–69	9,206	15,489	24,695	4,575	8,896	13,471	5,588	8,392	13,980	
70–74	6,058	10,772	16,830	3,935	6,903	10,838	3,415	6,619	10,034	
75–79	3,836	8,562	12,398	2,418	5,439	7,857	2,178	5,078	7,256	
80–84	2,110	7,423	9,533	1,773	4,798	6,571	1,354	4,740	6,094	
85–89	1,187	5,727	6,914	984	4,114	5,098	831	4,204	5,035	
≥90	713	5,382	6,095	528	3,971	4,499	484	3,768	4,252	
≥65	23,110	53,355	76,465	14,213	34,121	48,334	13,850	32,801	46,651	
Subtotal	2.96%	5.03%	4.15%	1.79%	3.08%	2.54%	2.17%	3.58%	3.00%	
Total	781,121	1,060,369	1,841,490	795,243	1,107,735	1,902,978	638,663	916,677	1,555,340	

APPENDIX D | **Measure Reporting Options**

The reporting options are presented for each measure: administrative and/or hybrid. Currently, when the hybrid option is available, TennCare MCOs are required to use the hybrid method.

Table D. 2017 Measure reporting options: Administrative/Hybrid							
Measure	Administrative	Hybrid					
HEDIS Effectiveness of Care							
Prevention and Screening							
Adult BMI Assessment (ABA)	✓	✓					
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC)	✓	✓					
Childhood Immunization Status (CIS)	✓	✓					
Immunizations for Adolescents (IMA)	✓	✓					
Human Papillomavirus Vaccine for Female Adolescents (HPV)	✓	✓					
Lead Screening in Children (LSC)	✓	✓					
Breast Cancer Screening (BCS)	✓						
Cervical Cancer Screening (CCS)	✓	✓					
Chlamydia Screening in Women (CHL)	✓						
Respiratory Conditions							
Appropriate Testing for Children With Pharyngitis (CWP)	✓						
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)	✓						
Pharmacotherapy Management of COPD Exacerbation (PCE)	✓						
Medication Management for People With Asthma (MMA)	✓						
Asthma Medical Ratio (AMR)	✓						
Cardiovascular Conditions							
Controlling High Blood Pressure (CBP)		✓					
Persistence of Beta-Blocker Treatment After a Heart Attack (PBH)	✓						
Statin Therapy for Patients with Cardiovascular Disease (SPC)	✓						

Measure	Administrative	Hybrid
Diabetes		
Comprehensive Diabetes Care (CDC)	✓	✓
Statin Therapy for Patients with Diabetes (SPD)	✓	
Musculoskeletal Conditions		
Disease-Modifying Anti-Rheumatic Drug Therapy for Rheumatoid Arthritis (ART)	✓	
Behavioral Health		
Antidepressant Medication Management (AMM)	✓	
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	✓	
Follow-Up After Hospitalization for Mental Illness (FUH)	✓	
Follow-Up After Emergency Department Visit for Mental Illness (FUM)	✓	
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Dependence (FUA)	✓	
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (SSD)	✓	
Diabetes Monitoring for People With Diabetes and Schizophrenia (SMD)	✓	
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (SMC)	✓	
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	✓	
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM)	✓	
Medication Management		
Annual Monitoring for Patients on Persistent Medications (MPM)	✓	
Overuse/Appropriateness		
Non-Recommended Cervical Cancer Screening in Adolescent Females (NCS)	✓	
Appropriate Treatment for Children With Upper Respiratory Infection (URI)	✓	
Avoidance of Antibiotic Treatment in Adults With Acute Bronchitis (AAB)	✓	
Use of Imaging Studies for Low Back Pain (LBP)	✓	
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (APC)	✓	
Measures Collected Through CAHPS Health Plan Survey		
Flu vaccinations for adults ages 18 to 64 (FVA)		

APPENDIX D | Measure Reporting Options

Table D. 2017 Measure reporting options: Administrative/Hybrid							
Measure	Administrative	Hybrid					
Medical Assistance With Smoking Cessation (MSC)							
HEDIS Access/Availability of Care Measures							
Adults' Access to Preventive/Ambulatory Health Services (AAP)	✓						
Children and Adolescents' Access to Primary Care Practitioners (CAP)	✓						
Initiation and Engagement of Alcohol and Other Drug (AOD) Dependence Treatment (IET)	✓						
Prenatal and Postpartum Care (PPC)	✓	✓					
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP)	✓						
HEDIS Utilization and Risk-Adjusted Utilization Measures							
Frequency of Ongoing Prenatal Care (FPC)	✓	✓					
Well-Child Visits in the First 15 Months of Life (W15)	✓	✓					
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (W34)	✓	✓					
Adolescent Well-Care Visits (AWC)	✓	✓					

APPENDIX E | CHIP Measures, Frequencies, and Population by Member Months

In the tables of this appendix, rates reported are for CKBC, the only HPA during HEDIS 2017. Cells are shaded gray for those measures that were not calculated or for which data were not reported. <u>HEDIS definitions</u> for measures apply to all lines of business.

Additional Utilization Measures: CHIP Plan-Specific Rates

Table E1. HEDIS 2017 Utilization Measures: CHIP— FPC and W15					
Measure/Data Element	Rate				
Frequency of Ongoing Prenatal Care (FPC):					
<21 Percent	7.80%				
21-40 Percent	5.85%				
41-60 Percent	10.73%				
61-80 Percent	15.85%				
81+ Percent	59.76%				
Well-Child Visits in the First 15 Months of Life (W1	5):				
0 Visits	3.28%				
1 Visit	0.60%				
2 Visits	0.90%				
3 Visits	2.69%				
4 Visits	4.78%				
5 Visits	12.54%				
6+ Visits	75.22%				

Table E2. HEDIS 2017 Utilization Measures: CHIP— Frequency of Selected Procedures (FSP)								
Age	Sex	Procedures / 1,000 Member Months						
Bariatric Weigl	Bariatric Weight Loss Surgery:							
0-19	М	0.00						
0-19	F	0.00						
20-44	М	0.00						
20-44	F	0.00						
45 (4	М							
45-64	F	0.00						
Tonsillectomy:								
0-9	M&F	1.17						
10-19	ΙνιαΓ	0.39						
Hysterectomy,	Abdor	ninal:						
15-44	F	0.04						
45-64	Г	0.00						
Hysterectomy,	Vagin	al:						
15-44	F	0.00						
45-64	Г	0.00						

Table E2. HEDIS 2017 Utilization Measures: CHIP— Frequency of Selected Procedures (FSP)								
Age	Sex	Procedures / 1,000 Member Months						
Cholecystector	Cholecystectomy, Open:							
30-64	М							
15-44	F	0.01						
45-64	'	0.00						
Cholecystectomy (laparoscopic):								
30-64	М							
15-44	F	0.39						
45-64	F	0.00						
Back Surgery:								
20-44	М	0.00						
20-44	F	0.02						
45-64	М							
45-04	F	0.00						
Mastectomy:								
15-44	F	0.00						
45-64	F	0.00						
Lumpectomy:								
15-44	F	0.05						
45-64	F	0.00						

Table E3. HEDIS 2017 Utilization Measures: CHIP— Ambulatory Care: Total (AMB)						
Age	Visits/ 1,000 M	ember Months				
Age	Outpatient Visits	ED Visits				
<1	722.93	41.15				
1-9	268.42	24.28				
10-19	228.20	25.60				
20-44	298.43	53.15				
45-64	281.69	14.08				
65-74						
75-84						
85+	62.50	62.50				
Unknown						
Total	250.88	26.88				

Table E4a. HEDIS 2017 Utilization Measures: CHIP— Inpatient Utilization General Hospital/Acute Care: Total (IPU)							
Per 1,000 Members Months Average							
Age	Discharges	Days	Length of Stay				
	Maternity						
10-19	0.82	2.08	2.56				
20-44	95.26	225.83	2.37				
45-64	56.34	119.72	2.13				
Unknown							
Total	9.29	22.16	2.38				

Table E4b. HEDIS 2017 Utilization Measures: CHIP—Inpatient Utilization General Hospital/Acute Care: Total (IPU)									
	Per 1,000 Members Months		Average Length of	Per 1,000 Members Months		Average Length of	Per 1,000 Member Months		Average Length of
Age	Discharges	Days	Stay	Discharges	Days	Stay	Discharges	Days	Stay
	Total Inpatient			Surgery			IV	ledicine	
<1	5.67	40.90	7.22	0.86	26.49	30.71	4.80	14.41	3.00
1-9	0.73	2.21	3.02	0.16	0.64	3.94	0.57	1.56	2.75
10-19	1.54	4.57	2.96	0.22	0.83	3.78	0.51	1.62	3.19
20-44	95.87	227.62	2.37	0.43	1.18	2.76	0.18	0.61	3.33
45-64	56.34	119.72	2.13	0.00	0.00		0.00	0.00	
65-74									
75-84									
85+	0.00	0.00		0.00	0.00		0.00	0.00	
Unknown									
Total	6.76	17.00	2.52	0.22	1.03	4.72	0.55	1.66	3.02

Table E5. HEDIS 2017 Utilization Measures: CHIP—Total IAD and Total MPT Rates									
Age	Sex	Any Services	Inpatient	Intensive Outpatient/ Partial Hospitalization	Outpatient/ED				
Identification of Alcohol and Other Drug Services: Total (IAD)									
	M	0.05%	0.00%	0.01%	0.05%				
0-12	F	0.01%	0.00%	0.00%	0.01%				
	Total	0.03%	0.00%	0.00%	0.03%				
	M	1.26%	0.25%	0.45%	1.06%				
13-17	F	1.00%	0.34%	0.35%	0.70%				
	Total	1.13%	0.30%	0.40%	0.88%				
	M	2.38%	0.57%	0.62%	1.94%				
18-24	F	1.81%	0.68%	0.34%	1.29%				
	Total	2.05%	0.63%	0.45%	1.56%				

Table E5. HEDIS 2017 Utilization Measures: CHIP—Total IAD and Total MPT Rates								
Age	Sex	Any Services	Inpatient	Intensive Outpatient/ Partial Hospitalization	Outpatient/ED			
	M	0.00%	0.00%	0.00%	0.00%			
25-34	F	0.32%	0.04%	0.00%	0.32%			
	Total	0.32%	0.04%	0.00%	0.32%			
	M							
35-64	F	0.25%	0.12%	0.00%	0.25%			
	Total	0.25%	0.12%	0.00%	0.25%			
	M	0.00%	0.00%	0.00%	0.00%			
65+	F							
	Total	0.00%	0.00%	0.00%	0.00%			
	M							
Unknown	F							
	Total							
	M	0.63%	0.13%	0.20%	0.52%			
Total	F	0.50%	0.17%	0.14%	0.36%			
	Total	0.56%	0.15%	0.17%	0.44%			
		Mental	Health Utilization: Tota	al (MPT)				
	M	6.72%	0.08%	0.03%	6.69%			
0-12	F	3.82%	0.05%	0.02%	3.81%			
	Total	5.30%	0.06%	0.02%	5.28%			
	M	7.56%	0.64%	0.20%	7.39%			
13-17	F	8.70%	1.20%	0.26%	8.38%			
	Total	8.12%	0.91%	0.23%	7.87%			
	M	4.90%	0.75%	0.13%	4.72%			
18-64	F	2.86%	0.43%	0.06%	2.74%			
	Total	3.39%	0.51%	0.08%	3.25%			

Table E5. HEDIS 2017 Utilization Measures: CHIP—Total IAD and Total MPT Rates								
Age	Sex	Any Services	Outpatient/ED					
	M	0.00%	0.00%	0.00%	0.00%			
65+	F							
	Total	0.00%	0.00%	0.00%	0.00%			
	M							
Unknown	F							
	Total							
	M	6.89%	0.32%	0.09%	6.80%			
Total	F	5.15%	0.47%	0.10%	5.03%			
	Total	5.99%	0.40%	0.10%	5.88%			

Utilization Measures: CHIP—Antibiotic Utilization: Total (ABX)

Table E6. HEDIS 2017 Utilization Measures: CHIP—Antibiotic Utilization									
Age	Sex			Average Scripts PMPY for Antibiotics of Concern	Percentage of Antibiotics of Concern of All Antibiotic Scripts				
	M	1.02	9.29	0.49	48.45%				
0-9	F	1.11	9.54	0.52	46.40%				
	Total	1.06	9.42	0.50	47.41%				
	M	0.64	10.59	0.31	48.18%				
10-17	F	0.84	10.56	0.38	45.94%				
	Total	0.74	10.58	0.35	46.94%				
	M	0.53	11.72	0.25	46.26%				
18-34	F	0.88	9.42	0.29	33.01%				
	Total	0.78	9.86	0.28	35.58%				

Table E6. HED	IS 2017 Ut	ilization Measures: CH	IIP—Antibiotic Utiliza	ation	
Age	Sex	Average Scripts PMPY for Antibiotics	Average Days Supplied per Antibiotic Script	Average Scripts PMPY for Antibiotics of Concern	Percentage of Antibiotics of Concern of All Antibiotic Scripts
	M				
35-49	F	0.68	8.18	0.16	23.20%
	Total	0.68	8.18	0.16	23.20%
	M				
50-64	F	0.00		0.00	
	Total	0.00		0.00	
	M				
65-74	F				
	Total				
	M				
75-84	F				
	Total				
	M	0.00		0.00	
85+	F				
	Total	0.00		0.00	
	M				
Unknown	F				
	Total				
	M	0.78	10.00	0.38	48.23%
Total	F	0.93	9.95	0.41	43.88%
	Total	0.86	9.97	0.39	45.77%

Table E7	. HED	IS 2017 Utiliz	zation Measures: C	HIP—Antibiotics o	f Concern Utili	ization					
		Average Scripts PMPY for									
Age	Sex	Quinolones	Cephalosporins 2nd-4th Generation	Azithromycins and Clarithromycins	Amoxicillin/ Clavulanates	Ketolides	Clindamycins	Misc. Antibiotics of Concern			
	М	0.00	0.18	0.18	0.12	0.00	0.02	0.00			
0-9	F	0.00	0.21	0.17	0.12	0.00	0.02	0.00			
	Total	0.00	0.19	0.17	0.12	0.00	0.02	0.00			
	М	0.01	0.07	0.13	0.08	0.00	0.02	0.00			
10-17	F	0.01	0.09	0.17	0.09	0.00	0.03	0.00			
	Total	0.01	0.08	0.15	0.09	0.00	0.02	0.00			
	М	0.03	0.03	0.09	0.07	0.00	0.03	0.00			
18-34	F	0.03	0.04	0.12	0.06	0.00	0.03	0.00			
	Total	0.03	0.04	0.11	0.06	0.00	0.03	0.00			
	М										
35-49	F	0.02	0.02	0.04	0.06	0.00	0.02	0.00			
	Total	0.02	0.02	0.04	0.06	0.00	0.02	0.00			
	М										
50-64	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
	Total	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
	М										
65-74	F										
	Total										
	М										
75-84	F										
	Total										
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
85+	F										
	Total	0.00	0.00	0.00	0.00	0.00	0.00	0.00			
	М										
Unknown	F										
	Total										

Table E7	Table E7. HEDIS 2017 Utilization Measures: CHIP—Antibiotics of Concern Utilization										
			Average Scripts PMPY for								
Age	Sex	Quinolones	Cephalosporins 2nd-4th Generation	Azithromycins and Clarithromycins	Amoxicillin/ Clavulanates	Ketolides	Clindamycins	Misc. Antibiotics of Concern			
	М	0.01	0.10	0.15	0.10	0.00	0.02	0.00			
Total	F	0.01	0.12	0.16	0.09	0.00	0.02	0.00			
	Total	0.01	0.11	0.15	0.10	0.00	0.02	0.00			

Table E8. HEDIS 2017 Utilization Measures: CHIP—All Other Antibiotics Utilization											
		Average Scripts PMPY for									
Age	Sex	Absorbable Sulfonamides	Amino- glycosides	1st Generation Cephalosporins	Linco- samides	Macrolides (not azith. or clarith.)	Penicillins	Tetra- cyclines	Misc. Antibiotics		
	М	0.03	0.00	0.06	0.00	0.00	0.43	0.00	0.00		
0-9	F	0.07	0.00	0.07	0.00	0.00	0.45	0.00	0.00		
	Total	0.05	0.00	0.07	0.00	0.00	0.44	0.00	0.00		
	М	0.04	0.00	0.05	0.00	0.00	0.18	0.06	0.00		
10-17	F	0.07	0.00	0.06	0.00	0.00	0.23	0.06	0.03		
	Total	0.05	0.00	0.05	0.00	0.00	0.21	0.06	0.02		
	M	0.04	0.00	0.04	0.00	0.00	0.12	0.08	0.01		
18-34	F	0.06	0.00	0.08	0.00	0.00	0.14	0.05	0.25		
	Total	0.06	0.00	0.07	0.00	0.00	0.13	0.06	0.18		
	М										
35-49	F	0.03	0.00	0.07	0.00	0.00	0.09	0.02	0.31		
	Total	0.03	0.00	0.07	0.00	0.00	0.09	0.02	0.31		
	М										
50-64	F	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		

Table E8	Table E8. HEDIS 2017 Utilization Measures: CHIP—All Other Antibiotics Utilization									
		Average Scripts PMPY for								
Age	Sex	Absorbable Sulfonamides	Amino- glycosides	1st Generation Cephalosporins	Linco- samides	Macrolides (not azith. or clarith.)	Penicillins	Tetra- cyclines	Misc. Antibiotics	
	М									
65-74	F									
	Total									
	М									
75-84	F									
	Total									
	М	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
85+	F									
	Total	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
	М									
Unknown	F									
	Total									
	M	0.03	0.00	0.05	0.00	0.00	0.27	0.04	0.00	
Total	F	0.07	0.00	0.07	0.00	0.00	0.29	0.04	0.06	
	Total	0.05	0.00	0.06	0.00	0.00	0.28	0.04	0.03	

Table E8. HEDIS 2017 Utilization Measures: CHIP—Standardize Healthcare-Associated Infection Ratio (HAI)								
Classification	Percentage	of Total Discharg	es From Hospita	ls With SIR				
Classification	High	Moderate	Low	Unavailable				
HAI-1: Central line-associated blood stream infection (CLABSI)	0.55%	0.02%	0.30%	0.13%				
HAI-2: Catheter-associated urinary tract infection (CAUTI)	0.30%	0.13%	0.48%	0.10%				
HAI-5: MRSA bloodstream infection (MRSA)	0.21%	0.14%	0.42%	0.23%				
HAI-6: Clostridium difficile intestinal infection (CDIFF)	0.44%	0.18%	0.29%	0.10%				

Health Plan Descriptive Information

Table E9. Board Certification (BCR)					
Type of Physician	Board Certification Percent				
Family Medicine	72.02%				
Internal Medicine	69.82%				
Pediatricians	80.99%				
OB/GYN Physicians	75.41%				
Geriatricians	71.43%				
Other Physician Specialists	73.90%				

HPA Population in CHIP Member Months

Table E10. HPA CHIP Population in Member Months							
Ago	Member Months						
Age	Male	Female	Total				
<1	4304	3813	8,117				
1-4	39825	37303	77,128				
5-9	110499	106459	216,958				
10-14	140569	134539	275,108				
15-17	85425	82504	167,929				
18-19	27202	29072	56,274				
0-19 Subtotal	407,824	393,690	801,514				
0-19 Subtotal: Percent	99.99%	88.87%	94.20%				
20-24	2	9944	9,946				
25-29	2	15605	15,607				
30-34	0	14106	14,106				
35-39	0	7558	7,558				
40-44	0	1931	1,931				
20-44 Subtotal	4	49,144	49,148				
20-44 Subtotal: Percent	0.00%	11.09%	5.78%				

APPENDIX E | CHIP Measures, Frequencies and Population

Table E10. HPA CHIP Population in Member Months						
Ago	Member Months					
Age	Male	Female	Total			
45-49	0	129	129			
50-54	0	13	13			
55-59	0	0	0			
60-64	0	0	0			
45-64 Subtotal	0	142	142			
45-64 Subtotal: Percent	0.00%	0.03%	0.02%			
65-69	0	0	0			
70-74	0	0	0			
75-79	0	0	0			
80-84	0	0	0			
85-89	0	0	0			
>=90	48	0	48			
>=65 Subtotal	48	0	48			
>=65 Subtotal: Percent	0.01%	0.00%	0.01%			
Total	407,876	442,976	850,852			